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Abstract 
Paracetamol (APAP) overdose is the leading cause of acute liver failure and a 
concerning global health issue. However, the current clinical treatment framework 
is heavily criticized for its sub-optimality. Within this thesis, a systems toxicology 
approach is taken in an attempt to provide further insight into the APAP overdose 
problem, and propose potential improvements to the current treatment framework. 
In Chapter 2, a proof-of-concept pre-clinical pharmacokinetic-pharmacodynamic 
(PKPD) model describing APAP metabolism and corresponding toxicity biomarkers 
(ALT, HMGB1, full K18, fragmented K18) is defined. A statistical model is combined 
with the PKPD framework to simulate in silico population groups with the aim of 
predicting initial APAP dose, time since overdose, and probability of liver injury. In 
chapter 3, an identifiability analysis is performed on the PKPD model to identify 
parameter uncertainties. The model is also extended, enabling predictions for 
individuals deemed both “healthy” and “high-risk”.  
In 2017 I was awarded the in vitro toxicology society mini-fellowship award, which 
funded 4 weeks of training in experimental wet-lab techniques. The training was 
used to investigate the effects of various combinations of APAP and its antidote, 
N’Acetylcysteine (NAC), on in vitro hepatocyte functionality. Subsequently, in 
chapter 4, the effect of the antidote (NAC) is incorporated into the PKPD model 
structure, and an additional toxicity measure is defined, describing severe loss of 
cell functionality. Different NAC regimens are tested, investigating their effect on 
both of our proposed toxicity measures. Through collaboration with the Royal 
Infirmary, Edinburgh, we obtained access to a clinical dataset of approximately 
3,600 APAP overdose patients. In Chapter 5, a population-pharmacokinetic (Pop-
PK) APAP model is defined, with PK parameters optimised based on this dataset. 
The framework has the ability to account for random inter-individual differences in 
PK parameter values. Current clinical toxicity thresholds are investigated and 
compared to those proposed by our model for various demographic groups. 
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1.1. Background 
1.1.1. Clinical problem 
Acetaminophen (paracetamol, APAP) is the most commonly used painkiller in the 
world [1] and, when taken in therapeutic doses, millions of people worldwide benefit 
from its effective and safe analgesic effects [2]. Whilst relatively safe and beneficial 
at therapeutic doses, APAP is also the most commonly used drug in overdose 
situations, accounting for 40% of all drug poisoning cases in the UK [3]. APAP 
overdose is the leading cause for acute liver failure (ALF) in the Western world [4] 
and therefore represents a concerning global health issue [5]. For example, in the 
USA, ALF is responsible for approximately 56,000 emergency room visits, 2,600 
hospitalizations and 500 deaths per year [6]. Between 2015-2016, there was an 
11% increase in deaths involving APAP in the UK [7]. In England and Wales, APAP 
poisoning results in approximately 40,000 hospital admissions, 20 liver transplants 
and 200 deaths per year [8].  
There is, however, an antidote for APAP overdose, N’acetylcysteine (NAC). Current 
decisions on whether this antidote should be given are based on the simple 
nomogram treatment framework [9]. This nomogram treatment framework can be 
seen in Figure 1-1. The red treatment line shown in Figure 1-1 defines a relationship 
between APAP concentration and time-since-APAP-dose. If a patient falls above 
this threshold, NAC treatment is given. It should be noted however that this 
treatment line is heavily dependent on accurate knowledge of time since APAP 
ingestion [10] information, which is often provided by the patient, and can therefore 
be highly inaccurate. Decisions of whether or not to continue NAC treatment are 
then guided by measuring changes in blood-based markers of potential liver injury: 
APAP concentration is measured to determine how much drug is currently 
circulating within the system; alanine aminotransferase (ALT) concentration is 
measured to determine liver injury status; and the international normalised ratio 
(INR) is calculated to determine hepatic transplant appropriateness [11].   
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Figure 1-1: The nomogram treatment framework used in the clinic to determine antidote 
necessity in the APAP overdose case. The red contour is the treatment line/threshold. Any 
patient with an APAP concentration – time since overdose related observation falling above the 
line should begin treatment, any patient with an observation below the line is deemed 
unnecessary for treatment. The nomogram treatment line has been reduced by 25% from the 
original threshold first defined in 1976 as a safety measure to account for patients who may 
potentially be high-risk prior to APAP overdose/measurement errors [9]. 
ALT is an enzyme within the liver that catalyzes the transfer of an amino group (L-
alanine) to a keto-group (𝛼-ketoglutarate) and, the products of this reaction are 
crucial for respiration [12]. Measurements of this biomarker within the blood, show 
that the enzyme has been released from hepatocytes, indicating cell death/damage 
[13]. INR is a measure of how long it takes for the blood to clot (prothrombin time) 
that is normalised to account for any potential differences in laboratories [14]. 
Measuring the rate of blood clotting is important; the liver is a primary source of 
circulating coagulation factors and liver injury is associated with alterations in blood 
coagulation [15]. Whilst ALT is currently the most widely used blood-based 
biomarker for measuring drug-induced-liver-injury (DILI) [16], it’s elevation is known 
to be non-DILI specific and only represents probable liver-injury post-occurrence 
[17]. Additionally, INR has been criticized for its lack of sensitivity; patients 
presenting with an acceptable INR measurement (too low to be deemed at risk), can 
be left untreated when they may in fact have a poor prognosis and could potentially 
benefit from a transplant [18].  
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Further increasing the complexity of the APAP toxicity identification problem, is the 
fact that some individuals may be more susceptible to toxicity than others, 
predominantly due to differences in the ability to synthesise or maintain sufficient 
glutathione (GSH) levels  [10]. Potential factors that may increase a patients 
susceptibility include age, pre-existing liver disease, concurrent use of alcohol or 
chronic APAP use [5]. A crucial factor is the patient’s nutritional state [19]. The 
nomogram treatment line shown in Figure 1-1 has been lowered by 25% from the 
original line that was first defined in 1976,  following recommendations from the 
Food and Drug Administration (FDA) in 1981 to account for such potential risk 
factors [9,20]. With an increase in both alcohol-related and eating disorder-related 
hospital admissions [21,22], there is an urgent need for further investigation of the 
utility of this “one-size-fits-all” threshold. 
Since uncertainty currently exists around accurate APAP overdose identification 
(due to the dependence on insensitive biomarkers and the requirement of an 
accurate knowledge of time since overdose), antidote (NAC) administration 
decisions can be imprecise. These imprecise decisions can result in either treatment 
refusal when it is in fact necessary, or unnecessary administration of the antidote to 
patients who are not likely to experience liver injury. Unnecessary NAC 
administration can cause a range of side-effects spanning from nausea and 
vomiting to anaphylactoid reactions, thereby exacerbating the problem of ill-
informed treatment [23]. Such inaccurate treatment decisions have led to an 
estimated cost of £58.1 million in the UK since 2012 [24]. It is clear that the sub-
optimal treatment framework for APAP overdose requires improvement. 
1.1.2. Biological overview 
In an attempt to improve the APAP overdose treatment framework, we build a 
mathematical model that is representative of the biological processes. This 
biological representation can be investigated computationally to provide both insight 
into the APAP overdose problem, and suggestions for improving the treatment 
framework. The biological processes that occur following an APAP dose are well 
defined in the literature. In this section, we define the key processes that form the 
basis of our mathematical model. 
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1.1.2.1. APAP metabolism 
Following APAP ingestion, metabolism predominantly takes place within the liver, in 
the phase II pathway, with a small proportion being metabolised in the Phase I 
pathway [25]. Within these two metabolic pathways, three principle mechanisms are 
involved: conjugation with a glucuronosyl group (UDP-glucuronic acid) in a process 
called glucuronidation within the phase II pathway; conjugation with a sulfo-group 
(PAPS) in a process called sulfation in the phase II pathway; and oxidation via the 
cytochrome P-450 dependent, mixed function phase 1 oxidative pathways [26]. 
These processes can be visualised in Figure 1-2. 
In therapeutic cases, metabolism occurs predominantly via glucuronidation and 
sulfation, with a small amount (<10%) being oxidized into the toxic metabolite, N-
acetyl-p-benzoquinone imine (NAPQI). Approximately 3-5% of APAP is excreted 
unchanged in the urine and less than 1% is recovered in the bile (an aqueous 
solution that is produced and secreted by the liver and consists mainly of bile salts, 
phospholipids, cholesterol, conjugated bilirubin, electrolytes and water [27]). 
Detoxification of NAPQI occurs via conjugation with hepatic stores of glutathione 
(GSH) [28]. In overdose cases, the UDP-glucuronic acid and PAPS pools deplete, 
leaving more APAP available for oxidation such that NAPQI can accumulate. If 
NAPQI levels become too high, the GSH pools will eventually be overwhelmed, 
resulting in excess levels of NAPQI which can bind to intracellular macromolecules 
causing lipid peroxidation of membranes and eventual hepatic toxicity [29]. The 
antidote currently used to treat APAP overdose, NAC, provides cysteine to 
hepatocytes, acting as a pre-cursor to GSH synthesis [30]. An increase in GSH 
synthesis increases detoxification capacity and reduces the likelihood of 
macromolecule binding, cell death, and subsequent progression into drug-induced 
liver injury (DILI). 
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Figure 1-2: APAP metabolism process. Extracellular APAP (𝐴𝑃𝐴𝑃𝑒) enters hepatocytes. 
Intracellular APAP (APAP) is predominantly metabolised through the phase II pathway. APAP 
conjugates with either a glucuronosyl group (UDP-glucuronic acid) to form APAP-glucuronide 
(𝐴𝑃𝐴𝑃𝐺) or a sulfo-group (PAPS) to form APAP-sulfate, 𝐴𝑃𝐴𝑃𝑆. When phase II pathways are 
saturated, APAP will also undergo phase I reactions. Here, APAP combines with the cytochrome 
P450 enzymes resulting in the production of a highly toxic metabolite, NAPQI. NAPQI is 
detoxified via conjugation with GSH and then excreted. In overdose cases, the GSH stores 
deplete and NAPQI is able to accumulate and react with various cellular components, forming 
toxic adducts and causing hepatocyte damage, which can result in toxicity biomarkers. The 
antidote for APAP overdose, NAC, works as a pre-cursor to GSH, therefore increasing the 
detoxification capacity in hepatocytes. 
1.1.2.2. Hepatocellular toxicity 
When toxicity occurs, cell death can usually be described by one of two forms: 
necrosis or apoptosis [31]. Necrosis is a rapid and irreversible form of cell death 
which occurs when an external trauma causes cells to quickly die.  Apoptosis is a 
much slower physiological process, occurring when the cell has the energy (ATP) 
to programme its own death [32]. In the APAP toxicity scenario, necrosis is thought 
to be the dominant form of hepatocellular cell death [33–35]. However, for mild 
APAP toxicity cases, the apoptotic form of cell death is also observed [33]. Having 
the capability to not only predict potential cell death in toxicity cases, but also gain 
further insight into the mechanism of cell death taking place can help to better 
understand the severity level of a toxicity case. In less severe cases, ATP stores 
may not be critically affected and therefore the cell may have the capability to 
programme its own death via apoptosis. If, however, the case of overdose is severe, 
this external threat may be too large, causing rapid inflammation of the cells and 
eventual necrosis. 
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1.1.2.3. Biological toxicity markers 
In terms of identifying potential liver toxicity, there have been many promising novel 
mechanistic biomarker candidates recently identified. The mitochondria within cells 
is the core of ATP and therefore energy production [36]. The presence of biomarker 
Glutamate dehydrogenase (GLDH) in circulation indicates mitochondrial 
dysfunction and subsequent loss of mitochondrial membrane integrity, which occurs 
during hepatocellular necrosis [37]. GLDH correlates with the currently used ALT, 
but is more tissue specific. Although GLDH has improved specificity when compared 
with ALT, this biomarker is not sensitive enough to predict APAP induced toxicity 
prior to the presence of ALT [38]. Another biomarker that correlates well with ALT 
and is released into the serum following tissue damage is an enzyme known as 
malate dehydrogenase (MDH), but this biomarker is known to be less tissue-specific 
[37]. Molecular forms of High-mobility group box 1 (HMGB1) and Keratin-18 (K18) 
have recently been experimentally established as blood-based biomarkers for 
APAP-hepatotoxicity [39]. Circulating hypo-acetylated HMGB1 and full-length K18 
illustrates cell necrosis. However, during apoptotic structural rearrangements, full-
length K18 undergoes caspase-mediated-cleavage and, subsequently, fragmented-
K18 can be released into the circulation, representing cell apoptosis [37]. Additional 
to these mechanism-based biomarkers, are microRNAs (miRNA) which are non-
coding RNAs involved in regulation of gene expression [40]. The most abundant 
hepatic miRNA, miR-122, is known to be released into circulation following liver 
damage and has been shown to have improved organ specificity over ALT [37]. 
1.1.3. Modelling overview 
1.1.3.1. Quantitative Systems Toxicology modelling 
As the number of drugs developed to improve the health of society quickly 
increases, so too does the requirement for efficient and accurate toxicity predictions 
[41]. The well-known Sulfanilamide tragedy (1937)  [42] caused over 100 deaths 
unexpectedly from nephrotoxicity (kidney toxicity), resulting in the Food Drug and 
Cosmetics Act (FDCA) being passed by congress in 1938. This set the precedent 
for the current toxicity testing strategy (assessing effects of drugs on animals prior 
to initial administration to humans) [43]. However, identifying toxicity following drug 
administration through such traditional preclinical testing strategies, particularly in 
the cases of rare adverse drug reactions (ADRs), has proven to be a difficult task 
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[44]. This issue has been recently improved by the advancement of technologies 
that now enable simultaneous measurements of transcriptomic, proteomic, and 
imaging readouts as well as organelle and cellular phenotypes [45]. In the 
informatics-accelerated healthcare sciences era, the goal is to combine systems 
modelling approaches with this increasing amount of data in order to efficiently and 
robustly make toxicity predictions [44]. Quantitative systems toxicology (QST) 
modelling comprises a useful tool to reduce and refine animal testing and is now 
considered as both an essential component of modern toxicity testing and a 
foundation for individualised therapeutic treatment [43]. However, since this 
approach is a computational representation of biology, and not the true biology itself, 
it is recognized that any uncertainty in predictions must be quantified and limitations 
specified, so that the models may be utilised to their full potential [46]. 
The three main current modelling approaches for toxicity identification are: 
Quantitative Structure Activity Relationship (QSAR) modelling, network based 
modelling, and pharmacokinetic-pharmacodynamic (PKPD) modelling [43]. These 
modelling techniques can be further separated into three main categories [47]: (i) 
“top down” modelling and simulation, which aims to understand the system’s 
characteristics based on observed data; (ii) “bottom up” highly mechanistic 
modelling, which is based on knowledge of the human biology and utilises in vitro 
experimentation for input data; and (iii) “middle out” which combines the “top down” 
and “bottom up” approaches, utilising in vivo data to determine unknown/uncertain 
model parameters.  
QSAR modelling is often used at the pre-clinical stage, due to its ability to screen 
through vast amounts of compounds and identify those that are likely to be active at 
a target site [48]. QSAR models are useful in situations when the mechanism of the 
toxicity is well understood, such as skin sensitization/mutagenicity [49,50]. In terms 
of DILI prediction, Cheng et al. [51] reported the first QSAR model in 2003. They 
built a training set of 382 drugs and drug-like compounds with dose-response data. 
They applied the model to a set of 54 external compounds, with 81% of the 
compounds being correctly classified. Typically, however, since this early study, 
most published QSAR models suffer from a low statistical performance or are limited 
to small, inaccurate datasets [52]. For example, a QSAR study of the permeability 
of drugs in the central nervous system (CNS) is based on incorrect descriptor values 
(including molecular weights differing by 14) for Acetylsalicylate and Aspirin [53]. 
Although guidance is provided, there are many issues that still exist within QSAR 
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modelling. Dearden et al. [54] reviewed 21 potential issues that exist within the 
approach which include: poor transferability;  unacknowledged omission of data-
points; and replication of compounds within a dataset. 
Network based modelling aims to understand how the integration of molecular 
events allows biological processes to occur [43]. The modelling is typically derived 
from the mathematical formalism of graph theory, aiming to describe complex 
qualitative relationships between multiple biological components. The resulting 
dynamical networks can be built using ordinary/partial differential equations, 
Boolean algebra or Bayesian inferences, ranging from continuous to discrete and 
deterministic to stochastic descriptions [43].  
The goal of pharmacokinetic (PK) data analysis is to estimate the parameters that 
determine the rates of drug absorption, distribution, metabolism and elimination [55]. 
Such models often contain both a pharmacokinetic component for the dose-plasma 
relationship and a pharmacodynamic component for the concentration-effect 
relationship [56]. Validated PKPD models have the capability, in theory, to predict 
responses at any time, following any dose administered, via any route. PKPD 
modelling now has a significant role in all phases of drug development: from pre-
clinical stages, to carry out toxicokinetic studies of chemical entities; to phase 1 
studies, to enable crucial decisions regarding tolerability/efficacy; and phase 2 
studies, to help analyse the dose-response relationship [57]. Successful PK studies 
resulting in clinical application span a wide variety of patients and conditions, 
including diabetes, clotting disorders, arthritis, organ transplantation and self-
poisoning [58]. In this thesis, we use a PKPD modelling approach to quantify the 
biochemical dynamics in APAP overdose. 
1.1.4. Review of relevant previously published models 
The drug induced liver injury (DILI)sim initiative is a partnership that has created a 
software (DILIsym), which applies various QST methods, aiming to better 
understand and predict liver toxicity [59]. Hepatotoxicity is modelled predominantly 
via the mechanisms of bile acid transporter inhibition, mitochondrial dysfunction, 
oxidative stress, and lipotoxicity [60]. DILIsym comprises of multiple sub models of 
these toxicity mechanisms, whilst additionally having the capacity to predict cell 
death mechanisms (e.g. via hepatic apoptosis, necrosis or regeneration) and also 
novel liver injury biomarkers concentrations [61]. The tool can be used to investigate 
the effect of various treatment regimens. For example, Woodhead et al. proposed 
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alterations to a novel antibiotic (BAL30072) treatment regimen in order to reduce 
potential liver injury side-effects using DILIsym [62]. Additionally, Longo and 
colleagues. used DILIsym to simulate hepatotoxic potential following treatment of 
adjunct therapies for Parkinson’s disease (Tolcapone and Entacapone) [63].  
Relevant to the work within this thesis, investigations through DILIsym suggest that 
newly proposed NAC dosing regimens are superior to the regimen currently used in 
the APAP overdose case, therefore recommending that modification of the current 
treatment nomogram should be considered [64]. Although promising, the modelling 
framework within DILIsym makes large simplifications of the underlying biology, and 
the predictivity of its results are heavily reliant on the (often in vitro) data used during 
parameter optimisation. We create a detailed mechanistic framework, for which the 
confidence of the data used during optimisation is tested and improved where 
necessary. Our final result is a modelling framework that accounts for individual 
variability between humans, and is optimised based on a clinical dataset of 3,616 
patients. Whilst DILIsym is currently the most comprehensive computational 
approach for integrating data into a DILI safety model, the approach is still in its 
infancy; it is based on a number of simplified modelling assumptions and has a 
reliance on parameterisation via only in vitro experimental data [65]. The addition of 
more detailed mechanistic descriptions and in vivo validation will further improve the 
potential of this computational framework.  
Promisingly, there has been much focus on further developing mechanistic models 
in the area of DILI. For example, researchers in the field have created many 
mathematical models to assess APAP metabolism and its effects on biological 
functionality. Reith et al. [66] provide a system of ordinary differential equations 
(ODEs). The parameters within the system are obtained by fitting to human data 
consisting of patients dosed with pain relief. The system has the aim of providing 
clarification of the role of the glucuronidation and sulfation pathways, outlining a 
basis for examining APAP metabolism in various disease states. Ochoa et al. [67] 
employ a multi-scale approach. They firstly create a spatiotemporal prediction of 
drug and metabolite concentrations within the liver, and then, at the whole-body 
level, include blood flow between organs.  Krauss et al. [68] further extend an 
already published physiologically based-pharmacokinetic (PBPK) model to include 
a genome scale network reconstruction of a human hepatocyte within the liver tissue 
compartment of the model. The model has the aim of quantifying the impact of 
paracetamol-induced liver failure by monitoring changes in 67 hepatic functions (for 
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example, production of cysteine, creatine, GSH and ATP) during a paracetamol 
overdose.  
Geenen et al. [69] also further develop a PBPK model by introduction of an 
additional sub-model. The group combine a PBPK model of APAP metabolism and 
disposition with a refined version of their previously developed mathematical 
systems model of hepatic glutathione homeostasis [70]. The combined model 
predicts that APAP-induced hepatic GSH depletion results in elevated 
concentrations of the biomarkers within their model (5-oxoproline and ophthalmic 
acid in blood and 5-oxoproline in urine). They also provide additional insight; the 
biomarker concentrations are also likely to be influenced by prolonged 
administration of APAP and by the concentrations of intracellular metabolites such 
as methionine. Using a system of ODEs with Michaelis-Menten kinetics to 
investigate the link between APAP, hepatic GSH status and concentrations of 
related intermediary metabolites, Stahl et al. [71] confirm the importance of 
methionine availability on hepatocellular GSH status. Leclerc et al. [72], investigate 
the effect of GSH depletion on reactive oxygen species (ROS) production by 
NAPQI by coupling a drug PK model with a systemic biology (SB) model (which 
uses a system of ODEs to represent the Nrf2 pathway). The group identify a 
transition between 0.025-0.25 μM APAP, from a NAPQI detoxification phase, to a 
NAPQI and ROS accumulation phase, due to depletion of GSH. 
Remien et al. [73] provide a predictive modelling framework for acetaminophen-
induced liver damage (MALD) by deriving ODEs describing changes  in AST, ALT 
and INR following an APAP dose. The authors optimise initial APAP dose amount 
and time since overdose by fitting the resulting ODEs to clinical data (from 53 
overdose patients). The model represents the first dynamical rather than statistical 
approach to determining poor prognosis in patients with APAP-induced-liver-injury, 
by using commonly measured patient biomarkers to estimate initial APAP dose 
amount, time since dose, and subsequent outcome. Remien et al. [74] extend this 
framework to a cell-based model. While the original MALD model has the ability to 
predict for acute APAP overdose cases, the extended model is aimed at also 
accounting for chronic overdose cases. The author’s results suggest that there is a 
threshold relating NAPQI and GSH production rates, where liver injury occurs 
rapidly. That is, when the rate of NAPQI production is less than that of GSH, the 
liver is unlikely to suffer damage. If, however, NAPQI production exceeds GSH, 
NAPQI accumulation will occur, leading to subsequent liver damage.  
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Ben-Shachar et al. [75] propose a retrospective study complementary to Remien’s 
model. Both models describe the detailed mechanisms by which APAP is detoxified 
in the liver in both therapeutic and overdose situations. Whilst Remien’s model aims 
to predict overdose occurrence, Ben-Shachar’s model aims to determine whether 
an overdose is likely to lead to fatal liver damage. The framework they propose is a 
multi-compartmental model (gut, plasma, liver, tissue, urine) consisting of 21 ODEs 
that describe APAP transport and metabolism. The liver compartment describes 
metabolism of APAP, with ODEs representing sulfation, glucuronidation, 
conjugation with GSH, production of toxic metabolites and subsequent liver 
damage. The study strengthens the evidence that APAP metabolism has a 
dependence on the expression level of certain key liver enzymes, but further 
extends the knowledge to include the effects of antidote treatment (NAC) on these 
aforementioned liver enzyme expression levels, and effects on subsequent toxic 
potential.  
Reddyhoff et al. [76] provide a cell-based model that describes the three major 
metabolic pathways that impact upon APAP clearance (sulfation, glucuronidation 
and oxidation). The aim of their model is to reduce the complexity of the APAP 
metabolism system so that analytical methods can be used for investigation. 
Sensitivity analysis is applied to investigate which parameters have the largest 
effect on progression to toxicity, identifying rates for glucuronidation and oxidation 
as key parameters. Results from this study suggest that the sulfation pathway is 
less influential on the dynamics of the systems when compared to the 
glucuronidation/oxidation pathways. Whilst predictive models for improving APAP 
overdose seem promising to date, most models rely on insensitive biomarkers, such 
as ALT, for the prediction of DILI [17]. Going forward, mathematical models that 
include the novel biomarkers discussed in Section 1.1.2 would be a significant 
addition to the current state of the art. In terms of these novel biomarkers for APAP 
toxicity there is currently only one modelling study within the literature that focuses 
on HMGB1, namely, Shoda et al. [60]. However, although insightful to the 
understanding of HMGB1, the focus of this work is on the role of HMGB1 with 
regards the innate immune response rather than APAP toxicity.  
Often, mathematical modelling approaches are applied to animal data, particularly 
at the proof-of-concept stage due to the quantity of data available and also the 
reduced amount of variability from the lab animals [77]. Translatability of these 
models to the human case is often then of particular interest [43,78]. In one such 
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translation study, Pery et al [79], find that toxicokinetic/toxicodynamic approaches 
based on alternative methods and modelling only, have the potential to predict in 
vivo liver toxicity with good accuracy comparable to in vivo methods. They conclude 
this result through the combination and calibration of a PBPK model with a 
toxicodynamic model for cell viability. There are also some human PBPK models 
already published which aim to improve treatment in the APAP overdose case. For 
example, Zurlinden et al [80] propose a mathematical model optimised against 
humans under overdose conditions. The model aim is to predict an APAP dose 
whilst elucidating the effects of blood sampling time and additional blood sampling 
requirements. Whilst the model can accurately predict initial dose for training and 
test datasets, it has poor predictability when applied to real clinical data. 
1.2. Research novelty 
Within this thesis, a new framework is provided for APAP toxicity identification using 
novel biomarkers to predict initial dose, time since ingestion and subsequent liver 
injury probability. Whilst Remien et al. [73] also suggest a predictive framework, the 
biomarker they use for toxicity prediction (ALT) is currently criticised for its lack of 
sensitivity. Within our framework, we combine this biomarker with additional novel 
biomarkers that are believed to have the potential to predict APAP-induced liver 
injury pre occurrence (namely, HMGB1, full K18 and fragmented K18). Whilst Shoda 
et al. [60] model HMGB1 in relation to the immune response, our focus with HMGB1 
differs, namely by using HMGB1 within a panel of DILI biomarkers, aiming 
specifically to improve APAP toxicity identification rather than immune function. In 
comparison to other biomarker based APAP toxicity studies, this study covers both 
overdose and non-overdose cases, identifying the key biomarkers that discriminate 
between the two situations.  
Whilst there is currently one APAP toxicity model which takes into consideration 
individuals that may have depleted GSH stores [81], the focus of their study is to 
understand how depleted nutritional levels and certain lifestyle choices affect GSH 
regeneration. We incorporate the fact that nutritional levels have subsequent effects 
on GSH levels, and use this to extend our model framework, enabling the 
quantification of how probable liver injury differs for nutritionally depleted individuals. 
In order to reduce the skepticism that often arises around QST models, we also 
propose an identifiability analysis technique, based on the profile likelihood 
approach [82]. This allows the assessment and improvement of any uncertainties in 
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the model predictions, whilst also enabling the modelling framework to be as 
biologically relevant as possible given the accessible data.   
Additionally, although Remien’s model [74] accounts for cell functionality dynamics 
following APAP dose, there is no accountability for effects of the NAC antidote. Our 
modelling framework extends previous work by predicting cell functionality 
dynamics in both APAP, and APAP plus NAC antidote cases. As a result, we have 
the ability to understand NAC effects on APAP dose likely to induce probable liver 
injury (based on novel biomarker concentrations) and also loss of cell functionality. 
Finally, we propose a new APAP overdose population pharmacokinetic model, 
optimised against approximately 3,600 overdose patients. We investigate various 
demographic groups (e.g. age, weight) with regards to their maximum tolerable 
APAP dose and find the demographic group that is predicted to have the lowest 
tolerance to APAP. We also compare current clinical toxicity thresholds against 
those predicted from our model and propose some potential adjustments that could 
provide substantial clinical impact. 
There have been limited mathematical approaches aimed at improving the APAP 
overdose problem to date. In the literature, there are deterministic approaches 
specifically aimed at modelling APAP metabolism. For example, the mechanistic 
models underpinning both DILIsym and the framework defined by Geenen et al. 
[69,83] are built using ordinary differential equations (ODEs) representing 
metabolism processes over time within various compartments of the body, including 
transfer of the drug between these compartments within a physiologically based PK 
(PBPK) framework. Parameters within these models are either fixed values from the 
literature, or optimised by fitting to experimental data. The predictivity of these 
models is therefore heavily dependent on the data used during optimisation, and 
with DILIsym, for example, having a large dependence on in vitro data, and Geenen 
et al basing their model on only limited data for clearance, uncertainty in parameter 
values remains a huge issue for these types of models.  
 Although we also take an ODE approach to modelling APAP metabolism and 
corresponding biomarkers, we consider these potential limitations by defining an 
uncertainty quantification technique. We define an identifiability analysis technique, 
which is able to determine areas of uncertainty within our model structure that 
require refinement/additional data during optimisation. We are subsequently able to 
define the uncertainty within our predictions, and improve confidence in our 
framework. Additional to this, we optimise our final clinical model against human 
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data from approximately 3,600 patients, rather than depending on in vitro/in vivo 
information. Mathematical models are often used as a basis for numerical analysis 
of the system to investigate the effects of variations in the mechanistic processes. 
For example, Remien at al. [74] conduct a local sensitivity analysis by perturbing 
parameters by 50% and analysing changes in subsequent biomarker outcomes. 
Additionally, in a secondary publication, they conduct a bifurcation analysis to better 
understand the thresholds for the transition from no liver injury, to severe liver injury. 
In a similar fashion, we conduct a local sensitivity analysis on our pre-clinical model 
parameters to determine those of particular importance prior to translation to the 
human clinical case, but we also apply an identifiability analysis to quantify the 
confidence in the parameters being perturbed. 
As well as modelling drug absorption, distribution, metabolism and excretion 
(ADME) processes over time, it is possible to also model spatial effects (e.g. spatial 
heterogeneity within tissues/organs). For example, Ochoa et al. [67] provide a 
model framework that uses coupled partial differential equations to model both 
hepatocyte and sinusoid functionality (with distribution described by an advection-
diffusion process), subsequently linking this spatial liver model to an ODE based 
PBPK whole body model. However, since our focus is to specifically model plasma 
(blood) toxicity biomarkers with the aim to better guide patient treatment, this organ 
level spatial detail is neglected to focus instead on identification of key relationships 
between plasma glutathione (GSH) as well as novel biomarkers. We particularly 
focus on the combination of biomarker simulations with statistical analyses to 
provide an improved APAP treatment framework.  
The key mathematical novelty of this study, is the combination of mathematical and 
statistical modelling approaches. Deterministic and statistical models are 
formulated, providing key mechanistic insight, particularly with regard to novel 
biomarker mechanisms, and also potential causes for inter-individual variability in 
the APAP overdose setting. Simulation of the mathematical models is utilised 
throughout to create virtual populations, which are combined with statistical 
visualisation and classification techniques, with the aim of predicting patient toxicity 
outcome. A more detailed description of the combination of mathematical and 
statistical approaches is represented by the schematic in Figure 1-3. Firstly, a dose 
is randomly selected from a uniform distribution, and the corresponding biomarker 
time-course profile is simulated using the mechanistic model (A). Similar to the dose 
selection, a time-point is randomly selected from a uniform distribution. From the 
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previously simulated biomarker time-course profile, the randomly selected time 
point is used as an index to extract the corresponding biomarker measurements (B). 
This information is combined to provide a single combination of biomarker 
concentrations for a simulated individual given a random dose of APAP, and having 
their biomarker concentrations measured at a random time-point (C).  
 
Figure 1-3: Schematic representation of process combining mechanistic and statistical 
modelling. (A,B,C) represent how the mechanistic model is used to retrieve simulated biomarker 
concentrations for an individual receiving a random dose, and having concentrations extracted 
at a random time-point. (D) represents how these biomarker concentrations are fed into the 
statistical models. (E,F,G) represents how the statistical models are used to visualise/predict 
the initial dose, time of biomarker extraction, and probability of liver injury. 
The mechanistic modelling is now combined with the statistical modelling (D) in one 
of two ways: the full combination of biomarker concentrations are used in 
conjunction with various statistical techniques to visualise /predict the initial 
dose/time of biomarker extraction (E,F), or the HMGB1 concentration alone is 
combined with a logistic regression model to predict the probability of liver injury. 
1.3. Thesis overview 
This thesis details the development of a systems toxicology approach with the aim 
of improving the current paracetamol overdose clinical framework. A PKPD 
modelling approach is taken, using systems of ODEs to represent paracetamol 
metabolism and the corresponding toxicity, represented by novel biomarker 
concentrations. The thesis consists of 4 research chapters, 3 of which have a pre-
clinical focus, with the final chapter focusing on the clinical application. 
Chapter 2 describes the development of a pre-clinical 2-compartment APAP PKPD 
model. The PK element represents APAP metabolism within the liver and the PD 
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element represents conventional (ALT) as well as novel (HMGB1, full K18 and 
fragmented K18) APAP toxicity biomarkers. Within our model, we assume that 
APAP toxicity is dependent upon the depletion of GSH. The panel of biomarkers are 
tested for significance in predicting the probability of liver injury (measured by 
experimental mouse histology scores), with HMGB1 alone being identified as the 
most significant predictor. The PKPD model is also simulated to create a virtual 
population of mice receiving an APAP dose between 0-600mg/kg. Biomarker 
concentrations are extracted at a random time-point to mimic the clinical scenario 
and are used to make predictions of initial dose, time since APAP administration, 
and subsequent liver injury. 
In Chapter 3 we refine the model developed in Chapter 2. The model refinement is 
led by the results of an identifiability analysis technique which is developed based 
on a profile likelihood approach [82]. I was introduced to this technique by Professor 
Jens Timmer’s research group during a two-week training visit, funded by the LJMU 
International Mobility Award that I received in 2017. In Chapter 2, all biomarkers are 
assumed to follow similar dynamics, which are represented by an indirect PD model 
(i.e. APAP is assumed to inhibit a pre-cursor, GSH, which then regulates the 
dynamics of the biomarkers). In Chapter 3, in order to improve the structural 
unidentifiability found in the original model, we develop piecewise linear equations 
to represent the biomarker dynamics of full and fragmented K18 (which are necrotic 
and apoptotic versions of the same biomarker). We also optimise the model against 
additional data, including fasted-mouse data. This data enables us to model the 
biomarker dynamics of a GSH-depleted mouse, relevant for the high-risk GSH-
depleted population that often present within the clinic. Robust, biologically relevant 
predictions for initial dose amount, time since administration and probability of liver 
injury are calculated for both “healthy” and “high-risk” populations using numerical 
and statistical methods. 
The framework described in Chapters 2 and 3 may be sufficient to make toxicity 
predictions upon initial investigation of a suspected APAP overdose case. However, 
the dynamics of those models do not take into account the effect of the APAP 
overdose antidote, NAC. Using the IVTS Mini-Fellowship Award that I obtained in 
2017, I undertook a four week wet-lab training placement at the University of 
Liverpool. The in vitro experimental data obtained is used within this thesis with two 
primary aims: (1) better understanding of the influence of NAC on the biomarker 
dynamics; and (2) better understanding of toxicity at the cellular level. The results 
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from the experiments are detailed within Chapter 4. The potential of biomarker data 
predicting cell functionality is discussed and modelled, as well as the effect of NAC 
administration schedules on our proposed toxicity thresholds (for both probable liver 
injury and loss of cell functionality). 
Chapters 2, 3 and 4 provide a predictive pre-clinical framework. However, having 
formed a new collaboration with Dr. James Dear (Queens Medical Research 
Institute QMRI, Edinburgh) we obtained access to a clinical dataset of approximately 
3,600 APAP overdose patients from 3 UK hospitals. Chapter 5 describes our clinical 
two compartment Pop-PK APAP model based on this data. We carry out a covariate 
correlation analysis and propose 3 human covariate factors that we predict are 
correlated with various PK parameters. We analyse differences in the maximum 
tolerable APAP dose in various patient groups, and find that younger, lower weight 
individuals have a lower tolerance to APAP. We also compare current clinical toxicity 
thresholds against those predicted from our model and propose some potential 
screening adjustments that with further investigation, could significantly impact the 
clinical environment.  
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Chapter 2: A pre-clinical systems 
toxicology framework – predicting 
liver injury potential from novel 
biomarker concentrations  
 
 
 
 
 
 
 
 
 
The research defined in this chapter has been published in Clinical Pharmacology 
and Therapeutics: Pharmacometrics and Systems Pharmacology (CPT: PSP): 
Mason CL, Leedale J, Tasoulis S, Jarman I, Antoine DJ, Webb SD. Systems 
Toxicology Approach to Identifying Paracetamol Overdose. CPT 
Pharmacometrics Syst Pharmacol. 2018;7(6):394–403. Available from: 
http://doi.wiley.com/10.1002/psp4.12298 
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2.1.  Background 
Whilst paracetamol/APAP is the most commonly prescribed painkiller worldwide [1], 
in the western world, this analgesic is also the leading cause of acute liver failure 
(ALF) [4]. There is an antidote to treat APAP overdose cases, N’acetylcysteine 
(NAC), which if provided in a timely manner following APAP doses, has been shown 
to reduce the likelihood of progression into drug-induced liver injury (DILI) [30]. The 
effectiveness of the antidote is thought to diminish in cases where it is  administered 
beyond 8 to 10 hours of initial APAP dose [84]. Although NAC is currently the most 
effective APAP overdose treatment, the antidote also has many associated adverse 
side effects. Typical side effects are those such as rash, vomiting and more 
uncommonly, anaphylactoid reactions [30]. The current decision to administer NAC 
is predominantly based upon the nomogram treatment line [9]. A visualisation of the 
treatment framework can be seen in Chapter 1, Figure 1-1. A patient’s point on this 
framework is found by determining the relationship between their measured APAP 
blood concentration and the time elapsed since APAP overdose. If the patient’s 
point on the framework falls above the nomogram treatment line, NAC 
administration should begin, however if they fall below the line, NAC treatment is 
deemed unnecessary. This initial decision to begin treatment is heavily dependent 
on the patient’s knowledge of time elapsed since ingestion [20]. However, this 
information is often highly unpredictable within the clinical setting. Once NAC 
treatment begins, the decision to continue treatment is based on measuring 
changes in the following biomarker concentrations – APAP and alanine 
aminotransferase (ALT). Additionally, the patient’s international normalised ratio 
(INR) is calculated [11].  
ALT elevation represents probable liver injury post-occurrence [17] and is the most 
widely used blood based biomarker for measuring DILI [16]. INR is an adjusted 
version of the prothrombin time (PT) test. The PT test evaluates an individual’s  
ability to appropriately form blood clots, and INR slightly adjusts this measurement 
to account for changes in PT reagents, allowing results from different laboratories 
to be compared [85]. AST is another DILI biomarker [16]. AST could be used for 
toxicity predictions as it accumulates in the blood due to liver damage, but it is not 
liver specific as it is also linked to other pathologies, e.g. heart injury [86]. Increased 
serum total bilirubin (TBL) is another potential marker; it is indicative of the 
substantial loss of functional hepatocytes [17]. However, since the marker identifies 
loss of hepatocytes, it does not predict hepatotoxicity potential but instead is a post-
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occurrence indicator, similar to ALT. In order to improve the treatment of APAP-
induced DILI via NAC therapy, biomarkers which can predict liver damage a priori 
are required. Recently, biomarkers K18 and HMGB1 have been shown to add value 
to the measurement of ALT [87] and have the potential to predict DILI pre-
occurrence. However, such new biomarkers are often examined singly and 
clarification of their functional relationships is required to aid clinical implementation 
[88]. In this chapter, we aim to combine these novel biomarkers with conventional 
biomarkers, with the objective of improving the prediction accuracy of APAP 
overdose cases. 
In silico modelling allows for the development of mechanistic understanding of 
biological systems which may not always be possible from in vitro/in vivo 
experiments alone. An inter-disciplinary, systems toxicology approach is a cost-
effective way of understanding and predicting drug efficacy and toxicology whilst 
additionally complying with the 3Rs (a scientific framework for the effective use of 
animals in research) [89]. There are many examples of successful in silico modelling 
frameworks that have been previously developed to study APAP metabolism and 
its associated toxic potential. Many are discussed in Chapter 1, but frameworks 
relevant to the work in this chapter are redefined here.  
For example, Reith et al. [66] propose a system of ODEs. The parameters within 
the system are obtained by fitting to human clinical data. The system has the aim of 
providing clarification of the role of the glucuronidation and sulfation pathways, 
outlining a basis for examining APAP metabolism in various disease states. Ochoa 
et al. [67] approach their modelling in a multi-scale manner, firstly creating a 
spatiotemporal prediction of drug and metabolite concentrations within the liver, and 
then, at the whole-body level, including blood-flow between organs. Remien et al. 
[73] derive ordinary differential equations (ODEs) describing changes  in AST, ALT 
and INR, creating a model (based on a single-time overdose) with the ability to 
predict acetaminophen-induced liver damage. The authors optimise initial APAP 
dose amount and time since overdose by fitting the resulting ODEs to clinical data 
(from 53 overdose patients). Remien et al. [74] subsequently provide a cell-based 
model extension to this framework. Reddyhoff et al. [76] also construct a cell-based 
model which describes major metabolic pathways impacting on APAP clearance. 
Sensitivity analysis determines the parameters that have the largest effect on the 
progression to toxicity. Ben-Shachar et al. [75] create a retrospective study 
complementary to Remien’s model. Whilst Remien’s model has the aim of predicting 
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overdose occurrence, Ben-Shachar’s has the aim of determining whether an 
overdose would lead to fatal liver damage. Our study also further extends Remien’s 
approach by combining ALT (used in their study) with additional novel biomarkers 
(K18 and HMGB1) that have the potential to predict APAP-induced liver injury pre-
occurrence. Additionally, the study is extended to non-overdose and overdose 
cases, attempting to identify the key biomarkers that discriminate between the two 
situations. Shoda et al. [60] also mechanistically model the biomarker HMGB1. They 
focus on the role of HMGB1 with regards to the innate immune response, concluding 
that HMGB1 is a key input for immune cell activation. Our focus is to instead 
investigate HMBG1 within a panel of DILI biomarkers, with the aim of predicting 
APAP toxicity in mice. 
In this chapter, we propose a novel framework with the aim of predicting initial APAP 
dose, time since administration and the probability of APAP-induced liver injury. The 
platform is distinctive primarily due to the use of novel biomarkers, optimised within 
the PKPD framework by combining the use of deterministic modelling with statistical 
PKPD analysis.  
The mouse is widely considered to be a good model for APAP toxicity prediction in 
humans [90] and due to the rich data sets available, we utilise mouse-derived data 
in this chapter to develop our new in silico framework. At this initial stage of model 
development, we wish to avoid the uncertainties associated with APAP human 
overdose data.  The human clinical APAP model is described in Chapter 5.  The 
basis of this current chapter is to demonstrate the development and validation of our 
new predictive framework using the more amenable mice data, prior to translation 
to the human situation.  
The results from our investigation define previously undocumented PK parameters 
for APAP in mice, which can now be used for further application throughout the field. 
Additionally, as mentioned above, novel biomarkers are included in the framework 
as a panel, rather than the current approach which is to consider them individually. 
The key aim of the modelling development at this initial stage is to determine which 
biomarkers are most predictive of APAP induced-DILI.  
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Chapter aims 
 Create a mechanistic PKPD model that represents APAP metabolism and 
corresponding biomarkers (ALT, HMGB1, K18) in mice. 
 Test biomarkers as a panel to determine the most significant in predicting 
DILI. 
 Combine analyses to provide a predictive DILI framework based on 
biomarker measurements only, eradicating the current requirement for verbal 
information regarding overdose amount and time elapsed since overdose. 
2.2.  Methods 
2.2.1.  Pharmacokinetic-Pharmacodynamic modelling 
2.2.1.1. Pharmacokinetic model development 
To understand how to effectively model the ADME processes, the observed APAP 
concentrations (from four datasets from two separate published studies [39,91] 
recording APAP concentration over time in mice following intraperitoneal 
administration of  50, 150, 500 and 530 mg/kg doses) were transformed into log-
space and plotted over time. From Figure 2-1, for the lower doses particularly (green 
and black profiles), and also the highest dose (red profile), it is clear to see that the 
distribution and elimination of APAP within these mice occurred over two phases. 
For the 500mg/kg dose, although this result did not seem so clear, the data had no 
observations beyond four hours and therefore the full course of distribution and 
elimination was difficult to conclude. Based on the results in Figure 2-1, we assumed 
that the distribution and elimination of APAP occurred over two-phases, and 
therefore a two compartmental modelling approach was necessary. A two 
compartmental model assumes that tissues within the body can be separated into 
two different compartments [92]. The first compartment mainly consists of the blood 
and well-perfused tissues such as heart, liver and brain etc. and the secondary 
compartment consists of poorly perfused tissues such as fat and bone. [93]. As 
mentioned, the liver is a well-perfused tissue, and therefore any liver-related 
dynamics within the model (sections 2.2.1.2 and 2.2.1.3) will occur within the central 
compartment. A two-compartmental model schematic is described in Figure 2-2. 
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Figure 2-1: Log-transformed paracetamol concentration versus time. The green profile 
represents the log-transformed APAP time course following an initial dose of 50mg/kg, the black 
profile represents the log-transformed APAP time course following an initial dose of 150 mg/kg, 
the pink profile represents the log-transformed APAP time course following an initial dose of 500 
mg/kg, and the red profile represents the log-transformed APAP time course following an initial 
dose of 530 mg/kg. 
 
Figure 2-2: Two-compartment PK model schematic. A dose of APAP is absorbed into the 
central compartment at a rate 𝑘𝑎. The central compartment has a theoretical volume, 𝑉𝑐. APAP 
is secondarily transferred to the peripheral compartment (theoretical volume 𝑉𝑝) at a rate 𝑘12. 
APAP is transferred from the peripheral compartment to central compartment at a rate 𝑘21. 
APAP is then eliminated from the central compartment at a rate 𝑘𝑒𝑙. 
 
Based on the model schematic in Figure 2-2, which is assumed to represent APAP 
metabolism in mice, two ordinary differential equations (ODEs) were used to 
represent changes in APAP concentration within the two PK compartments (central 
and peripheral) of the mice in the following system, 
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 𝑑[Cc]
𝑑𝑡
=
𝑘𝑎𝐷0𝑒
−𝑘𝑎𝑡
𝑉𝑐
+ 𝑘21[Cp]
𝑉𝑝
𝑉𝑐
− 𝑘12[Cc] − 𝑘𝑒𝑙[Cc], (2-1) 
where [Cc] represents the central compartment concentration of APAP (mol/l), 
[Cp] represents the peripheral compartment concentration of APAP (mol/l), 𝑘𝑎 
represents the absorption rate from the peritoneal cavity (h-1), 𝐷0 represents the 
initial dose (mg), 𝑘21 represents the transfer rate from the peripheral to the central 
compartment (h-1), 𝑘12 represents the transfer rate from the central to the peripheral 
compartment (h-1), 𝑉𝑝 represents the theoretical volume of the peripheral 
compartment (l/kg), 𝑉𝑐 represents the theoretical volume of the central compartment 
(l/kg), 𝑘𝑒𝑙 represents the overall elimination rate (summation of both excretion and 
metabolism processes) (h-1), and 𝑡 represents the time variable (h). Note that our 
model is representative of intraperitoneal administration. For applications to oral 
administration, the absorption rate parameter, 𝑘𝑎, would be multiplied by a 
bioavailability fraction to implicitly take into account effects of gastric emptying and 
absorbed fraction. 
We used the method of Laplace transforms [94] to solve the equations for APAP in 
the central and peripheral compartment. Briefly, Laplace transformation works by 
transforming differential equations on the time domain, 𝑡, to a frequency domain, 𝑠. 
It is then possible to analytically solve these simpler equations, and transform them 
back to the original time domain. The methodology of solving equations (2-1) and 
(2-2) via Laplace transformation is described below. 
If we wish to transform a function of time, for example, 𝐴(𝑡), via Laplace 
transformation ℒ, the Laplace notation can be applied: 
ℒ(𝐴(𝑡)) = ∫ 𝑒−𝑠𝑡𝐴(𝑡)𝑑𝑡
∞
0
, 
(2-3) 
 
where 𝑠 is the frequency domain we wish to transform the variable 𝐴 onto. 
The Laplace transform of a first order differential is, for example, defined by: 
𝑑𝐴
𝑑𝑡
≃ 𝑠ℒ(𝐴)−𝐴(0), (2-4) 
 
 𝑑[Cp]
𝑑𝑡
=  𝑘12[Cc]
𝑉𝑐
𝑉𝑝
− 𝑘21[Cp], (2-2) 
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where 
𝑑𝐴
𝑑𝑡
 is the rate of change of variable 𝐴 over the time (𝑡) domain, 𝑠 is the 
frequency domain we wish to transform the variable 𝐴 onto, ℒ(𝐴) is the Laplace 
transform of variable 𝐴 and 𝐴(0) is the initial concentration (at 𝑡 = 0) of variable 𝐴. 
We can now apply this theory and transform our differential equations ((2-1) and 
(2-2)) into Laplace form: 
𝑠ℒ([Cc]) − [Cc](0) =
𝑘𝑎𝐷0ℒ(𝑒
−𝑘𝑎𝑡)
𝑉𝑐
+
𝑘21ℒ([Cp])𝑉𝑝
𝑉𝑐
− 𝑘12ℒ([Cc]) − 𝑘𝑒𝑙ℒ([Cc]), 
(2-5) 
𝑠ℒ([Cp]) − [Cp](0) =
𝑘12𝑉𝑐ℒ([Cc])
𝑉𝑝
− 𝑘21ℒ([Cp]) 
(2-6) 
The Laplace transform of the exponential is found using the following: 
 
ℒ(𝑒−𝑘𝑎𝑡) = ∫ 𝑒−(𝑠+𝑘𝑎)𝑡𝑑𝑡 =
∞
0
1
𝑠 + 𝑘𝑎
 (2-7) 
For simplicity, we let 
𝑌1 = ℒ([Cc]),         𝑌2 = ℒ([Cp]) 
Therefore equations (2-5) and (2-6) can now be re-written: 
 
𝑆𝑌1 − [Cc](0) =  
𝑘𝑎𝐷𝑜 
𝑉𝑐(𝑆 + 𝑘𝑎)
+
𝑘21𝑉𝑝𝑌2
𝑉𝑐
− 𝑘12𝑌1 − 𝑘𝑒𝑙𝑌1 (2-8) 
 
𝑆𝑌2 − [Cp](0) =
𝑘12𝑉𝑐𝑌1
𝑉𝑝
− 𝑘21𝑌2 (2-9) 
Initially (at  𝑡 = 0), there is no APAP in either the central or peripheral compartment, 
therefore, 
[Cc](0) = 0,           [Cp](0) = 0 
We can now use this information to solve equation (2-9) for 𝑌2, namely: 
𝑆𝑌2 − 0 =
𝑘12𝑉𝑐𝑌1
𝑉𝑝
− 𝑘21𝑌2. (2-10) 
Rearranging gives,  
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𝑌2 = 
𝑘12𝑉𝑐𝑌1
𝑉𝑝(𝑆+𝑘21)
. 
 
(2-11) 
Substituting this result for 𝑌2 ((2-11)) into equation (2-8)) we can solve for 𝑌1 as 
follows: 
 𝑆𝑌1 = 
𝑘𝑎𝐷𝑜 
𝑉𝑐(𝑆 + 𝑘𝑎)
+
𝑘21𝑉𝑝𝑘12𝑉𝑐𝑌1
𝑉𝑐𝑉𝑝(𝑆 + 𝑘21)
− 𝑘12𝑌1 − 𝑘𝑒𝑙𝑌1. (2-12) 
Rearranging to give, 
 
𝑆𝑌1 + (𝑘12 + 𝑘𝑒𝑙)𝑌1 −
𝑘21𝑘12𝑌1
(𝑆 + 𝑘21)
=  
𝑘𝑎𝐷𝑜 
𝑉𝑐(𝑆 + 𝑘𝑎)
, (2-13) 
and factorising for 𝑌1 gives, 
 𝑌1 (𝑆 + 𝑘12 + 𝑘𝑒𝑙 −
𝑘21𝑘12
(𝑆 + 𝑘21)
) =  
𝑘𝑎𝐷𝑜 
𝑉𝑐(𝑆 + 𝑘𝑎)
. (2-14) 
If we allow 
 𝛼 + 𝛽 =  𝑘21 + 𝑘12 + 𝑘𝑒𝑙  (2-15) 
and 
 𝛼𝛽 =  𝑘𝑒𝑙𝑘21,  (2-16) 
then 
 
𝑌1 = 
𝑘𝑎𝐷𝑜 
𝑉𝑐
(
1
𝑆 + 𝑘𝑎
) (
𝑆 + 𝑘21
(𝑆 + 𝛼) + (𝑆 + 𝛽)
).  (2-17) 
 Taking the inverse Laplace transform of 𝑌1, we get: 
 [Cc](𝑡) = ℒ
−1(𝑌1),  (2-18) 
from which we get:  
[Cc](𝑡) =
𝑘𝑎𝐷0
𝑉𝑐
[
(𝑘21 −  𝛼)
(𝑘𝑎 −  𝛼)(𝛽 − 𝛼)
𝑒−𝛼𝑡 +
(𝑘21 − 𝛽)
(𝑘𝑎 −  𝛽)(𝛼 − 𝛽)
𝑒−𝛽𝑡
+
(𝑘21 − 𝑘𝑎)
(𝛼 − 𝑘𝑎)(𝛽 − 𝑘𝑎)
𝑒−𝑘𝑎𝑡], 
(2-19) 
 
where 𝛼 and 𝛽 are related to the model parameters as follows, 
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𝛼 =
1
2
(𝑘12 + 𝑘21 + 𝑘𝑒𝑙 + √(𝑘12 + 𝑘21 + 𝑘𝑒𝑙)2 − 4𝑘21𝑘𝑒𝑙), 
and 
𝛽 =
1
2
(𝑘12 + 𝑘21 + 𝑘𝑒𝑙 − √(𝑘12 + 𝑘21 + 𝑘𝑒𝑙)2 − 4𝑘21𝑘𝑒𝑙). 
We fitted equation (2-19) to the four aforementioned datasets simultaneously using 
a Nelder-Mead search algorithm [95] (Fminsearch tool in Matlab  [96]). Parameters 
𝑘𝑎, 𝑘21, 𝑉𝑐, 𝛼 and 𝛽 were optimised in order to minimise the difference between the 
model output and the observed APAP mice data. Note that all subsequent data 
fitting in this thesis also employs this algorithm. Optimised parameter values (from 
the model defined in this chapter) are defined in the results section of this chapter. 
2.2.1.2. Glutathione depletion model 
APAP is metabolised predominantly by the phase II pathway via glucuronidation 
and sulfation, but at high doses, the sulfation process saturates and an increased 
amount of APAP is then metabolised by the phase I (CYP) pathway. In this case, 
APAP combines with cytochrome P450 to create N-acetyl-p-benzoquinoeimine 
(NAPQI), a highly toxic metabolite [97]. NAPQI can be detoxified by glutathione 
(GSH). However, with large doses of APAP, GSH stores deplete [98] and NAPQI 
accumulates leading to the possibility of DILI. For this reason, the biomarker 
response dynamics were modelled to be dependent on GSH depletion. For a 
visualisation of the key APAP metabolism processes, please refer to Figure 1-2. 
To formulate the rate of change of GSH, the following mass-action-based ODE was 
considered 
𝑑[gsh]
𝑑𝑡
= 𝑘𝑖 − 𝑘𝑜[gsh] − 𝑘𝐺[𝑁𝐴𝑃𝑄𝐼][gsh], (2-20) 
 
where 𝑘𝑖 (h
-1) is the background production rate of GSH, [gsh] (mol/l) is the 
concentration of GSH, 𝑘𝑜 (h
-1) is the natural decay/background-usage rate of GSH, 
[NAPQI] is the concentration of NAPQI (mol/l) and 𝑘𝐺  (μM
−1h−1) is the decay rate 
of GSH due to binding with NAPQI. The model is extended by assuming the rate of 
change of NAPQI as follows, 
𝑑[NAPQI]
𝑑𝑡
= 𝜉𝑘𝑒𝑙[Cc] − 𝑘𝐺[NAPQI][gsh] − 𝑘𝑝[NAPQI], 
(2-21) 
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where 𝜉 is the proportion of CYP-activated APAP that is transformed into NAPQI,  
𝑘𝑒𝑙  is the total rate of APAP elimination as described above, and 𝑘𝑝 (h
-1) is the rate 
at which NAPQI binds to other (non-GSH) cellular proteins.  
Because NAPQI is short-lived and the associated reactions are known to be rapid 
on the time-scale of APAP depletion, we assume [NAPQI] is at a quasi-steady state 
on the time-scale of APAP PK, namely, 
0 = 𝜉𝑘𝑒𝑙[Cc] − 𝑘𝐺[NAPQI][gsh] − 𝑘𝑝[NAPQI], (2-22) 
and thus, 
[NAPQI] =
𝜉𝑘𝑒𝑙[Cc]
𝑘𝐺[gsh] + 𝑘𝑝
. (2-23) 
Substituting this term into equation (2-20) we obtain, 
𝑑[gsh]
𝑑𝑡
= 𝑘𝑖 − 𝑘𝑜[gsh] −
[gsh]𝜉𝑘𝑒𝑙[Cc]
[gsh] + 𝑘𝑝𝑟
, (2-24) 
where 𝑘𝑝𝑟 = 
𝑘𝑝
𝑘𝐺
, represents the ratio of NAPQI forming other protein adducts relative 
to detoxification by GSH. We then assume a constant GSH background level to be 
𝑔𝑠ℎ0, so that in the absence of APAP and at steady-state we have  𝑘𝑖 = 𝑘𝑜𝑔𝑠ℎ0. 
Using this, we obtain 
𝑑[gsh]
𝑑𝑡
= 𝑘𝑜𝑔𝑠ℎ0 − 𝑘𝑜[gsh] −
𝜉𝑘𝑒𝑙[gsh][Cc]
[gsh] + 𝑘𝑝𝑟
. (2-25) 
In summary, the first term in equation (2-25) relates to the natural production of 
GSH. The second term in the equation represents the background usage of GSH. 
The final term in the equation represents the loss of free GSH due to interaction with 
NAPQI. 
2.2.1.3. Pharmacodynamic biomarker model  
In order to determine the most relevant model to represent the biomarker dynamics 
following an APAP dose, biomarker effect vs drug concentration plots were 
produced for each biomarker. This helped to visualise the relationship between the 
drug (APAP) and subsequent biomarkers (ALT, HMGB1, full K18, and fragmented 
K18). Effect versus concentration plots for each biomarker can be seen in Figure 
2-3. The results from Figure 2-3 identified a temporal delay between drug and 
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biomarker accumulation. This hysteresis relationship implies that APAP likely 
regulates a pre-cursor, (in this case GSH) which then influences each biomarker 
response, and therefore an indirect PD model was chosen to account for this 
hysteresis delay [99]. 
 
Figure 2-3: Biomarker effect versus concentration plots. A visualisation of the relationship 
between APAP and each biomarker. (A) shows the relationship between APAP and ALT, (B) 
shows the relationship between APAP and HMGB1, (C) shows the relationship between APAP 
and full K18 and (D) shows the relationship between APAP and fragmented K18. 
The toxic response to APAP overdose was mathematically described with 
individual, indirect PD models representing biomarker concentrations ([𝑟] = ALT, 
HMGB1, K18 and Fragmented K18) over time, as described in equation (2-26), 
𝑑[r]
𝑑𝑡
= 𝑟0𝑘𝑜𝑢𝑡 (
𝑅50
𝑛 + 𝑔𝑠ℎ0
𝑛
𝑅50
𝑛 )(1 −
[gsh]𝑛
𝑅50
𝑛 + [gsh]𝑛
) − 𝑘𝑜𝑢𝑡[r], (2-26) 
where 𝑟0 is the biomarker baseline concentration, 𝑘𝑜𝑢𝑡 is the natural decay rate of 
the biomarker (h-1), 𝑅50 represents the concentration of (GSH) which causes the 
biomarker production (response) to be half its maximal value (mol/l), and 𝑛 is a 
parameter that reflects the steepness of the biomarker production term [100]. Whilst 
parameter values 𝑟0 and 𝑔𝑠ℎ0 can be identified directly from the data (for each 
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biomarker, the baseline value was fixed at the average of all control values provided 
for that biomarker within the study by Antoine et al. that was used during 
optimisation [39]). Parameters 𝑘𝑜𝑢𝑡, 𝑅50 and 𝑛 were optimised by individually fitting 
the model output to the data measuring biomarker concentration over time following 
a 530 mg/kg dose of APAP [39]. 
All initial conditions for the PKPD model are detailed in Table 2-1. 
Model initial conditions 
Variable Initial condition (𝜇mol/l) 
[Cc]  0 
[Cp]  0 
[gsh]  696.9136 
[alt]  0.7621 
[hmgb1]  0.0005 
[fullk18]  0.0146 
[fragk18]  0.0642 
Table 2-1: Model initial conditions. Initial conditions for each variable within the dynamical 
system. Biomarker baseline values were fixed at the average values of control measurements 
from the data used for optimisation [39]. 
2.2.1.4. Sensitivity analysis 
The output of the model was analysed to determine its sensitivity with regard to any 
local perturbations in parameters. This was carried out using the sensitivity analysis 
tool in Mathworks’ Simbiology  [101].  Parameters were varied in ranges such that 
the lowest bound was one order of magnitude lower than the parameter value, and 
the highest bound was one order of magnitude higher than the parameter value. 
Sensitivity outputs were normalised to allow comparison.  
The general methodology of this analysis tool can be described with the case of an 
example. 
If we define the model output as 𝑥(𝑡) and a model parameter as 𝑦, then the time-
dependent sensitivity of output 𝑥 with respect to parameter 𝑦 is given by the scaled 
time-dependent derivative, 
  
𝜕𝑥 𝑥⁄
𝜕𝑦 𝑦⁄
, 
 
 
(2-27) 
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where the numerator is the sensitivity output and the denominator denotes the 
sensitivity input to the analysis given by parameter 𝑦. We then calculate the 
corresponding time-integral sensitivity coefficients (𝑆𝑞), which give an indication of 
the total sensitivity of the model parameter 𝑦 on output 𝑥 over the entire time course 
of the simulation 
  
𝑆𝑞 = ∫ |
𝜕𝑥/𝑥
𝜕𝑦/𝑦
|
𝑡=𝑡(𝑒𝑛𝑑) 
𝑡=0
𝑑𝑡. 
 
 
(2-28) 
Further details can be found in [102]; however, the ultimate result is a number for 
each parameter, representative of how sensitive the output is to perturbations in this 
parameter. A larger value indicates a higher sensitivity, and therefore only small 
changes in this parameter would result in large changes in the output, and vice-
versa. 
2.2.2.  Statistical modelling 
The PKPD model was used to create an in silico population for statistical testing. 
The aim was to determine whether or not we could predict the initial APAP dose, 
time elapsed since dose, and probability of liver injury for an in silico individual with 
a suspected overdose based on a single measurement of the panel of biomarkers. 
2.2.2.1. In silico population simulation 
Each computationally-derived dataset used within the analysis consisted of 1,000 
in silico individuals simulated under different scenarios: given a random APAP dose, 
and selected from a uniform distribution of range 0-1,000 mg/kg. Once a random 
dose was chosen, the mechanistic model (with all parameters other than dose fixed 
at their optimised value) was simulated for this dose. As visually displayed in the 
mechanistic modelling section of Figure 1-3, this resulted in corresponding 
concentration-time profiles (APAP, GSH, ALT. HMGB1, full K18, fragmented K18). 
A random time-point from a uniform range between 0-24 hours was selected. This 
time point was used as an index to extract a single observation from each biomarker 
time course. The result was a single combination of biomarker concentrations for an 
in silico individual (where the initial dose and time of biomarker extraction are 
random). This process was repeated 1000 times to create various scenarios for an 
in silico individual for testing. All biomarker concentrations in the computationally-
derived dataset were normalised in the range [0,1] using the min-max normalisation 
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method [103] to account for varying orders of magnitude. Experimental noise was 
replicated in silico by applying observed in vivo standard deviations in biomarker 
concentrations from an APAP study performed by Antoine et al. [39] (ALT s.d = 
11.22, HMGB1 s.d = 0.00097, K18 s.d = 2.39, fragmented K18 s.d = 0.12 mol/l). 
2.2.2.2. Visualisation 
To examine class structure and separability whilst retaining model variation, we 
applied Principal Component Analysis (PCA) and constructed two-dimensional 
scatter plots of the in silico derived data projected onto the ﬁrst two principal 
components. Additionally, to visually expose class structure, a fast tree-based 
implementation of the T-distributed Stochastic Neighbour Embedding (T-SNE) 
method  was employed [104]. 
Principal component analysis (PCA) 
PCA is a common statistical technique used to reduce the dimensionality of high 
dimensional data [105]. This is a useful technique when data has more than 3 
dimensions (or variables) and is therefore difficult to visualize. The method works 
by identifying patterns in high dimensional data, expressing such data in a way that 
highlights any similarities and differences in the data points, and compressing in 
relation to the identified patterns. This subsequently reduces the dimensionality of 
the data with little loss of information [106]. 
In order to visualise the data in a new subspace with reduced dimensions, the 
following steps must be followed [107]: 
 Remove the label from each variable and assume that each is representative 
of a dimension. Include each dimension in a matrix, for example, 𝐴. 
 Compute the mean for every dimension within the dataset (column within 
matrix 𝐴) 
 Compute the covariance matrix of the whole dataset (𝐴) using the following 
formula for calculating the covariance between two variables: 
𝑐𝑜𝑣(𝑋, 𝑌) =
1
𝑛 − 1
∑ (𝑋𝑖 − ?̅?)
𝑛
𝑖=1
(𝑌𝑖 − ?̅?), 
 
(2-29) 
where 𝑋 and 𝑌 are the two variables we wish to calculate the covariance 
between. The total number of observations is represented by 𝑛, the current 
observation for variable 𝑋 is represented by  𝑋𝑖, the mean of all of the 
observations in variable 𝑋 is represented by ?̅?, the current observation for 
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variable 𝑌 is represented by 𝑌𝑖 and the mean of all of the observations in 
variable 𝑌 is represented by ?̅?. 
The covariance between each variable is calculated to form a covariance 
matrix for (𝐴), (cov(𝐴)). 
 Compute eigenvectors and corresponding eigenvalues of cov(𝐴). The 
eigenvalues of cov(𝐴) are roots of the characteristic equation, 
det(𝐴 − 𝜆𝐼) = 0 
 
(2-30) 
  
For each eigenvalue, 𝜆, we have:  
(A − λI)v = 0, (2-31) 
 where v is the eigenvector associated with eigenvalue λ. 
 Sort the eigenvectors by decreasing eigenvalues. For a 2-dimensional 
visualisation, choose the 2 eigenvectors with the largest eigenvalues, these 
two eigenvectors should then be used to form a new matrix, 𝐵. 
 Use the transposition of this new matrix (𝐵) to transform each original sample 
onto a new subspace by simply calculating: 
𝐶 = 𝐵′𝐴, (2-32) 
where 𝐵′ is the transformation matrix, 𝐴 is the original dataset matrix and 𝐶 
is the transformed dataset matrix (mapped onto a new subspace). 
While the original dataset can have any number of dimensions (or variables), matrix 
𝐶 will have 2 dimensions. These dimensions represent linear combinations of the 
original variables, with the first vector in matrix 𝐶 accounting for most of the variance 
in the original data, and the second vector in matrix accounting for the second most 
amount of variance in the original data. This explains why the eigenvectors with the 
highest eigenvalues are chosen to be included in matrix 𝐶. The transformed data 
can now be visualised in two dimensions, plotting one component of matrix 𝐶 
against the other, retaining most of the information (or variation) of the data. 
While the original dataset can have any number of dimensions (or variables), matrix 
𝐶 will have 2 dimensions. These dimensions represent linear combinations of the 
original variables, with the first vector in matrix 𝐶 accounting for most of the variance 
in the original data, and the second vector in matrix accounting for the second-most 
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amount of variance in the original data. This explains why the eigenvectors with the 
highest eigenvalues are chosen to be included in matrix 𝐶. The transformed data 
can now be visualised in two dimensions, plotting one component of matrix 𝐶 
against the other, retaining most of the information (or variation) of the data. 
t-distributed Stochastic Neighbour Embedding (TSNE) 
TSNE is a visualisation technique used to reduce high dimensional data, so that it 
can be visualised in lower dimensions.  The method works by minimizing the 
divergence between two distributions: one that measures pairwise similarities of the 
input objects (in high-dimensional space) and one that measures pairwise 
similarities of the corresponding low-dimensional points found from the embedding 
[104]. Calculating the conditional probability that a high-dimensional point 𝛺1𝑖 would 
choose the high-dimensional point 𝛺1𝑗 as its neighbour (if neighbours are picked in 
proportion to their probability density under a Gaussian/Normal distribution), results 
in determining the similarity of points 𝛺1𝑖 and 𝛺1𝑗  [108]. For nearby points, the 
conditional probability is relatively high, whereas for points that are widely 
separated, the conditional probability is almost infinitesimal [109]. 
Mathematically, the conditional probability, 𝑝𝑗|𝑖 , that the high-dimensional 𝛺1𝑖would 
pick the high dimensional 𝛺1𝑗 is represented by: 
𝑝𝑗|𝑖 =
𝑒
−(
∥𝛺1𝑖−𝛺1𝑗∥
2
2𝜎𝑖
2 )
∑ 𝑒
−(
∥𝛺1𝑖−𝛺1𝑘∥
2
2𝜎𝑖
2 )
𝑘≠𝑖
, (2-33) 
where ∥ ⋯ ∥ is the norm of the element, ensuring a strictly positive resultant vector, 
and  𝜎𝑖 is the variance of the Guassian that is centred on data point 𝛺1𝑖 . 
If we wish to define the pairwise similarities in the high-dimensional space, 𝑝𝑖𝑗, the 
obvious representation would be 
𝑝𝑖𝑗 =
𝑒
−(
∥𝛺1𝑖−𝛺1𝑗∥
2
2𝜎2
)
∑ 𝑒
−(
∥𝛺1𝑘−𝛺1𝑙∥2
2𝜎2
)
𝑘≠𝑙
, (2-34) 
where 𝛺1𝑖 , 𝛺1𝑗 , 𝛺1𝑘, 𝛺1𝑙 are all different points within the high-dimensional data set 
𝛺1, and  𝜎 is the total variance of the high-dimensional dataset. This makes the 
pairwise distance relative to every other pairwise distance present within the 
dataset. 
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However, if the high-dimensional data point 𝛺1𝑖 is an outlier (all pairwise distances 
∥ 𝛺1𝑖 − 𝛺1𝑗 ∥
2 are large for 𝛺1𝑖) then 𝑝𝑖𝑗 will be extremely small for all values of 𝑗, 
so the location of its low dimensional map-point, 𝛺2𝑖 , has very little effect on the cost 
function, meaning that the position of the map point is not well determined by the 
positions of the other map points. To resolve this issue, we assume that the joint 
probabilities 𝑝𝑖𝑗 in the high-dimensional space, are symmetrized conditional 
probabilities. This allows each data point to make a significant contribution to the 
cost function. The joint probabilities in the high dimensional space can therefore be 
defined as 
𝑝𝑖𝑗 =
pj|i + 𝑝𝑖|𝑗
2𝑁
, (2-35) 
where 𝑝𝑖𝑗 are the pairwise similarities in the high-dimensional space, pj|i is the 
conditional probability that high-dimensional 𝛺1𝑖  would choose high-dimensional 
𝛺1𝑗 , pi|j is the conditional probability that high-dimensional 𝛺1𝑗 would choose high-
dimensional 𝛺1𝑖 and 𝑁 is the total number of observations. Since we are only 
interested in pairwise comparisons, we set 𝑝𝑖|𝑖 = 0. 
The similarities between the low dimensional counterpart points, 𝛺2𝑖 and 𝛺2𝑗 (which 
are the original data points 𝛺1𝑖 and 𝛺1𝑗 having been mapped onto a lower 
dimensional space) can be represented by the conditional probability (or pairwise 
similarity) 𝑞𝑖𝑗, which is normalized by the student t-kernel with a single degree of 
freedom. This normalization is preferred since the heavy tails of a student t-kernel 
allow dissimilar high-dimensional input objects 𝛺1𝑖  and 𝛺1𝑗 to be modelled by low 
dimensional counterparts 𝛺2𝑖  and 𝛺2𝑗 that are too far apart. More space is created 
during this normalization so that small pairwise distances can be accurately 
modelled in the low-dimensional embedding [104]. 
Mathematically, the conditional probability or pairwise similarity between the two 
points in low-dimensional space, 𝑞𝑖𝑗 , is represented by 
𝑞𝑖𝑗 =
(1+∥ 𝛺2𝑖 − 𝛺2𝑗 ∥
2)
−1
∑ (1+∥ 𝛺2𝑖 − 𝛺2𝑗 ∥2)
−1
𝑘≠𝑙
. (2-36) 
Again, since we are only interested in pairwise comparisons, we set 𝑞𝑖𝑖 = 0. 
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The locations of the embedding points are then determined by minimizing the 
Kullback-Liebler divergence between the joint distributions 𝑃 and 𝑄 (𝐾𝐿(𝑃||𝑄)): 
𝐶 = 𝐾𝐿(𝑃||𝑄) =∑∑𝑝𝑖𝑗 log (
𝑝𝑖𝑗
𝑞𝑖𝑗
)
𝑵
𝒋
𝑵
𝒊
, (2-37) 
where 𝐶 is the cost function to be minimized. This cost function is minimized by the 
gradient descent method. The gradient of 𝐶 can be given by 
𝛿𝐶
𝛿𝛺1𝑖
= 4∑ (𝑝𝑖𝑗 − 𝑞𝑖𝑗)(𝛺2𝑖 − 𝛺2𝑗)(1+∥ 𝛺2𝑖 − 𝛺2𝑗 ∥
2)
−1
.
𝑗
 (2-38) 
While the original dataset can have any number of dimensions (or variables), the 
embedded points will have 2 dimensions, making visualisation much easier, so that 
clusters may be better identified. These dimensions should represent the data in a 
way such that there is minimal difference to the structure (in terms of points that are 
nearby each other) in higher dimensions. 
2.2.2.3. Classification 
In order to test the predictive potential of biomarker concentrations, critical ranges 
for predicting time since administration were defined as (0-2], (2-5], (5-10], (10-15] 
and (15-24] hours. For dose, the ranges were [0-200], [201-400] and [401-1,000] 
mg/kg, capturing therapeutic, small, and large (overdoses), respectively. Various 
classification techniques were applied to determine the utility of the biomarkers. 
Multinomial logistic regression [110] was used as a method that fits well when 
multiple response categories are available. Since response categories were in an 
ordinal manner, ordinal multinomial logistic regression was also used. Both linear 
and quadratic discriminant analysis were employed [111]. A naïve Bayes classifier 
[112] was also used to predict class probability. Additional model-free classification 
techniques (k-nearest neighbour (k-nn) and optimal weighted nearest neighbour) 
were also employed [113,114] to test for robustness. Since classes are not 
previously defined for model-free classification techniques, observations group 
together based solely on their similarity, and the aim is to determine whether similar 
observations automatically group into our desirable classes.  The methodology of 
each classification technique is described below.  
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Multinomial logistic regression 
Multinomial logistic regression was applied in an attempt to predict time since 
administration and initial dose categories. This method uses more than one 
predictor variable (in this instance, multiple biomarkers) to predict the probability of 
falling in the class of a nominal outcome variable (in this instance, multiple 
categories for time since administration or initial dose). The observed data (𝑙𝑜𝑔𝑖𝑡(𝑌), 
representing either time since administration or initial dose) is assumed to be a 
linear function of the predictor variables ( 𝑋1, 𝑋2, 𝑋3, 𝑋4 and 𝑋5 representing 
biomarker concentrations APAP, ALT, HMGB1, Full K18 and Fragmented K18, 
respectively). The equation for the model is written in terms of the logit equation, 
since we are interested in predicting the probability of falling into a category rather 
than predicting a continuous value. If all of the predictor variables are significant, 
and therefore included in the model, the relationship between predictor and outcome 
variables can be represented using a generalised linear model: 
 𝑙𝑜𝑔𝑖𝑡(𝑌) = 𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + 𝛽4𝑋4. 
(2-39) 
The objective of multinomial logistic regression is to optimise the parameters 𝐵𝑖, 𝑖 =
1…4, so that the model provides the best fit to the observed (either time since 
administration or initial dose) data. Since we are using a probabilistic model, 
Ordinary least squares will not suffice as a fitting method and maximum likelihood 
estimation should be used to optimise for the parameters. For various values of 
𝑋1, 𝑋2,𝑋3 and 𝑋4, the probability of falling into a particular class can be estimated by 
applying a logistic transformation to equation (2-39) according to the logistic 
cumulative distribution function, resulting in the following: 
 
𝜋 =
1
1 + 𝑒𝑙𝑜𝑔𝑖𝑡(𝑌)
.    
 
(2-40) 
The key assumptions are: 
 The dependent variable is measured on a nominal level. This assumption 
holds since the time since administration classes are sub-categories ranging from 
0-24 hours and the initial dose classes are sub-categories ranging from 0-600 
mg/kg.    
 One or more of the independent variables are continuous, ordinal or 
nominal. The predictor variables in our model are represented by biomarker 
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concentrations (APAP, ALT, HMGB1, full K18 and fragmented K18), all of which 
are measured on a continuous scale.   
 Observations must be independent. Additionally, the dependent variable 
should have mutually exclusive/exhaustive categories (i.e. each observation must 
belong to an outcome group, and they must only belong to one outcome group, not 
many). In the data used for this analysis, each in silico mouse is independent of 
one another, and each in silico mouse must fall into category [0-2, 2-5, 5-10, 10-15, 
15-24] hours for time since administration or [0-200, 201-400, 401-600] mg/kg for 
initial dose. For both models, each in silico mouse can only be assigned one score.   
 Multi-collinearity should not be present between any predictor variables. This 
assumption was tested using the Variance Inflation Factor (VIF) test. The VIF is 
indicative of the amount of variance an estimated regression coefficient is increased 
by due to multi-collinearity. Since the VIF is representative of increased variance, 
the square root of this result would be indicative of the increased standard error. As 
an example, a variable with VIF 9 has a standard error 3 times larger than it would 
be if the variable was uncorrelated with the other variables. A recommended 
reasonable range for the VIF is 1 – 10 [115]. Predictor variables for all models were 
tested and remained within this range, therefore multi-collinearity does not exist 
between the predictor variables and the assumption is met.  
 Outliers/highly influential points should not be present in the observed 
data. No outliers were detected.   
 Adequate sample size; a recommended sample size is 10 times the number 
of predictor variables. There were 5 predictor variables, and therefore 50 
observations would be sufficient. The in silico derived data consists of 1,000 
observations. 
 
Once multinomial logistic regression was deemed a feasible test for the data, 
variations of two models were investigated; one for predicting initial dose category 
and one for time since administration category. Biomarkers APAP, ALT, HMGB1, 
full K18 and fragmented K18 were the independent variables tested for predictivity. 
A forward stepwise logistic regression analysis was applied to test the panel of 
predictors. This means that the most significant predictor (biomarker) is entered into 
the model first, and one additional predictor is included at each stage, but only if the 
overall significance of the model is improved by its inclusion.  
Multinomial logistic regression assumes that the dependent variable is nominal, and 
makes no explicit use of the fact that categories may be ordered. Ordinal logistic 
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regression accounts for the fact the dependent variable is categorised on an ordered 
scale [116].  
Discriminant analysis 
Linear Discriminant Analysis (LDA) works by transforming high dimensional data 
into a lower dimensional space by maximizing the ratio of between-class variance 
and within-class variance [117]. Tharwat et al. [117] detail the three necessary steps 
for carrying out linear discriminant analysis: 
1. Calculate the between-class variance, 𝑆𝐵:  
 
𝑆𝐵 =∑(𝜇𝑐 − ?̅?)
𝑐
(𝜇𝑐 − ?̅?)
T, (2-41) 
where 𝜇𝑐 represents the mean of the class (𝑐), and ?̅? represents the total mean of 
the data. Therefore, 𝑆𝐵 represents the separation distance between the mean of the 
𝑖th class and total mean (or the between class variance of the 𝑖th class). The 
superscript T represents the transpose operation. 
2. Calculate the within-class variance (covariance), 𝑆𝑊:   
𝑆𝑊 =  ∑(𝑥𝑖𝑐 − 𝜇𝑐)(𝑥𝑖𝑐 − 𝜇𝑐)
𝑇
𝑐
, (2-42) 
where 𝑥𝑖𝑗 represents the 𝑖th sample in the 𝑗th class, and 𝜇𝑗 represents the mean of 
the class. Therefore, 𝑆𝑊 represents the separation distance between the sample of 
interest, and the mean of the class to which the sample belongs (or the within-class 
variance of the 𝑗th class). 
3. Construct the lower-dimensional space 
Once the between-class variance and within-class variance have been calculated, 
the data can then be transformed into a lower dimensional space which shows the 
maximal variance between classes relative to the variance within classes. This is 
done by maximizing Fisher’s criterion: 
𝑊lda = arg max
𝑊
𝑊𝑇𝑆𝐵𝑊
𝑊𝑇𝑆𝑊𝑊
 , (2-43) 
where 𝑊 is the transformative (or projection) matrix of the LDA technique. 
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While LDA assumes a common covariance matrix between all of the classes, 
quadratic discriminant analysis (QDA) assumes that each class has its own 
covariance matrix [118]. 
Naïve Bayes 
The Naïve Bayes classifier is used to predict the probability that a sample of interest 
belongs to a particular class [112]. The classifier is based on Bayes’ theorem, which 
computes the probability of an event, based on the probabilities of other events that 
influence it [119]. This classifier adds strong (naïve) independence assumptions to 
Bayes’ theorem, assuming that the presence (or absence) of a feature of interest 
within a class is completely unrelated to the presence (or absence) of any other 
feature [120].  
Mathematically, the probability of a class is found using Bayes’ theorem 
 
𝑝(𝐶|𝐹1, … , 𝐹𝑛) =
𝑝(𝐶)𝑝(𝐹1, … , 𝐹𝑛|𝐶)
𝑝(𝐹1, … , 𝐹𝑛)
,      (2-44) 
where 𝐶 is the dependent class variable, which is conditional on several feature 
variables 𝐹1, … , 𝐹𝑛. The values of the features 𝐹𝑖 are given, so the denominator of 
equation (2-44) is effectively constant, and the numerator is equivalent to the joint 
probability model: 
𝑝(𝐶, 𝐹1, … , 𝐹𝑛). (2-45) 
 
Using applications of the definition of conditional probability, (2-45) can be rewritten 
as 
𝑝(𝐶)𝑝(𝐹1|𝐶)𝑝(𝐹2|𝐶, 𝐹1)𝑝(𝐹3|𝐶, 𝐹1, 𝐹2)…𝑝(𝐹𝑛|𝐶, 𝐹1, 𝐹2, 𝐹3, … , 𝐹𝑛−1). (2-46) 
With naïve Bayes, it is assumed that each feature 𝐹𝑖 , is conditionally independent of 
every other feature 𝐹𝑗 , for 𝑗 ≠ 𝑖. This means that 
 𝑝(𝐹𝑖|𝐶, 𝐹𝑗) = 𝑝(𝐹𝑖|𝐶)      
(2-47) 
for 𝑖 ≠ 𝑗, and so the joint model (equation (2-47)) can be expressed as  
 
𝑝(𝐶, 𝐹1, … , 𝐹𝑛) = 𝑝(𝐶)𝑝(𝐹1|𝐶)𝑝(𝐹2|𝐶)𝑝(𝐹3|𝐶)…𝑝( 𝐹𝑛|𝐶),         
(2-48) 
or, equivalently, 
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𝑝(𝐶, 𝐹1, … , 𝐹𝑛) = 𝑝(𝐶)∏𝑝(𝐹𝑖|𝐶).
𝑛
𝑖=1
      (2-49) 
This means that under the independence assumptions used in naïve Bayes, the 
conditional distribution over the class variable (𝐶) can be expressed as: 
 
𝑝(𝐶|𝐹1, … , 𝐹𝑛) =
1
𝑍
𝑝(𝐶)∏𝑝(𝐹𝑖|𝐶)
𝑛
𝑖=1
      (2-50) 
where 𝑍 (the evidence, or 𝑝(𝐹𝑖)) is a scaling factor dependent only on  𝐹1, … , 𝐹𝑛 and 
therefore a constant when the features are known [120]. 
K-nearest neighbour (KNN) 
The KNN method uses the local neighbourhood to make a prediction, and samples 
are classified based on their level of similarity [121]. The level of similarity between 
two samples is measured by their distance between one another. The number of 
samples chosen to be added to the class is defined by the user as K. When a new 
sample is added, the centre of the class is updated, and it is this point that is used 
to find the neighbour with the shortest distance. We used Euclidean distance as a 
distance measure, 𝐷: 
 
𝐷(𝑥1, 𝑥2) = √∑(𝑥1𝑖 − 𝑥2𝑖)
2
𝑛
𝑖=1
,      (2-51) 
 
where 𝑥1 and 𝑥2 are the points of interest we wish to measure the distance between, 
𝑥1𝑖 is the 𝑖th observation we wish to test as the current point, 𝑥2𝑖 is 𝑖th observation 
we wish to test as the new point and  𝑛 is the total number of pairwise combinations 
of points. 
Optimal weighted nearest neighbour 
The optimal weighted nearest neighbour extends the KNN classification method by 
assigning neighbours that are particularly close, a higher weight in the decision than 
neighbours that are further away. 
Rather than finding 𝑘 nearest neighbours, in the weighted classification, 𝑘 + 1 
nearest neighbours are found. This (𝑘 + 1)th nearest neighbour is used to 
standardise all other distances and results in the normalised distance function, 𝐷𝑁 
[122]. This via 
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𝐷𝑁(𝑥, 𝑥𝑖) =
𝑑(𝑥, 𝑥𝑖)
𝑑(𝑥, 𝑥𝑘+1)
   for 𝑖 = 1, … , 𝑘 ,  (2-52) 
where 𝐷𝑁 is the normalised distance, 𝑑 is the current distance of interest,  𝑥𝑖 is the 
current observation of interest, and 𝑥 is a new observation. The normalised distance 
𝐷𝑁 is then transformed into a weight 𝑊 with the use of a kernel function, 𝐾(𝐷𝑁), with 
the maximum weighted observation being assigned to the class at each iteration 
[122]. 
2.2.2.4. Predicting initial dose and time since administration as 
continuous variables 
Multiple linear regression 
To test the use of biomarkers in predicting time since administration and initial dose 
separately, multiple linear regression analysis was applied. This method takes a 
very similar approach to the multinomial logistic regression method, details of which 
can be found in section 2.2.2.3. However, in the linear regression setting, the 
outcome variable must be continuous rather than nominal/categorical. Since we are 
interested in predicting a continuous value, the relationship between predictor and 
outcome variables can be represented using a generalised linear model. The 
assumptions required for this analysis to be valid are similar to those necessary for 
multinomial logistic regression. There is one additional assumption required for 
linear regression analysis: 
 Residuals should be approximately normally distributed. A histogram and 
normal P-P plot of the standardized residuals in the models predicting both 
time since administration and initial dose were inspected, as shown in Figure 
2-4. 
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Figure 2-4: Data diagnostic plots. (A,C) Histogram – Visualisation of how the standardized 
residuals are distributed for the multiple linear regression models predicting time since 
administration and initial dose respectively. For data to be diagnosed as normally distributed, 
the mean value should be approximately 0 and the standard deviation should be approximately 
1. (B,D) Normal P-P plot of regression standardised residual for the models predicting time since 
administration and initial dose respectively. The cumulative probability expected from the model 
is plotted against the observed cumulative probability. For the data to be diagnosed as 
approximately normally distributed, most results (circles) should lie along the diagonal line. 
2.2.2.5. Predicting the probability of liver injury  
The biomarker time-course experimental data [39] used to create the PD model in 
this chapter also provided a corresponding histology score for each mouse from the 
range [0, 1, 2, 3]. These histology scores were binarised based upon previously 
published criteria [39]. Within this criteria, histology scores range from [0-4]: 0- 
normal histology; 1–minimal to mild necrosis; 2–mild to moderate necrosis; 3–
moderate to severe necrosis; and 4–severe necrosis. With advice from biological 
collaborators, we defined any mouse with an observed histology score of 0, 1 or 2 
as having a corresponding binary score of 0 (no liver injury) and any mouse with an 
observed histology score of 3 or above as having a binary score of 1 (liver injury), 
since our interest was in discriminating between liver injury or no liver injury. 
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Forward-stepwise binary logistic regression [123] was applied in order to 
understand the most significant biomarker, or panel of biomarkers for DILI. The most 
significant biomarkers were then used in combination with PK-PD model simulations 
to predict the DILI probability [124].  
2.3. Results 
2.3.1.  PKPD model optimisation 
Simulations of the PKPD models using the optimised parameters can be seen in 
Figure 2-5. Visually, the model simulations provide a good fit to the experimental 
data. Additionally, with an R2 value of 0.8304 for the PK model, and values of 
0.7513, 0.9634, 0.7413, and 0.6526 for the PD models for ALT, HMGB1, K18 and 
fragmented K18, respectively, the in silico model appears to recapitulate the in vivo 
experimental dynamics very well. Optimised parameters for all of the PK-PD models 
can be found in Error! Reference source not found.. A key parameter of interest i
s the 𝑅50 parameter in the biomarker PD models. This parameter defines a 
concentration of GSH at which the biomarker reaches half of its maximal production 
rate (MPR), and can therefore be used to determine the fastest responding 
biomarker following an APAP dose. For biomarkers ALT, HMGB1, K18 and 
fragmented K18, the 𝑅50 values are 227.67, 399.08, 212.87 and 72.09 mol/L 
respectively. Therefore, in the model, as GSH depletes from a baseline of 696.91 
mol/L [125] and reaches a concentration 399.08 mol/L (42.73% depletion), 
HMGB1 reaches half of its MPR and is therefore considered to be the fastest 
responding biomarker. GSH must be further depleted to 227.67 mol/L and 212.87 
mol/L (67-69% depletion), respectively, before biomarkers ALT and K18 reach half 
of their MPR. Approximately 90% GSH depletion is required for fragmented K18 to 
reach half of its MPR in the model.  
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Figure 2-5: In silico simulation outputs from the optimised model compared with the 
experimental data. (A) APAP PK simulations (solid lines) comparable to original data values 
with green, black, magenta and red representing APAP time-course following a 50, 150, 500, 
and 530 mg/kg dose respectively. (B) GSH simulations (black dashed lines) comparable to 
original data (blue). Individual PD simulation (black dashed lines) comparable to data (blue) for 
biomarkers ALT (b), HMGB1 (C), Full K18 (D), and Fragmented K18 (E). 
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Table 2-2: Parameters and corresponding standard error estimates 
for PKPD model. 
Model Parameter Optimised 
or Fixed? 
 Value Standard 
Error 
Parameter 
Description 
Optimising 
Dataset 
PK 𝑘a  
(h-1) 
Optimised 9.05 1.85 Absorption 
rate from 
peritoneal 
cavity 
[39,91] 
𝑘𝑒𝑙  
(h-1) 
Optimised 5.2 x 10-1 4 x 10-2 Total 
elimination 
rate 
𝑘12  
(h-1) 
Optimised 4.2 x 10-1 6 x 10-4 Distribution 
rate from 
central to 
peripheral 
compartment 
𝑉𝑐  
(l/kg) 
Optimised 2 x 10-2 1 x 10-3 Theoretical 
volume of 
central 
compartment 
𝑉𝑃  
(l/kg) 
Optimised 1 x 10-2 Fixed Theoretical 
volume of 
peripheral 
compartment 
𝑘21  
(h-1) 
Optimised 1.01 4.44 x 10-1 Distribution 
rate from 
central to 
peripheral 
compartment 
PD- GSH 𝑔𝑠ℎ0   
(mol/l) 
Fixed 696.9136   Baseline 
value of GSH 
[125] 
[39] 
𝑘𝑝𝑟  Optimised 71.06 
 
2848.6441 Ratio of 
NAPQI 
forming other 
protein 
adducts 
relative to 
detoxification 
𝜉  Optimised 6.8 x 10-1 1.73 x 10-1 Proportion of 
CYP activated 
APAP that is 
transformed 
into NAPQI 
𝑘𝑜  
(h-1) 
Optimised 2.5 x 10-1 2.3196 Natural 
decay/backgr
ound usage 
rate of GSH 
𝑘𝑒𝑙  
(h-1) 
Fixed  5.2 x 10-1  Total 
elimination 
rate 
PD-ALT 𝑅0 (mol/l) Fixed 7.62 x 10
-1  Baseline 
value of ALT 
[39] 
48 
 
𝑛  Optimised 9.26 1.7422 Reflects the 
steepness of 
the biomarker 
production 
term 
𝑔𝑠ℎ0  
(mol/l) 
Fixed 696.9136  Baseline 
value of GSH 
𝑅50 
(mol/l) 
Optimised 227.67 
 
14.0245 Concentration 
of GSH which 
causes ALT 
concentration 
to be half its 
maximum 
value 
𝑘𝑜𝑢𝑡  
(h-1) 
Optimised 2 x 10-4 < 1 x 10-4 Natural 
decay/backgr
ound usage of 
ALT 
PD-
HMGB1 
𝑅0 (mol/l) Fixed 5 x 10
-4  Baseline 
value of 
HMGB1 
[39] 
𝑛  Optimised 4.90 
 
1.57 x 10-1 Reflects the 
steepness of 
the biomarker 
production 
term 
𝑔𝑠ℎ0  
(mol/l) 
Fixed 696.9136  Baseline 
value of GSH 
𝑅50 
(mol/l) 
Optimised 399.08 24.8957 Concentration 
of GSH which 
causes 
HMGB1 
concentration 
to be half its 
maximum 
value 
𝑘𝑜𝑢𝑡  
(h-1) 
Optimised 3.5 x 10-1 1.59 x 10-1 Natural 
decay/backgr
ound usage of 
HMGB1 
PD-Full 
K18 
𝑅0 (mol/l) Fixed 1.46 x 10
-2  Baseline 
value of full 
K18 
[39] 
𝑛  Optimised 10.42 
 
4.3 x 10-3 Reflects the 
steepness of 
the biomarker 
production 
term 
𝑔𝑠ℎ0  
(mol/l) 
Fixed 696.9136  Baseline 
value of GSH 
𝑅50 
(mol/l) 
Optimised 212.87 
 
1.23 x 10-1 Concentration 
of GSH which 
causes Full 
K18 
concentration 
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to be half its 
maximum 
value 
𝑘𝑜𝑢𝑡 (h-1) Optimised 7 x 10-4 1.23 x 10-1 Natural 
decay/ 
background 
usage of Full 
K18 
PD-Frag-
K18 
𝑅0 (mol/l) Fixed 6.42 x 10
-2  Baseline 
value of 
Fragmented 
K18 
[39] 
𝑛  Optimised 2.30 
 
1.46 x 10-2 Reflects the 
steepness of 
the biomarker 
production 
term 
𝑔𝑠ℎ0  
(mol/l) 
Fixed 696.9136  Baseline 
value of GSH 
𝑅50 
(mol/l) 
Optimised 72.09 
 
4.03 x 10-1 Concentration 
of GSH which 
causes Frag-
K18 
concentration 
to be half its 
maximum 
value 
𝑘𝑜𝑢𝑡 (h-1) Optimised 2 x 10-2 1.17 x 10-2 Natural 
decay/backgr
ound usage of 
Fragmented 
K18 
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2.3.2.  PKPD model validation 
In order to test the accuracy of the in silico model, experimental data (from 
collaborators at University of Liverpool) consisting of 4 different APAP doses [0, 150, 
300, 530] mg/kg in mice and their corresponding biomarker concentrations at 5 h 
was used for validation. The in silico model was simulated using identical doses and 
the resultant biomarker concentrations were extracted at 5 h post-dose and 
compared to the corresponding in vivo mouse data. Both datasets comprised of CD-
1 type mice. For GSH, there appeared to be an adaptive response in the validation 
data at low doses which was not included in the in silico model and therefore was 
not portrayed in the simulation However, this is a minor discrepancy and given the 
large dose range in this validation, the in silico output matched the validation data 
very well. Results can be seen in Figure 2-6.   
 
Figure 2-6: In silico simulated data versus dose/response validation data used to test the 
accuracy of the in silico model in new scenarios. 
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2.3.3. Visualisation of in silico derived data 
The utilisation of biomarkers in class prediction (time since administration and initial 
dose) can be seen by the projection of the in silico derived biomarker data on to the 
first two principal components (which account for 97% of the variability within the 
dataset, Figure 2-7 (A)-(B)). Each PCA plot was separated with respect to time since 
administration and dose amount. Classes were clearly distinguished in both 
instances, however, the level of class overlap with respect to dose was much lower. 
Visualising the data with the T-SNE method (Figure 2-7 (C)-(D)) further enhances 
the PCA visualisation, allowing initial dose to be separated more clearly.  
Additionally, the time-since-administration classes were more separable with the T-
SNE method, particularly with earlier time ranges. 
2.3.4. Classification of in silico derived data 
The classification results were consistent across the different methodologies (Table 
2-3). Should a new observation arise, this framework could predict in which ‘time-
since-administration’ and ‘dose’ category it belongs in with 73.7% and 86.5% 
accuracies respectively.  
Classification Method Time Accuracy Dose Accuracy 
Multinomial Logistic Regression 72.8% 86.5% 
Ordinal Multinomial Logistic Regression 57% 85.9% 
Naïve Bayes 68.9% 84.4% 
Linear Discriminant Analysis 65.7% 86% 
Quadratic Discriminant Analysis 73.7% 85.3% 
K-nearest neighbour 66.4% 85.9% 
Optimal Weighted Nearest Neighbour 67.6% 85.8% 
Table 2-3: Classification results for predicting time since administration and initial dose 
based upon biomarker concentrations. 
2.3.5. Predicting initial dose and time since administration 
as continuous variables 
Virtual animals each have two values assigned to them: time since administration, 
and initial dose. These values can be within the ranges shown in Table 2-4. Using 
multiple linear regression analysis, the exact time-since-administration value could 
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be predicted with a residual standard error and accuracy of 3.6 h, whilst the exact 
dose could be predicted with only an error of 56.81 mg/kg (Table 2-5). 
In both models (predicting time, and dose) the APAP concentration was the highest 
model coefficient, meaning it was this biomarker that had the most influence on the 
resulting prediction. Whilst Full K18 was a predictive biomarker for both outcomes, 
fragmented K18 was not a significant biomarker for predicting time since 
administration. It was however, the second most important biomarker in predicting 
initial dose amount. HMGB1 was the second most important biomarker in 
determining the time since APAP dose, however was insignificant for predicting 
initial dose amount. For both models (predicting time since overdose, and initial 
dose amount) although the conventional biomarker (ALT) was significant, it had the 
least impact on the output when compared to the other biomarkers included in each 
model.     
 
 
Figure 2-7: Visualisation of time since administration and dose results. For time since 
administration, dark green represents class [0-2), orange represents [2-5), blue represents       
[5-10), pink represents [10-15) and pale green represents [15-24) hours. For dose, green 
represents [0-200], orange represents [201-400] and blue represents [401-600] mg/kg.  (A)-(B) 
2-dimensional PCA visualisation of in silico mouse observations with respect to time since 
administration and dose respectively. (C)-(D) 2-dimensional TSNE visualisation of in silico 
mouse observations with respect to time since administration and dose respectively. 
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Predicted value Potential range 
Time since administration [0-24h] 
Initial dose [0-600mg/kg] 
Table 2-4: Ranges of potential time since administration and initial dose values for virtual 
animals. 
 
 
 Dependent Variable 
(coefficient and related error) 
 
 Time (1) 
 
Dose (2) 
APAP Concentration -18.141*** 
(1.095) 
 
445.602*** 
(13.865) 
ALT concentration 2.402** 
(0.988) 
 
94.724*** 
(12.830) 
HMGB1 concentration -15.928*** 
(0.636) 
 
 
Full K18 concentration 8.964*** 
(0.837) 
 
241.527*** 
(12.958) 
Fragmented K18 concentration  310.574*** 
(13.260) 
 
Constant 14.812*** 
(0.268) 
 
67.068*** 
(3.193) 
Observations 
Residual Std. Error (df == 994) 
1,000 
3.593 
1,000 
56.805 
 
Note: *p<0.1; **p<0.05; ***p<0.01 
  
Table 2-5: Multiple linear regression analysis results. Summary statistics for models used 
to predict both time since administration and dose.  The first number in each element of the 
table represents the biomarker coefficient in the regression model, whilst the second number 
represents the coefficient’s corresponding error. For example, -18.141 is the APAP 
concentration coefficient in the model predicting time since administration, and this coefficient 
has an error of 1.095. The significance of each biomarker in the model is indicated by the 
number of asterisks (see note). 
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2.3.6.  Predicting the probability of liver injury 
From the forward-stepwise logistic regression analysis, it appeared that many 
panels of biomarkers could provide significant predictions of liver injury potential. As 
expected, the currently used panel (APAP and ALT) was significant (p-value 0.008). 
APAP alone was also significant at the same level (p-value 0.008). APAP and full 
K18 combined was also a significant panel (p-value 0.03). However, the model 
which used HMGB1 concentration alone as a predictor had the highest significance 
(p-value 0.003). 
Upon applying a binary logistic regression analysis in SPSS statistical software, the 
output was a logit equation based solely on HMGB1 concentration, 
  
𝐿𝑒𝑞  = 0.635[hmgb1] − 3.870. 
 
(2-53) 
This equation was substituted into a standard probability equation, resulting in the 
final liver damage probability equation used in our analysis, 
  
Probability of liver damage =
1
1 + e−𝐿𝑒𝑞
. 
 
(2-54) 
Figure 2-8 (A)-(F) represents the fold-changes in biomarker concentrations with 
respect to time following various doses. As expected, for higher doses, APAP and 
related toxicity biomarker concentrations were significantly increased during the 
time course, whilst conversely, GSH was significantly decreased, representing 
depletion of stores. Figure 2-8 (G) shows how the probability of serious liver injury 
(dependent only on HMGB1 concentration as predicted by the logistic regression 
model) changes over time for doses between 0-600 mg/kg. A threshold probability 
of 0.5 (i.e. 50% liver injury likelihood) was used to determine likeliness of DILI. Any 
observation within the white contour boundary was therefore predicted likely to be 
a concentration representative of liver injury (i.e. greater than 50% chance). For 
lower toxic doses, according to the model, HMGB1 concentrations that likely 
indicate liver injury were most apparent between 5 to 10 h post-dose. As the dose 
increased, HMGB1 concentrations appeared to remain higher for longer, and the 
time-frame for probable liver injury increased to approximately 5 to15 h.  
Currently, toxicity is thought to be apparent in mice after a 300 mg/kg dose, shown 
by the red line in Figure 2-8 (G). Application of our binary logistic regression model 
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(based solely on HMGB1 concentration) suggests that there is more than 50% 
chance of liver injury at a 200 mg/kg dose, shown by the white contour in Figure 2-8 
(G). The currently used toxic dose (300 mg/kg) coincided with around 90% GSH 
depletion which can be seen in Figure 2-8 (B). This toxicity threshold and GSH 
depletion level is  a relationship well known in the literature [97]. This toxic level was 
also the dose at which fragmented K18 elevations began, as shown in Figure 2-8 
(F). The toxic dose proposed by the in silico model (200 mg/kg) was the dose at 
which ALT and full K18 began to elevate (Figure 2-8 (C) and Figure 2-8 (E) 
respectively) and HMGB1 first reached peak concentration (Figure 2-8 (D)).  
With the aim to use biomarker concentrations to not only predict initial dose and 
time since ingestion, but also to get a quantitative prediction for probability of liver 
injury progression from one combined biomarker sample, the PCA/T-SNE analysis 
was combined with our proposed framework for predicting the probability of liver 
injury. Figure 2-9 shows the clear clustering of observations with biomarker 
concentrations that represent a high probability of liver injury (bottom left-hand 
corner of the parameter space). High probability cases were distinctively separable 
from low probability cases.   
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Figure 2-8: (A)-(F) Fold-changes in biomarker concentration relative to their baseline 
values over time [0-24] hrs for APAP, GSH, ALT, HMGB1, Full K18 and Fragmented K18 
respectively, following APAP doses ranging from 0-600 mg/kg. (G) Proposed framework 
for predicting probability of liver injury dependent upon dose, time and HMGB1 
concentration. The white contour indicates the threshold of probability 0.5 of liver injury, the 
red dashed-line represents currently used APAP dose for toxicity studies in mice, the white 
dashed-line represents toxic dose proposed by our model, the green dashed-line indicates 
current known therapeutic dose for mice. 
 
A 
C D 
E 
G 
F
F 
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Figure 2-9: Two-dimensional TSNE visualisation of in silico mouse observations with 
respect to estimated probability of liver injury. 
2.3.7.  Sensitivity analysis 
Whilst the results of the pre-clinical framework appear to be positive at this stage, it 
is important to think forward to translation. By determining sensitive parameters 
within the pre-clinical model structure, we can focus on ensuring we have 
confidence in these sensitive parameters at the translation stage. We therefore 
calculated time-dependent sensitivities of all model variables (APAP, GSH, ALT, 
HMGB1, Full K18 and Fragmented K18 concentrations) with respect to all model 
parameters using the sensitivity analysis tool in Mathworks’ Simbiology  [101].  
Details of the sensitivity analysis methodology can be found in Section 2.2.1.4. 
The results of the analysis in Figure 2-10 portray the level of sensitivity each of the 
in silico outputs has with regard to perturbations in each of the model parameters. 
With reference to Figure 2-10, we observe that any parameters deemed to be 
sensitive by this analysis also have small standard errors for the parameter 
estimates, providing confidence in the robustness of these predicted values. 
Although some parameters had greater standard error estimates e.g. 𝑘𝑝𝑟; and 𝑘𝑜, 
from the GSH model; the sensitivity analysis showed that these were not highly 
sensitive and therefore impact minimally on the outputs of the model.   
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Importantly, this sensitivity analysis allowed us to identify the most sensitive 
parameters which would potentially require most attention if translating this model 
to a human clinical Pop-PKPD framework. The most sensitive parameter was the 
baseline level of GSH, 𝑔𝑠ℎ0 (Figure 2-10). In addition to this parameter, the total 
APAP elimination rate, 𝑘𝑒𝑙 and the theoretical volume of the central compartment, 
𝑉𝑐 were also highlighted as being sensitive and so they should therefore be given 
special consideration when translating into the clinical context. For the PD element 
of the model, the proportion of CYP-activated APAP which is transformed into 
NAPQI, 𝜉, was also deemed sensitive. Since this quantity will be dependent on 
baseline GSH this result is not particularly surprising, and the importance of further 
investigation into this parameter has already been highlighted. Biomarkers ALT and 
Full K18 were identified as being sensitive to parameter changes. Biomarkers 
HMGB1 and Fragmented K18, however, were identified as being relatively less 
sensitive and more robust to parameter changes.  
 
Figure 2-10: Sensitivity analysis of the in silico model parameters – visualising the 
change in model output with regard to perturbations in model parameters. 
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2.4. Chapter discussion 
The current clinical framework for predicting whether or not APAP antidote treatment 
is necessary is highly dependent upon information provided by the patient such as 
when the dose was taken and in what quantity. This information is often vague 
and/or unreliable. Consequently, critically vulnerable patients are often left 
untreated or, conversely, NAC is unnecessarily administered. Changes in legislation 
have already led to an estimated increased cost of £8.3 million per year due to 
overused NAC treatment [24]. Within this chapter, we have used mathematical and 
statistical analysis to provide a proof-of-concept tool which has the ability of 
predicting individuals requiring treatment, based on a single measurement of 
biomarkers with improved sensitivity over those currently used within the clinic. 
Using a systems toxicology approach, we have developed an optimised PK-PD 
model for APAP and corresponding liver injury biomarkers. The model can be used 
to conduct various investigations within an APAP dosing range of 0-600 mg/kg 
without the requirement for further in vivo testing. Importantly, this provides greater 
scope for reducing the dependency on animal testing in toxicity and complying with 
3Rs principles [89]. A key result from our analysis could be used to refine 
experiments (i.e. our model proposed that toxicity in mice could be seen following 
any dose above 200mg/kg rather than the currently used 300mg/kg). That is, not 
only may experimentalists be dosing mice at amounts higher than necessary, they 
may also be missing vital information apparent at lower doses.  
We aimed to determine the most significant, and fastest responding biomarkers to 
be used in toxicity predictions. Currently, APAP-induced liver toxicity is thought to 
occur when GSH depletes by around 80-90% [97]. Our framework suggests that 
this coincides with elevated fragmented K18 levels. The in silico PD model, and its 
reported R50 values, suggest that levels of HMGB1, ALT and Full K18 elevate prior 
to this depletion level, elevating at 43%, 67% and 69% respectively. As a result, 
HMGB1 in particular could be considered as an earlier indicator of DILI. 
The identification of more accurate predictions of dose timing and amount, informed 
by biomarker concentration samples, will improve nomogram treatment line 
accuracy [20]. Predictions for the time since administration were successfully 
categorised into (0-2], (2-5], (5-10], (10-15], and (15-24] hour ranges based on 
APAP, ALT, HMGB1 and full K18 concentration values with 73.7% accuracy. Should 
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this framework be translated to a similar level of efficiency in the human clinical 
case, this information will have impact regarding the determination of the potential 
liver injury, with less dependency on patient information. Additionally, an exact time 
since overdose value was predicted with an accuracy of 3.6 h. Similarly, initial dose 
was able to be classified into [0-200], [201-400], [401-600] mg/kg categories with 
86.5% accuracy and an exact dose predicted with an expected error of ± 56.81 
mg/kg. A panel of biomarker measurements could be used in this manner to provide 
the dose and time information, which will identify a (time-dose) point on the liver 
injury framework, provided in Figure 2-8, from which one can read off an 
instantaneous probability of liver injury and how this probability is predicted to 
change as time progresses. Obtaining dose and time information based on 
biomarker concentrations and combining this with our proposed liver injury 
framework shows the utility of these biomarkers in predicting dose amount, time 
since ingestion and most importantly, the subsequent probability of liver injury.  
Although ALT concentration is currently used as a clinical measure to inform 
potential toxicity, it was found to have the least importance in the regression model 
for predicting time since administration and initial dose amount as continuous 
variables. Out of all the biomarkers used in the multiple linear regression analysis, 
HMGB1 was found to be the most predictive. This analysis suggests therefore, that 
not only is HMGB1 an earlier indicator of DILI, but it is also an important biomarker 
in accurately predicting the time elapsed since administration. Furthermore, logistic 
regression analysis identified HMGB1 as the most significant predictor for liver 
injury, in line with recent studies defining HMGB1 as a more sensitive DILI predictor 
[126]. As noted above, the focus of this chapter has been the biomarkers that work 
well for DILI prediction due to APAP with the aim to provide an improved proof-of-
concept framework. HMGB1 is highlighted by our analysis as the most important in 
DILI prediction.  
The pre-clinical framework proposed within this chapter has the potential for 
substantial clinical impact once translated to human. The analysis was applied to 
mice due to the relative abundance and quality of data (especially for toxicity cases) 
and the quantity of relevant biomarker data required to properly characterise such 
a mathematical and statistical predictive framework. The aim within this chapter, 
was to investigate the utility of the panel of biomarkers in DILI prediction, and to 
determine whether or not they warrant investigation in a human clinical study. Prior 
to translation to human studies, identifying sensitive parameters within the model is 
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vital. From our sensitivity analysis, the most sensitive parameter was the baseline 
level of GSH, 𝑔𝑠ℎ0 (Figure 2-10). Since this value was based on experimental 
estimates in this study [125], we are confident that the results are robust for the 
mouse situation. However, this parameter is clearly of importance for the predictivity 
of this model structure so will need to be of particular focus when translating to the 
clinical case. Additionally, biomarkers ALT and Full K18 were identified as being 
sensitive to parameter changes, highlighting the need for sufficiently dense data for 
these biomarkers if they are to be used in a translated human model. Our clinical 
research is discussed in Chapter 5.  
An advantage of the framework proposed in this chapter is that the same biomarkers 
can be measured in both humans and animals via the same methodologies. 
Moreover, the model hepatotoxin we have employed, APAP, is directly comparable 
between human and mice with respect to both the toxicity mechanism and the action 
of the antidote, NAC. Taking these points into consideration, in its current form, our 
framework is highly predictive and provides promise for clinical use in discriminating 
time since administration, initial dose amount and subsequent probability of liver 
injury. This would be a significant application and could instruct the determination of 
NAC intervention in patients suspected of APAP overdose. In the next chapter, we 
carry out an uncertainty analysis on our model framework to study the robustness 
of its predictions and quantify any parameter uncertainties. 
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Chapter 3: A pre-clinical systems 
toxicology framework – Improving 
the confidence, biological 
relevance and clinical application 
potential  
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3.1. Background 
In Chapter 2, we describe a modelling framework that uses a single sample 
approach to biomarker quantification (rather than the multiple sample approach 
currently required within the clinic) with the aim of predicting the probability of liver 
injury. The research in Chapter 2 identifies which biomarkers are the most significant 
in the prediction of liver injury, and provides a framework which, if extended to the 
human case, would be easily interpretable for clinicians, increasing the 
effectiveness of APAP overdose treatment. 
However, something which must be crucially noted, is that the utility of a 
mathematical model is limited by assumptions which are often necessary for 
simplification. This is due to mathematical models being an abstract representation 
of the true biology.  Consequently, there are often multiple aspects of a model that 
potentially contain uncertainty. Not all states of a dynamical model can be directly 
measured experimentally, and conversely, not all experimental data may be useful 
for model calibration, since the data itself may contain errors not accounted for by 
the model. These limitations can raise skepticism around the employment of model 
predictions. While it would be unrealistic to attempt to completely eradicate every 
level of error, it is crucial that any parameter uncertainties should be assessed, 
reported and minimised in order for model predictions to be truly useful [46]. There 
are many existing and developing techniques to quantify uncertainty, and the 
chosen method often depends on the aims of the model. For example, if there is a 
small level of uncertainty in parameters and the model of interest is relatively simple, 
a local sensitivity analysis may be sufficient (perturbing parameters individually and 
monitoring changes in output) [127]. For larger models, where parameters are 
reasonably known within some sort of range, Monte-Carlo (MC) probabilistic 
methods are usually the first method of choice, particularly in the health and 
environmental sectors [128]. The most highly used probabilistic method for 
stochastic inverse problems (attempting to estimate original parameters from noisy 
data) is Bayesian inference [129]. If both the structure of the model, and the data 
used in optimisation require testing for uncertainty, identifiability analysis can be 
employed to determine whether model parameters can be uniquely identified based 
upon the structure of both the model and data used [130]. 
In this chapter, we aim to quantify any uncertainties in the model defined in Chapter 
2 with the following ideas in mind: APAP is predominantly metabolised in the liver 
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via glucuronidation and sulfation pathways, with a small fraction being oxidised into 
the toxic metabolite, NAPQI; and detoxification of NAPQI occurs via conjugation 
with hepatic stores of glutathione (GSH) [28]. Therefore, although initial dose and 
time since ingestion are known to be the most important indicators of overdose 
severity level, additional factors affecting an individual’s ability to synthesise or 
maintain sufficiently high levels of GSH should also be considered [10]. Such factors 
may include age, pre-existing liver disease, concurrent use of alcohol and/or other 
liver-metabolised medications, genetic predispositions and acuity/chronicity of 
APAP use [5]. In 1981 the FDA recommended the original nomogram line should 
be reduced by 25% to account for potentially high-risk patients/measurement errors 
[9].  
The model defined in Chapter 2 optimises parameters by fitting to fed-mouse data 
and therefore is analogous to applications relating to individuals with unimpaired 
clearance capacity. Through the application of an identifiability analysis technique, 
in this chapter we identify areas within the model structure that require improvement 
and use this knowledge to make the structure more relevant to the current APAP 
toxicity clinical environment. There are many other in silico models that focus on 
describing and understanding APAP-induced toxicity (as described in Chapter 1). 
However, there is currently only one in silico APAP model which takes into 
consideration individuals that may have depleted GSH stores. Navid et al. (2013) 
define a multi-compartmental PBPK model of APAP metabolism, with the aim of 
understanding how nutritional deficiencies and certain lifestyle choices (such as 
alcohol consumption) may affect GSH regeneration [81]. Whilst they focus on how 
various factors may affect GSH synthesis, their model does not extend to how 
depleted GSH stores can subsequently alter toxic effects. Within the mathematical 
model defined in this chapter, we account for the fact that certain factors may affect 
GSH regeneration, but we also model how toxic effects may differ in individuals with 
both normal/suppressed GSH restoration ability.  
This chapter provides an extension to our modelling approaches defined in Chapter 
2, this time quantifying the effects of various factors impacting upon GSH availability. 
The mathematical model is refined using techniques from uncertainty analysis to 
account for mechanistic changes indicative of suppressed GSH capacity, and 
optimised against additional data to improve its scope and predictive potential. 
Crucially, the availability of GSH is known to be heavily dependent on the nutritional 
level of a patient. When optimising against additional data, we therefore choose to 
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include fasted mouse data to reflect this. The model defined in this chapter provides 
predictions of initial dose, time since ingestion and probability of liver injury for both 
healthy and high-risk populations, with a much greater level of confidence than the 
predictions provided in Chapter 2. 
Chapter aims 
 Carry out identifiability analysis on the model framework defined in Chapter 
2 to determine areas of uncertainty. 
 Refine the model structure dependent on results from identifiability analysis, 
and optimise against additional data where necessary. 
 Provide an improved model framework which is more biologically relevant, 
and which cannot only make predictions for the general individual, but also 
for individuals who are already deemed high risk. 
3.2. Methods 
3.2.1. Experimental data description 
The mathematical model in this chapter was parameterised against multiple 
experimental datasets. For the APAP PK element of the model, four datasets from 
two separate published studies [25, 26] recording APAP concentration over time in 
mice following intraperitoneal administration of  50, 150, 500 and 530 mg/kg doses 
were used for optimisation of both the framework defined in Chapter 2 and the 
framework defined within this chapter. For the biomarker PD element of the model, 
in Chapter 2, one experimental dataset was used during parameter optimisation [39] 
which recorded biomarkers (GSH, ALT, HMGB1, full and fragmented K18) over time 
following a 530 mg/kg APAP dose. In this chapter, this dataset was also used for 
optimisation of the PD model parameters, but with the addition of two other datasets 
from two separate studies by Antoine et al. and Mason et al. [35,131]. The first, [35], 
provided biomarker concentrations GSH, ALT, HMGB1, full and fragmented K18 at 
5 and 24 hours for both fed and fasted mice following a 530 mg/kg APAP dose. The 
second, [131], provided dose-response data for mouse biomarker concentrations 
GSH, ALT, HMGB1 and fragmented K18 at 5 hours following APAP doses 
[0,150,300,530,750,1,000] mg/kg. 
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3.2.2. Identifiability analysis 
Identifiability analysis was performed to visualise changes in the sum of squared 
errors (SSE) following parameter perturbations and, subsequently, to determine the 
identifiability of each parameter in the model. Since expertise around this 
methodology was not available at my home institution, I used funding from the LJMU 
International Mobility Award, obtained in 2017, to fund an uncertainty analysis 
training placement at the Freiburg Institute for Advanced Studies (FRIAS). I spent 
two weeks with Professor Jens Timmer’s research group, who introduced me to the 
methodology and applications of identifiability analysis; particularly, the profile 
likelihood approach they had developed [130]. Within this chapter, we apply a 
method of identifiability analysis similar to the profile likelihood approach defined by 
the (FRIAS) research group. Parameter estimates are either deemed identifiable, 
practically unidentifiable, or structurally unidentifiable [132]. During this analysis, 
each individual parameter was tested separately for identifiability. This “test 
parameter” was varied by 20% intervals (from -50% to +200% of its original value). 
In each iteration, the modified test parameter was fixed, while all the other 
parameters in the model were varied in two ways: either fixed at the optimum values 
(as found from previous multi-start optimisation); or randomly sampled from a Latin 
hypercube (bounds for sampling can be found in section 3.2.4 of this chapter). For 
each test parameter iteration, the parameter set corresponding to the lowest SSE 
value was then identified. During both sensitivity and identifiability analyses, model 
parameters are perturbed and subsequent changes in model output are studied. 
However, parameters are not re-optimised during sensitivity analysis. Identifiability 
analysis seeks to determine whether distinct model parameterisations could provide 
the same model solution. 
Examples of each resultant case for a parameter (identifiable, practically 
unidentifiable, structurally unidentifiable) can be visualised in Figure 3-1. Similar to 
the profile likelihood approach, an identifiable parameter is defined as a parameter 
which, when perturbed from its initial (optimal) value (both positively and negatively), 
results in an increased SSE and therefore predicts a greater error between the 
model output and the data. If the SSE increases on only one side (i.e. in the positive 
or negative direction) of the test parameter, and remains relatively unchanged on 
the other side, this parameter is defined as practically unidentifiable; that is, either 
increasing or decreasing the test parameter value causes an increased error 
between the model output and the data. However, since the error between model 
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output and data reduces as we head towards the test parameter, but then remains 
relatively unchanged for further perturbations in that direction, we cannot be 
confident that the parameter is uniquely optimal, since there are multiple values that 
provide the same approximate SSE. Since the optimum path does change in one 
direction, however, we have confidence that we are capturing some of the structure, 
and often these kind of ‘practical unidentifiabilities’ can be resolved by including 
more calibration data [130]. If the SSE value does not change either side (i.e. in the 
positive or negative direction) of the original test parameter value, this parameter is 
known as structurally unidentifiable. This means that parameter optimisation via 
data-fitting is relatively insensitive to the choice of this parameter; the parameter 
cannot be uniquely determined and therefore even if removed entirely, values of 
other parameters could be suitably adjusted to compensate for the change in the 
model structure.  
 
Figure 3-1: Identifiability definitions in relation to parameter perturbations and 
corresponding minimum SSE profile. As a parameter is perturbed (in both the positive and 
negative direction), if the minimum SSE increases, this parameter will be deemed identifiable. 
If the minimum SSE only increases in response to parameter changes in one direction (either 
negative or positive) this parameter is deemed practically unidentifiable. If a parameter is 
changed in both the positive and negative direction, and there is no corresponding change in 
the minimum SSE, this parameter is deemed structurally unidentifiable. 
3.2.3. Model refinement 
3.2.3.1. APAP pharmacokinetic model 
The PK model structure remained unchanged from the model defined in Chapter 2 
(see equations (2-1) and (2-2)), but is summarised below for completeness. Two 
ordinary differential equations (ODEs) were used to represent changes in APAP 
concentration within two PK compartments (central and peripheral) in the following 
system, 
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 𝑑[Cc]
𝑑𝑡
=
𝑘𝑎𝐷0𝑒
−𝑘𝑎𝑡
𝑉𝑐
+ 𝑘21[Cp]
𝑉𝑝
𝑉𝑐
− 𝑘12[Cc] − 𝑘𝑒𝑙[Cc], 
(3-1) 
 
 𝑑[Cp]
𝑑𝑡
=  𝑘12[Cc]
𝑉𝑐
𝑉𝑝
− 𝑘21[Cp], 
(3-2) 
 
where, as in Chapter 2, [Cc] is the central compartment concentration (mol/l) of 
APAP, [Cp] is the peripheral compartment concentration (mol/l) of APAP, and 𝑘𝑎 
represents the absorption rate (h-1) from where APAP is administered (the peritoneal 
cavity in this case). The initial dose (mol/kg) is given by 𝐷0, 𝑘21 represents the 
transfer rate (h-1) from peripheral to central compartment, 𝑘12 represents the transfer 
rate (h-1) from central to peripheral compartment, 𝑉𝑝 is the theoretical volume (l/kg) 
of the peripheral compartment, 𝑉𝑐 is the theoretical volume (l/kg) of the central 
compartment, 𝑘𝑒𝑙 represents the overall elimination rate (summation of excretion 
and metabolism processes) (h-1), and 𝑡 represents the time variable (h).  
3.2.3.2. Pharmacodynamic models 
In Chapter 2, the pharmacodynamic (PD) element of the model was parameterised 
using a dataset consisting of GSH and biomarker (ALT, HMGB1, full and fragmented 
K18) time-course concentrations following a 530 mg/kg intraperitoneal APAP dose 
[39]. In this chapter, we extended this optimisation to also include dose-response 
data consisting of plasma biomarker concentrations at 5 hours following APAP 
doses ranging from 0-1,000 mg/kg [131] and a dataset consisting of biomarker 
concentrations at 5 and 24 hours for both fed and fasted mice following a 530 mg/kg 
APAP dose [35]. This extension was necessary in order to account for differing 
mechanisms of cell death, i.e. apoptosis versus necrosis, and also to account for an 
increased dosing range more representative of the clinical environment. 
Glutathione depletion dynamics 
As in Chapter 2, paracetamol toxicity biomarker dynamics were assumed to be 
directly dependent on GSH depletion; i.e., during APAP overdose cases when GSH 
pools deplete, NAPQI accumulates, potentially leading to liver toxicity and 
associated biomarker release. The GSH model component remained identical to 
the model previously defined in Chapter 2 (see equation (2-25)), namely: 
𝑑[gsh]
𝑑𝑡
= 𝑘𝑜(𝑔𝑠ℎ0 − [gsh]) −
𝜉𝑘𝑒𝑙[Cc][gsh]
[gsh] + 𝑘𝑝𝑟
 , 
(3-3) 
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where, as in Chapter 2, 𝑘𝑜 is the basal removal rate (h
-1) of GSH (including 
background usage), 𝑔𝑠ℎ0 is the baseline concentration (mol/l) of GSH in the APAP-
free steady state, 𝜉 is the proportion of eliminated APAP that is transformed into 
NAPQI, 𝑘𝑒𝑙 is the APAP elimination rate, 𝑘𝑝𝑟 can be thought of as the proportion of 
NAPQI forming other protein adducts, relative to being detoxified by GSH, although 
the parameter represents the GSH concentration at which GSH degradation due to 
binding with NAPQI has reached 50% of its maximal value (mol/l). The term 
[gsh] represents the concentration (mol/l) of GSH. Further details on the derivation 
of this GSH model can be found in Chapter 2. For the fasted case, basal GSH 
dynamics are modified to simulate a delay in GSH repletion due to depleted co-
factors stemming from the reduced food intake. These slower dynamics are 
incorporated by rescaling 𝑘𝑜 by an additional parameter, 𝛿 < 1 (so that 𝑘𝑜 becomes 
𝛿𝑘𝑜 < 𝑘𝑜). That is, the GSH model for the fasted case is now defined below: 
 
𝑑[gshf]
𝑑𝑡
= 𝛿𝑘𝑜(𝑔𝑠ℎ0 − [gshf]) −
𝜉𝑘𝑒𝑙[Cc][gshf]
[gshf] + 𝑘𝑝𝑟
 . 
(3-4) 
 
  
ALT and HMGB1 dynamics 
Following an APAP overdose, the toxic response of biomarkers ALT and HMGB1 
were mathematically modelled in the same way as the framework detailed in 
Chapter 2, namely: 
𝑑[r]
𝑑𝑡
= 𝑟0𝑘𝑜𝑢𝑡 (
𝑅50
𝑛 + 𝑔𝑠ℎ0
𝑛
𝑅50
𝑛 )(1 −
𝑔𝑚𝑎𝑥[gsh]
𝑛
𝑅50
𝑛 + [gsh]𝑛
) − 𝑘𝑜𝑢𝑡[r], 
(3-5) 
 
where, as in Chapter 2, [r] is the biomarker concentration (mol/l), 𝑟0 is the 
respective biomarker baseline (mol/l), 𝑘𝑜𝑢𝑡 is the natural decay rate (h
-1) of the 
biomarker, 𝑅50 represents the concentration (mol/l) of (GSH) at which the 
biomarker response to GSH is half its maximal rate, and 𝑛 is a Hill coefficient 
indicating the steepness of the biomarker response [100]. Parameter 𝑔𝑚𝑎𝑥 is a new 
addition to this model and represents the maximal regulatory effect of GSH on 
biomarker production. In the fed case, we set 𝑔𝑚𝑎𝑥 = 1 such that GSH depletion is 
solely responsible for augmented biomarker production and therefore for the APAP-
free steady state, the biomarker is only produced at low, basal levels maintaining 
the background steady state value, 𝑟0. For the fed case, this element of the model 
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was therefore identical to that employed in Chapter 2. However, experimental 
observations showed that background biomarker levels were higher for fasted 
animals. We therefore allowed 𝑔𝑚𝑎𝑥 < 1 in the fasted case to account for these 
higher background values.  
K18 dynamics 
Keratin-18 (K18) is an intermediate filament protein expressed in abundant levels in 
hepatocytes [39]. This protein undergoes caspase-mediated cleavage during 
apoptosis, resulting in the release of fragmented K18 upon cell death [133]. This 
feature makes K18 a useful biomarker to distinguish between apoptosis and 
necrosis as the presence of full (as opposed to fragmented) K18 instead suggests 
the occurrence of necrosis [134]. Full and fragmented K18 were therefore modelled 
in this chapter as necrotic and apoptotic forms of the same single biomarker, K18. 
However, we could not find sufficient data for K18 to parameterise a model of the 
form shown in equation (3-5) for both full and fragmented K18. We were limited to 
data for full K18 following a 530mg/kg APAP dose; although we had access to dose-
response data spanning a wide range of doses for biomarkers ALT, HMGB1 and 
fragmented K18, this was unavailable for full K18 at the time of investigation. We 
therefore adopted a simple form of dynamics for K18 using piecewise linear 
representations of the non-linear terms in (3-5) , as illustrated in Figure 3-2. That is, 
the dynamics of the necrotic marker, full K18, were modelled in the following way,   
𝑑[k18]
𝑑𝑡
= 𝑟0
18𝑘𝑜𝑢𝑡
18 + 𝑘𝑚a𝑥𝑘𝑖𝑛
18𝐻(𝑔𝑠ℎ𝜃2 − [gsh]) − 𝑘𝑜𝑢𝑡
18 [k18], 
(3-6) 
 
where 𝑟0
18 is the baseline concentration (mol/l) of full K18; the natural decay rate 
of the biomarker is represented by 𝑘𝑜𝑢𝑡
18 ; the production rate of the biomarker is 
represented by 𝑘𝑖𝑛
18; the GSH threshold below which additional K18 production is 
induced due to cell death is represented by 𝑔𝑠ℎ𝜃2; the concentration of full K18 
(mol/l) is represented by [k18]; and 𝑘𝑚𝑎𝑥 is a measure of the production capability 
of full K18 (0<𝑘𝑚𝑎𝑥<1); since there is a finite quantity of cells, there is a maximum 
amount of biomarker that can be produced. In the fed case, we take 𝑘𝑚𝑎𝑥 = 1. Since 
fasting in mice causes extensive cell loss at early time points [35], the amount of 
biomarker able to be produced from a smaller amount of cells will therefore be 
smaller. To account for this, in the fasted case, we allowed  𝑘𝑚𝑎𝑥 < 1.  The Heaviside 
function 𝐻(𝑥) = 1 when 𝑥 ≥ 0 whereas 𝐻(𝑥) = 0 when 𝑥 < 0. 
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Figure 3-2: Relationship between full and fragmented K18 biomarker production and GSH 
concentration. Black lines represent the full K18 relationship, and red lines represent the 
fragmented K18 relationship (solid lines represent the fed case and dashed lines represent the 
fasted case). As GSH depletes from baseline, 𝑔𝑠ℎ0, and reaches a certain threshold, 𝑔𝑠ℎ𝜃2, 
production of full and fragmented K18 begins. Full K18 production continues for any GSH 
concentration below this threshold, however, fragmented K18 production ceases beyond a GSH 
concentration of 𝑔𝑠ℎ𝜃1 in the fed case and 𝑔𝑠ℎ𝜃1 + 𝜀 in the fasted case. 
 
Similarly, the dynamics of fragmented K18 were modelled in the following way,  
𝑑[fk18]
𝑑𝑡
= 𝑟0
𝑓18𝑘𝑜𝑢𝑡
𝑓18 + 𝑘𝑖𝑛
𝑓18 (𝐻([gsh] − 𝑔𝑠ℎ𝜃1 − 𝜀) − 𝐻([gsh] − 𝑔𝑠ℎ𝜃2))
− 𝑘𝑜𝑢𝑡
𝑓18[fk18], 
(3-7) 
 
Where [fk18] is the concentration (mol/l) of fragmented K18,  𝑟0
𝑓18
 is the baseline 
concentration (mol/l) of fragmented K18; the natural decay rate (h-1) of the 
biomarker is represented by 𝑘𝑜𝑢𝑡
𝑓18
, the production rate of the biomarker (h-1) is 
represented by  𝑘𝑖𝑛
𝑓18
 is the production rate, the GSH threshold below which 
augmented production of fragmented K18 production is initiated is represented by 
𝑔𝑠ℎ𝜃2, and the GSH threshold below which augmented production ceases due to a 
switch from apoptosis to necrosis is represented by  𝑔𝑠ℎ𝜃1. Since there is this switch 
from apoptosis to necrosis, we do not need a parameter within this model to 
represent the maximum production capability of fragmented K18 (𝑓𝑘𝑚𝑎𝑥); as 
extensive cell loss occurs, the mode of cell death switches from apoptosis to 
necrosis, and therefore production of apoptosis will completely cease. For the fed 
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case, production begins at the GSH concentration represented by 𝑔𝑠ℎ𝜃2(mol/
l)  and ceases at the GSH concentration represented by 𝑔𝑠ℎ𝜃1(mol/l). For the 
fasted case however, necrosis will be more apparent than apoptosis, and less GSH 
depletion will be required before apoptosis is no longer sustainable. To account for 
this, 𝜀 represents the change in GSH threshold denoting the switch to necrosis, i.e., 
𝜀 = 0 in the fed case and 𝜀 > 0 in the fasted case.  
 All initial conditions for this PKPD model are detailed in Table 3-1. The fed and 
fasted models will begin at different initial conditions. Lack of nutrition is known to 
have effects on GSH synthesis levels [81], therefore, even with no APAP present, 
GSH concentration is likely to be depleted at time 0. Since the biomarkers within our 
model are directly dependent on GSH depletion, this will in turn result in higher 
baseline levels for the biomarkers in the fasted case when compared to the fed case. 
Although our fed and fasted biomarker models begin at different concentrations, 
since food was re-introduced to the mice used in the experiments for optimisation, 
the biomarker profiles will eventually return to the fed steady-state. 
Model initial conditions 
Variable Initial condition (Fed 
case - 𝜇mol/l) 
Initial condition 
(Fasted case - 
𝜇mol/l) 
[Cc]  0 0 
[Cp]  0 0 
[gsh]  559.47497 374.0909 
[alt]  0.7626 0.9528 
[hmgb1]  0.0005 0.0007 
[fullk18]  0.0088 0.0113 
[fragk18]  0.0977 0.1634 
Table 3-1: Model initial conditions. Initial conditions for each variable within the dynamical 
system. For the fed case, the initial condition for GSH is an optimised value, found by fitting the 
fed GSH model to 3 different datasets for fed mice dosed with APAP [35,39,131]. The initial 
conditions for ALT, HMGB1, full K18 and fragmented K18 are fixed as the average of the control 
values for each respective biomarker in the fed case from each study  [35,39,131]. For the fasted 
case, the initial conditions for GSH ALT, HMGB1, full K18 and fragmented K18 are fixed as the 
average of the control values for each respective biomarker in the fasted case from Antoine et 
al.’s study [35]. 
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3.2.4.  Parameter optimisation 
A multi-start technique was applied during parameter optimisation in an attempt to 
find the globally optimal parameter set following refinement of the original model. All 
dynamical models were optimised by minimising the sum of squared errors (SSE) 
between model simulated output and experimental data (Fminsearch, Matlab [96]). 
As described in Chapter 2, the Matlab minimisation function uses a Nelder-Mead 
search algorithm to iteratively search the parameter space until a local minimum is 
found [95]. Although the algorithm is a local minimiser, Latin hypercube sampling 
(LHS) was used to generate 1,000 different initial estimates for each parameter. 
Ranges for the bounds of each parameter are defined in Table 3-2. 
3.2.5. Virtual population simulation 
Model predictions were made for three virtually simulated populations: healthy, high-
risk, and a mixture of healthy and high-risk individuals. Healthy populations were 
based on biomarker concentrations simulated with parameter values derived from 
the fed mouse data. High-risk populations were based on biomarker concentrations 
simulated with parameter values derived from fasted mouse data. The mixed 
population was based on a weighting of the biomarker concentrations simulated with 
parameter values derived from fed/fasted data, with respect to the proportion of 
healthy/high risk patients that are seen in the clinic. Namely, Craig et al. [135] 
analysed overdose patterns in 663 patients over 16 years and found that 42.3% 
patients had psychiatric history, 45.3% had alcohol abuse, and 44.7% combined the 
overdose with alcohol. We take the mean of these values (44.1%), and in line with 
this, in our mixed population case, 44.1% of the population were assumed to be 
high-risk and 55.9% were assumed to be healthy.  
As in Chapter 2, each virtual population dataset consisted of 1,000 independent and 
individually distributed in silico individuals. Within this chapter, the in silico mice were 
administered a random dose selected from a uniform distribution of range 0-1,000 
mg/kg. As in Chapter 2, biomarker concentrations were subsequently extracted at 
a random time-point from a uniform range between 0-24 hours. Simulated 
concentrations were normalised in the range [0,1] using the min-max normalisation 
method [103] to account for varying orders of magnitude. As in Chapter 2, 
experimental noise was replicated in the in silico data by applying observed in vivo 
standard deviations in biomarker concentrations from an APAP study performed by 
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Antoine et al. (2009) (ALT s.d = 11.22, HMGB1 s.d = 0.00097, K18 s.d = 2.39, 
fragmented K18 s.d = 0.12 mol/l). 
Latin Hypercube Sampling (LHS) parameter bounds 
Model Parameter Lower bound Upper bound 
PK 𝑘a (h
-1) 0 20 
𝑉𝑐 (l/kg) 0 1 
𝑉𝑃 (l/kg) 0 1 
𝑘12 (h
-1) 0 1 
𝑘21 (h
-1) 0 10 
𝑘𝑒𝑙 (h
-1) 0 1 
GSH 𝑔𝑠ℎ0 (mol/l)  0 700 
𝑘𝑝𝑟  0 100 
𝜉  0 1 
𝑘𝑜 (h
-1) 0 1 
𝛿 (h-1) 0 1 
ALT 𝑛  1 6 
𝑅50 (mol/l) 0 700 
 
𝑘𝑜𝑢𝑡 (h
-1) 0 1 
gmax  0 0.99998 
HMGB1 𝑛  1 3 
𝑅50 (mol/l) 0 700 
 
𝑘𝑜𝑢𝑡 (h
-1) 0 1 
𝑟gmax  0 1 
K18 𝑘𝑖𝑛
18 (h-1) 0 6 
𝑘𝑜𝑢𝑡
18  (h-1)  0 1 
𝑘𝑚𝑎𝑥  0 1 
𝑔𝑠ℎ𝜃2 (mol/l) 0 700 
f-K18 𝑘𝑖𝑛
𝑓18
 (h-1) 0 6 
𝑘𝑜𝑢𝑡
𝑓18
 (h-1)  0 1 
𝑔𝑠ℎ𝜃2 (mol/l) 0 700 
𝑔𝑠ℎ𝜃1 (mol/l) 0 700 
𝜀 (mol/l) 0 100 
Table 3-2: Parameter bounds used for Latin Hypercube Sampling of initial estimates for 
the parameter optimisation. For each parameter within the mathematical model, initial 
estimates for parameter optimisation were chosen through Latin hypercube sampling. The lower 
and upper bounds for each parameter in this Latin hypercube is detailed. 
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3.2.6. Predicting time since administration and initial dose 
as continuous variables 
To test the use of biomarkers in predicting time since administration and initial dose 
separately, multiple linear regression analysis was applied to the in silico derived 
data, as in Chapter 2 (section 2.2.2). As described in Chapter 2, there are various 
assumptions that should be tested in order for multiple linear regression analysis to 
be applied. As a reminder, the key assumptions are: 
 The outcome variable is measured on a continuous level; 
 One or more of the predictor variables are continuous, ordinal or 
nominal; 
 Observations must be independent; and 
 Multi-collinearity/Outliers/highly influential points should not be 
present in the observed data.  
All of these assumptions held for the in silico derived data from this chapter. 
An additional assumption of multiple linear regression is: 
 Residuals should be approximately normally distributed; a histogram 
and normal P-P plot of the standardized residuals in the models 
predicting both time since administration and initial dose were 
inspected. Results for the ‘healthy’ dataset are shown in Figure 3-3, 
but results were similar in the ‘average’ and ‘high-risk’ datasets. 
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Figure 3-3: Data diagnostic plots. (A, C) Histogram – Visualisation of how the standardized 
residuals are distributed for the models predicting time since administration and initial dose 
respectively. For data to be diagnosed as normally distributed, the mean value should be 
approximately 0 and the standard deviation should be approximately 1. (B, D) Normal P-P plot 
of regression standardised residual for the models predicting time since administration and initial 
dose respectively. The cumulative probability expected from the model is plotted against the 
observed cumulative probability. For the data to be diagnosed as approximately normally 
distributed, most results (circles) should lie along the diagonal line. 
3.2.7.  Visualisation 
For each in silico individual, as in Chapter 2, the t-Distributed Stochastic Neighbour 
Embedding (T-SNE) method [104] was applied to visualise the dataset constituted 
by the aforementioned variables (APAP, GSH, ALT, HMGB1, K18, fragmented 
K18). Two-dimensional scatter plots of the embedded data were employed in order 
to examine class structure and separability whilst retaining model variation. For a 
more detailed description of the TSNE method, please refer to section 2.2.2 
(Chapter 2). 
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3.2.8.  Classification 
In order to test the predictive potential of biomarker concentrations, critical ranges 
for predicting time since administration were defined as (0-2], (2-5], (5-10], (10-15] 
and (15-24] hours. For dose, the ranges were [0-200], [201-400] and [401-1,000] 
mg/kg, capturing therapeutic, small, and large (overdoses), respectively. The same 
classification techniques applied in Chapter 2 were applied and compared here. 
Please refer to section 2.2.2 (Chapter 2) for a more detailed description of each 
technique. 
3.2.9.  Predicting the probability of liver injury 
The binary logistic regression framework described in Chapter 2 has been recently 
published [131]. The framework uses experimental biomarker time-course data, 
predicting a corresponding histology score for each mouse. When developing the 
framework, the whole panel of biomarkers (ALT, HMGB1, full and fragmented K18) 
were tested, and the analysis found HMGB1 concentration to be the most significant 
in predicting the probability of liver injury. The resultant logistic regression model 
was used within this chapter, in combination with PK-PD model simulations (from 
the newly refined model) to predict the drug-induced liver injury (DILI) probability.  
3.3. Results 
3.3.1.  Identifiability analysis – original model (defined in 
Chapter 2) 
In order to determine the robustness of the parameter set defined for our previous 
model (Chapter 2), we carried out an identifiability analysis on the model framework. 
This analysis allowed us to determine whether the parameters we proposed were 
unique within our system, helping to analyse whether or not these parameters are 
in fact representative of the mechanisms we desire. Additionally, the analysis 
provided information that allowed us to determine whether sufficient data had been 
included in the parameter optimisation, ensuring the parameters can be defined with 
confidence. Parameters in the model structure (defined in Chapter 2) were 
individually perturbed to visualise resultant differences between model output and 
experimental data. These changes were assessed to determine the identifiability of 
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each parameter in the original model structure. As seen in Figure 3-4, 10 out of 21 
parameters were identifiable. The ALT component of the model was identifiable, 
and all but one of the parameters in the PK component were identifiable. However, 
the HMGB1 component of the model was structurally unidentifiable, and practical 
unidentifiabilities exist in all other elements of the model. Five parameters were 
concluded to be practically unidentifiable. There were 3 practical unidentifiabilities 
within the GSH component: the ratio of NAPQI forming other protein adducts relative 
to being detoxified by GSH (𝑘𝑝𝑟), the proportion of eliminated APAP that is 
transformed into NAPQI (𝜉), and the basal removal rate of GSH (𝑘𝑜). The remaining 
practical unidentifiabilities were found within the K18 and fragmented K18 
components of the model: the decay rate of full K18 (K18−𝑘𝑜𝑢𝑡), and the fragmented 
K18 Hill coefficient (fragmented k18 - 𝑛). The remaining 6 parameters were 
structurally unidentifiable. These included the theoretical volume of the peripheral 
compartment (𝑉𝑝) from the PK component and all parameters from the HMGB1 
component:  the Hill coefficient (HMGB1 - 𝑛), the GSH concentration at which the 
augmented production rate of HMGB1 reaches 50% of its maximum (HMGB1 - 𝑅50), 
and the decay rate (HMGB1 - 𝑘𝑜𝑢𝑡). Two out of three parameters within the 
fragmented K18 component were structurally unidentifiable: the GSH concentration 
at which the augmented production rate of fragmented K18 reaches 50% of its 
maximum (fragmented K18 - 𝑅50), and the decay rate (fragmented K18 - 𝑘𝑜𝑢𝑡). 
3.3.2. Model refinement 
Following model refinement and re-parameterisation against the multiple datasets 
(increased dose range and fasted data), we identified a number of parameter 
adjustments. In cases where parameters are common to both model structures, 
percentage changes in their optimised values following re-parameterisation are 
shown in Table 3-3. The baseline level of GSH, 𝑔𝑠ℎ0, was optimised against the 
data in the new model structure, rather than fixed as in the previous model (Chapter 
2). The resultant value reduced by almost 20% to 559.47 mol/l. The proportion of 
CYP-activated APAP that is transformed into NAPQI, 𝜉, increased to around 80%, 
but there was also an increased level of NAPQI detoxification resulting from the re-
parameterisation (represented by a 22.1% decrease in parameter 𝑘𝑝𝑟, the ratio of 
NAPQI forming other protein adducts relative to detoxification). The new parameter, 
𝛿, incorporated an effective delay in GSH repletion in the fasted case due to 
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depleted co-factors. The optimised value was 0.0483 and considerably reduced the 
timescale of GSH dynamics in the fasted case.   
 
 
Figure 3-4: Identifiability analysis of the model structure defined in Chapter 2. Each test 
parameter is fixed at 20% intervals, and the other parameters in the model are allowed to vary. 
The percentage change of resultant optimised function values (SSE) are plotted at each interval 
(on log-scale). The lowest SSE change is represented by white; darker colours show an 
increase in SSE change. The highest SSE change is represented by black. Blue dashed bounds 
indicate where the parameter is identifiable at the 0.5% level. Red bounds indicate where the 
parameter is identifiable at the 1% level. A parameter is identifiable at the 1% level if it is 
bounded by red in both the positive and negative parameter-change directions. If the parameter 
is bounded by red in one direction and blue in the other direction, it is identifiable at the 0.5% 
level but practically unidentifiable at the 1% level. A parameter is practically unidentifiable if it is 
bounded by red/blue in either the positive or negative parameter change direction, and 
unbounded in the opposite direction. A parameter is structurally unidentifiable if it is unbounded 
in both positive and negative parameter-change directions (no red/black bounds exist for the 
whole range of parameter changes). For example (ALT- 𝑹𝟓𝟎) is identifiable at the 1% level, 
(K18- 𝑹𝟓𝟎)  is identifiable at the 0.5% level but practically unidentifiable at the 1% level, 
(fragmented K18- 𝒏) is practically unidentifiable, 𝑽𝒑 is structurally unidentifiable. 
Following model refinement, we found that an increased amount of GSH depletion 
was required for the GSH-induced ALT response to be half of its maximal value in 
the refined model structure. Namely, 67% GSH depletion was required in the 
framework described in Chapter 2, whereas almost 94% was required in the 
framework described within this chapter. Although more GSH depletion was also 
required for HMGB1 induction within the new framework, this biomarker response 
was still faster than that of ALT, since it had reached 50% maximal response rate at 
80 
 
around 86.5% GSH depletion. For Full-K18, results from the optimisation suggest 
that augmented production of the biomarker will occur when GSH decreases below 
174.5205 mol/l (~68.8% depletion). Fragmented K18 was also induced at this level 
of GSH; however, if GSH was further depleted to 167.3663 mol/l, augmented 
production of this apoptosis marker would cease, and the necrotic, full version of 
the biomarker would then dominate. In the fasted case, this threshold increased by 
5.0457 mol/l (𝜀) such that the necrotic switch (as indicated by the absence of K18 
fragmentation) occurred when GSH is depleted beyond 172.412 mol/l. Optimised 
model simulations were plotted and compared with the APAP PK time-course data 
(Figure 3-5), the biomarker PD time-course data (Figure 3-6) and the APAP dose- 
biomarker response data (Figure 3-7). The refined model provided a much better 
replication of the dose-response data, which is a key result from this chapter (Figure 
3-7). 
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  Optimised value  
Model Parameter Original 
(Chapter 2) 
Refined model % 
change  
APAP 𝑘a (h
-1) 9.05 8.6152 -4.8% 
𝑘𝑒𝑙 (h
-1) 0.52 0.5459 +5% 
𝑘12 (h
-1) 0.42 0.4502 +7.2% 
𝑉𝑐 (l/kg) 0.02 0.0220 +10% 
𝑉𝑃 (l/kg) 0.01 0.2102 +2000% 
𝑘21 (h
-1) 1.01 1.0315 +2.1% 
GSH 𝑔𝑠ℎ0 (mol/l) 696.9136  559.47497 -19.7% 
𝑘𝑝𝑟  71.06 55.33401 -22.1% 
𝜉  0.68 0.80571 +18.5% 
𝑘𝑜 (h
-1) 0.25 0.78807 +215% 
ALT 𝑅0 (mol/l) 0.7626 0.7626 0% 
𝑛  9.26 4.3324 -53.2% 
𝑅50 (mol/l) 227.67 35.6531 -84.3% 
𝑘𝑜𝑢𝑡 (h
-1) 0.0002 0.0004 +1% 
HMGB1 𝑅0 (mol/l) 0.0005 0.0005 0% 
𝑛  4.90 2.3445 -51.2% 
𝑅50 (mol/l) 399.08 75.2828 -81.1% 
𝑘𝑜𝑢𝑡 (h
-1) 0.35 0.0964 -72.5% 
Full K18 𝑟0
18(mol/l) 0.0146 0.0088 -39.73% 
𝑘𝑜𝑢𝑡
18  (h-1) 0.0007 0.0031 +342.9% 
Fragmented-
K18 
𝑟0
𝑓18
(mol/l) 0.0642 0.0977 +52.2% 
𝑘𝑜𝑢𝑡
𝑓18
(h-1)  0.02 0.0031 -84.5% 
Table 3-3: Parameter changes following model refinement. Any parameter that remained 
within the new model structure is defined, with its original value and the re-parameterised value. 
Percentage changes are also defined. 
 
82 
 
 
 
Figure 3-5: APAP PK Model simulations versus time-course data. APAP 
concentration simulations are plotted for 50 (green), 150 (blue), 500 (pink) and 530 
(black) mg/kg doses of APAP.  
 
Figure 3-6: Biomarker PD Model simulations versus time-course data. Fed and 
fasted simulations (green and red respectively) are plotted for GSH and biomarkers 
(ALT, HMGB1, Full and fragmented K18) following a 530 mg/kg dose of APAP. 
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Figure 3-7: Model simulations versus dose-response data. Solid lines represent the 
experimental data used for calibration. Black dashed lines represent dose-response 
simulations of GSH and biomarkers (ALT, HMGB1 and fragmented K18) in fed mice for 
a range of APAP doses (0, 150, 300, 530, 750, 1,000 mg/kg) using the refined model. 
Red dashed lines represent dose-response simulations of GSH and biomarkers (ALT, 
HMGB1 and fragmented K18) in fed mice for a range of APAP doses (0, 150, 300, 530, 
750, 1,000 mg/kg) using the original model (defined in Chapter 2).  
 
3.3.3.  Identifiability analysis – refined model 
Following an identifiability analysis of the original model structure (results of which 
are defined in section 3.3.1 of this chapter), we refined the original model in an 
attempt to resolve some of the structural unidentifiabilities found from the analysis. 
This included, for example, rather than assuming similar dynamics for K18, 
modelling biomarkers full K18 and fragmented K18 to be necrotic and apoptotic 
versions of the same biomarker. All modelling refinements made in an attempt to 
improve structural unidentifiability issues are defined in section 3.3.2 of this chapter. 
As well as attempting to improve the structural unidentifiabilities concluded from the 
analysis, we also worked to improve the practical unidentifiabilities found within the 
model. To do so, we optimised the refined model against an extended experimental 
dataset. Whilst the initial model (Chapter 2) was optimised against data from one 
study [39], the refined model was optimised against data from three studies 
[35,39,131]. Since additional data was required, we chose to use fasted mouse data 
within optimisation, so that our model may be extended to make predictions for 
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individuals with suppressed GSH levels. While the identifiability analysis of the 
original model framework provided interesting insight, it was important to determine 
whether the changes made to improve the system were justifiable and had improved 
the confidence within the system. We therefore conducted an identifiability analysis 
on the refined model structure for comparison.  
To conduct this analysis, parameters in the refined model were individually 
perturbed to visualise resultant differences between model output and experimental 
data. These changes were assessed to determine the identifiability of each 
parameter. Results can be seen in Figure 3-8. In the refined model, 16 out of 27 
parameters were now identifiable. Parameter identifiability remained for the ALT 
component, and the GSH component of the model was now also completely 
identifiable. The PK component remained identifiable, other than the volume of the 
peripheral compartment (𝑉𝑝), which remained structurally unidentifiable. There were 
some unidentifiabilities still present within this updated model. Other structurally 
unidentifiable parameters included: 𝑅50, 𝑘𝑜𝑢𝑡  and 𝑔𝑚𝑎𝑥 from the HMGB1 
component; and  𝐾18𝑘𝑜𝑢𝑡, 𝑓𝑘𝑖𝑛, 𝑓𝑘𝑜𝑢𝑡, 𝑔𝑠ℎ𝜃1 and 𝜀 from the full and fragmented K18 
component. Practical unidentifiabilities remained for two parameters: the HMGB1 
Hill coefficient (𝑛) and the production capability of full K18 (𝑘𝑚𝑎𝑥). 
We now compare the results of applying an identifiability analysis to the original 
model structure defined in Chapter 2, and also the refined model defined here within 
this chapter. Comparative results can be seen in Figure 3-9. Less than half of the 
parameters (47%) were identifiable in the original model structure (only the ALT 
component of the model was completely identifiable), 24% of the model parameters 
were practically unidentifiable and 29% were structurally unidentifiable. However, 
following model refinement, the identifiability results improved; the percentage of 
identifiable parameters increased to above half of the parameters (60%). Parameter 
identifiability remained for the ALT component of the model and the percentage of 
practical unidentifiabilities reduced from 24% to 7%. The percentage of structural 
unidentifiabilities was approximately the same in both the original and refined model 
(29% compared to 33%). Whilst the GSH component was unidentifiable in the 
original model, it was completely identifiable in the refined model. Although 
unidentifiabilities improved for parameters in the HMGB1, K18 and f-K18 
components, some unidentifiabilities remained. 
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Figure 3-8: Identifiability analysis of the refined model structure. Figure annotation is the 
same as for Figure 3-4. Example results from figure: The ALT 𝑹𝟓𝟎 parameter is identifiable at 
the 1% level, the HMGB1 𝒏 parameter is practically unidentifiable, the PK 𝑽𝒑 is structurally 
unidentifiable. 
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Figure 3-9: Parameter identifiability comparison between the original and refined model. 
Each column represents a different sub-component of the APAP PKPD model. Each element 
(or square) represents the parameter’s identifiability within the model. Triangles in the bottom 
left-hand corner of each element represent the parameter’s identifiability in the original model 
structure. Triangles in the top right-hand corner of each element represent the parameter’s 
identifiability in the refined model structure. If the triangle is red, the parameter is structurally 
unidentifiable; if the triangle is yellow, the parameter is practically unidentifiable; if the triangle 
is green, the parameter is identifiable. If the triangle is grey, the parameter was not present 
within the corresponding model structure, and therefore could not be tested for identifiability. 
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3.3.4.  Predicting initial dose and time since administration 
as continuous variables 
We used the refined PKPD framework to simulate biomarker concentrations 
representative of 3 sub-populations; a “healthy” population, “high-risk” population 
and “mixed” population (virtual population details are described in section 3.2.5 of 
this chapter). Within each sub-population, each individual was provided a random 
dose of APAP, and biomarker concentrations were extracted at a random time-
point. As in Chapter 2 (section 2.3.5) a multiple linear regression analysis was 
applied to the in silico derived data in an attempt to predict the exact time since 
ingestion and initial APAP dose. For the healthy population, an exact time since 
administration could be estimated with an error of approximately 3.9 hours, and an 
exact initial dose amount could be estimated with an error of approximately 66.14 
mg/kg (Table 3-4). 
Time since administration could be predicted more accurately in the high-risk 
population, with a standard error of 2.118 hours. Initial dose was much harder to 
predict in the high-risk population, however, with the standard error being almost 
triple that of the model for the healthy population (184.1 mg/kg). Predictions for an 
assumed mixed population were similar to that of the healthy population, with a 
slight improvement in predicting time since administration (standard error 3.485 
hours) and a slight reduction in accuracy for predicting initial dose (standard error 
73.73 mg/kg). When predicting time since administration, in the healthy population, 
all biomarkers were significant, in the high-risk population, all biomarkers were 
significant, however, in the mixed population, ALT and fragmented K18 were no 
longer significant. When predicting dose, in the healthy population, all biomarkers 
except HMGB1 were significant, in the high-risk population, all biomarkers except 
fragmented K18 were significant, and in the mixed population, all biomarkers were 
significant.  
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Healthy Population 
 
 
High-risk Population 
 
Mixed Population 
Predictors 
 
Time 
 
Dose Time 
 
Dose Time 
 
Dose 
APAP Conc. -
16.549*** 
(1.1785) 
 
673.985*** 
(17.0745) 
-9.5093*** 
(0.5963) 
 
1295.366*** 
(47.8525) 
-18.122*** 
(0.9542) 
 
909.341*** 
(17.8005) 
ALT conc. 8.972*** 
(0.9533) 
 
 
515.625*** 
(13.8110) 
5.5034*** 
(0.6537) 
 
695.2118*** 
(52.4551) 
 
 
 
655.0837*** 
(17.2145) 
HMGB1 
conc. 
-
22.035*** 
(0.9113) 
 
 -8.8119*** 
(0.5440) 
 
367.0774*** 
(43.6578) 
-17.869*** 
(0.7705) 
 
289.2333*** 
(14.3736) 
FullK18 
conc. 
7.521*** 
(1.0632) 
 
479.137*** 
(15.4035) 
21.0427*** 
(0.4743) 
 
-
154.2403*** 
(38.0652) 
22.3833*** 
(0.9145) 
 
229.0486*** 
(17.0605) 
Fragmented 
K18 conc. 
-4.599* 
(1.3895) 
151.975*** 
(20.1309) 
 
3.8472*** 
(0.5962) 
 
 
 33.8383* 
(15.5231) 
 
 
Constant 14.918*** 
(0.3074) 
 
77.247*** 
(4.4529) 
5.8083*** 
(0.2527) 
-80.145*** 
(20.2759) 
12.6308*** 
(0.3694) 
 
-65.6354*** 
(6.8914) 
Residual 
Std. Error (df 
== 994) 
 
3.907 
 
66.14 
 
2.118 
 
184.1 
 
3.485 
 
73.73 
 
Note:  
 
*p<0.05 
 
**p<0.01 
 
***p<0 
   
Table 3-4: Multiple linear regression analysis results. Independent variable coefficients for 
predicting time since administration (Time) and initial dose (Dose) respectively for healthy, high-
risk and mixed populations. The first number in each element of the table represents the 
biomarker coefficient in the regression model and the second number represents the 
corresponding error. For example, -16.549 is the APAP concentration coefficient in the healthy 
population model predicting time since administration, and this coefficient has an error of 
1.1785. The standard error of overall model predictions is provided. The significance of each 
biomarker in the model is indicated by the number of asterisks (see note). 
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3.3.5. Visualisation and classification of in silico derived 
data 
As in Chapter 2, T-SNE visualisation was applied to the in silico derived data to 
investigate time/dose class structure/separability. Subsequently, various 
classification techniques were also employed, using the biomarker concentrations 
of the in silico observations in an attempt to classify a time/dose category. 
Differences in levels of discrimination regarding initial dose and time since 
administration for healthy, high-risk and mixed populations can be seen for each 
case by embedding the in silico derived data in two-dimensions using T-SNE (Figure 
3-10). Both variables, time since administration and initial dose, were reasonably 
separated in all healthy, high-risk and mixed populations. This result was supported 
by the reasonable accuracy rates of the classification techniques. Time since 
administration was difficult to discriminate from the biomarker concentrations in the 
healthy population, as shown by the cluster of observations of the right-hand side of 
Figure 3-10(A)). However, these same observations corresponded to low-dose 
situations, as shown in Figure 3-10(B) which visualises this same cluster of 
observations with regards to the initial dose,  
From measuring biomarker concentrations, a correct time since administration 
category could be predicted with 69.9% accuracy for the healthy population, and a 
correct initial dose category can be predicted with 91.5% accuracy. These results 
are indicated in Table 3-5. A time since administration category was easier to predict 
in the high-risk population (80.4% accuracy). However, predictions for initial dose in 
the high-risk population were less accurate than in the healthy population (79%). If 
an observation was assumed to be taken from a mixed population, the prediction 
accuracy was similar to that of a healthy population, with results of 69.94% and 
89.5% for time since administration and initial dose respectively. In our previous 
study, a correct time category could be predicted with 72.8% accuracy and a correct 
dose category could be predicted with 86.5% accuracy (Chapter 2, section 2.3.4). 
For a healthy population, the time classification results slightly worsened with our 
new framework. However, the dose classification results slightly improved. 
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B 
 
C 
 
 
D 
 
E 
 
F 
 
Figure 3-10: Visualisation and classification of time-since-administration and dose 
results for healthy, high-risk and mixed populations. For time-since-administration, dark 
green represents class [0-2), orange represents [2-5), blue represents [5-10), pink represents 
[10-15) and pale green represents [15-24) hours. For dose, green represents [0-200], orange 
represents [201-400] and blue represents [401-1,000] mg/kg. TSNE visualisations of in silico 
mouse observations with respect to time since administration and initial dose can be seen in 
(A)-(B) for the healthy population, (C)-(D) for the high-risk population and (E)-(F) for the mixed 
population. 
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 Healthy 
Population 
High-risk Population Mixed Population 
Classification  
Method 
 
Time 
 
Dose Time 
 
Dose Time 
 
Dose 
KNN 
Regression 
66.2% 91.5% 80.4% 79% 69.5% 87.4% 
Naïve Bayes 
 
64.4% 91.3% 76.2%        72.7%      68.2% 88.5% 
Multinomial 
logistic 
regression 
68% 90.8% 73.1% 77.1% 75.7% 89.5% 
Ordinal 
logistic 
regression 
53.7% 90% 67.8% 78.1% 57.2% 87.5% 
Linear 
discriminant 
Analysis 
59.3% 90.7% 72.5% 77.9% 65.8% 87.8% 
Quadratic 
discriminant 
analysis 
69.9% 90.4% 76.8% 71.7% 69.94% 86.8% 
Table 3-5: Classification accuracy of predictions based on biomarker concentrations for 
healthy, high-risk and mixed populations. For example, the Quadratic discriminant analysis 
model can predict the correct time since administration category in the healthy population with 
69.9% accuracy. 
3.3.6.  Predicting the probability of liver injury 
Figure 3-11 shows how the probability of liver injury changes over time for both 
healthy and high-risk populations, for doses between 0-1,000 mg/kg. The model-
derived probabilities were dependent only on HMGB1 concentration (as predicted 
by our previous logistic regression model in Chapter 2). A threshold probability of 
0.5 was used to determine the threshold likelihood of DILI (white boundaries in 
Figure 3-11). Any observation within the white contour boundary was therefore 
predicted to be representative of probable liver injury.  
For the healthy population, the time-frame for biomarker concentrations 
representing those of probable liver injury was around 2 to 18 hours. The APAP 
dose threshold predicted to induce toxicity was approximately 350 mg/kg. Note that 
this prediction is only slightly above the currently used toxic dose (300 mg/kg) [97] 
whereas the framework provided in the previous chapter, predicted toxicity would 
be apparent at an APAP dose above 200mg/kg. The framework for a healthy 
population suggests that there is almost 100% chance of liver injury when the dose 
is only slightly higher than 350mg/kg. 
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B 
 
Figure 3-11: Proposed framework for predicting the probability of liver injury dependent 
upon dose, time and HMGB1 concentration. The plotted frameworks are representative of 
both healthy (A) and high-risk (B) populations. In each, the white contour indicates the threshold 
of 0.5 probability of liver injury; the red dashed-line represents the currently used APAP dose 
for toxicity studies in mice; the white dashed-line represents toxic dose as proposed by our 
model; and the green dashed-line indicates currently considered therapeutic dose for mice. In 
the high-risk population, the toxic dose proposed by our model and the therapeutic dose are 
identical. 
For the fasted population, however, at the currently recommended therapeutic 
APAP dose (60 mg/kg), there was approximately 50% chance of liver injury 
progression. For any dose above the known therapeutic threshold, liver injury 
progression was predicted to be highly probable (above 60%); beyond 
approximately 2.5 h post-dose, HMGB1 concentrations remained indicative of highly 
probable liver injury for the whole time-course. 
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3.3.7.  Visualising the probability of liver injury following 
an APAP dosed based on biomarker concentrations 
In Chapter 2, we carried out a forward step-wise binary logistic regression analysis 
to determine the most significant panel of biomarkers in predicting the probability of 
liver injury. The analysis concluded that HMGB1 was the most significant biomarker 
for predicting DILI probability, with the output from SPSS software being a logit 
equation based solely on this biomarker concentration, 
 
𝐿𝑒𝑞  = 0.635[hmgb1] − 3.870. 
 
(3-8) 
Within this chapter, using the refined model, we simulated multiple in silico 
populations. For each observation within both the “healthy” and “high-risk” 
populations, simulated HMGB1 concentrations were substituted into equation (3-8). 
Then, using the standard probability equation, we calculated for each in silico 
individual the probability of liver damage as follows 
 
Probability of liver damage =
1
1 + e−𝐿𝑒𝑞
. 
 
(3-9) 
Each in silico observation was then visualised and discriminated by their resultant 
liver injury probability using the TSNE method (Figure 3-12). Relatively safe/unsafe 
observations were identifiable in both healthy and high-risk populations. For the 
healthy population (Figure 3-12(A)) most of the observations had less than around 
35% chance of DILI progression. The small group of observations representing at-
risk individuals can be identified at the top, right-hand side of the image, portrayed 
by red markers. In stark contrast, most of the in silico observations had almost 100% 
chance of liver injury progression in the high-risk population, as can be seen by the 
dominance of red markers in Figure 3-12(B). The observations corresponding to 
lower injury potential are indicated in both the central and the left-hand side of the 
plot. 
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Figure 3-12: two-dimensional TSNE visualisation of in silico observations with respect to 
their estimated probability of liver injury. Separated liver injury probabilities are visualised 
for a range of in silico generated inputs for both healthy (A) and high-risk (B) populations. 
Predicted DILI probabilities (0-1) for each individual observation are indicated by the colour bar. 
Dark blue represents 0% chance of liver injury progression, while dark red represents 100% 
chance. 
3.4. Chapter discussion 
The current clinical APAP treatment framework is known to be inaccurate, mainly 
due to a dependency on known time of APAP ingestion, but also due to inaccurate 
estimates of initial dose and being heavily based on biomarkers that are currently 
criticised for being insensitive [136]. In Chapter 2, we detailed a computational 
framework for predicting the probability of liver injury based on novel biomarker 
concentrations. Whilst mathematical models are increasingly being accepted as an 
efficient tool in toxicity testing [44,78], they are only a representation of the biology, 
and due to the necessity of assumptions for simplification, many uncertainties can 
arise (in both parameter estimates and subsequent output). For this reason, the 
most useful mathematical models are provided with a level of quantified uncertainty 
in their predictions, so that the frameworks can be utilised in the safest, most 
95 
 
efficient manner possible. We therefore used this chapter to determine any levels of 
uncertainty that were present in the framework defined in Chapter 2, and used the 
results to try and improve any uncertainties where possible. The identifiability 
analysis performed within this study did in fact highlight parameter unidentifiabilities 
within the original model that required addressing. The identifiability analysis 
established where the model defined in Chapter 2 required structural changes and 
also where more data was required in order to increase confidence in predictions. 
Using the results, we have re-structured the model where necessary and re-
parameterised against additional data (from both fed and fasted mice). A 
comparative identifiability analysis of the newly defined model structure found that 
only 7% of parameters are now practically unidentifiable (compared with 24% 
previously).  
As well as improving confidence in the mathematical representation of the system, 
we have now provided a model that is more representative of the clinical 
environment by firstly including a wider range of APAP doses (previously the model 
could account for an APAP dose range [0-600] mg/kg, whereas now we can account 
for a range of [0-1,000] mg/kg). Furthermore, the new treatment framework can now 
be adjusted for individuals considered to be at high risk of APAP-induced liver injury 
[5]. To account for the fact that many overdose patients tend to have an increased 
underlying susceptibility to APAP-induced liver injury, we chose to optimise our 
model against both fed and fasted mouse data. When training the biomarker models 
against multiple datasets and comparing to the model defined in Chapter 2, which 
is calibrated against only 530 mg/kg APAP dose time-course data, there were 
noticeable adjustments in the parameter values, particularly for the GSH model. 
Many of these changes are intuitive and may be representative of changes in 
mechanisms due to fasting. Additionally, changes may be attributable to the fact 
that the model can now better account for a larger variety of dosing scenarios. The 
significant changes in parameter values highlight the importance of optimising 
against a range of both therapeutic and toxic datasets and both healthy and 
unhealthy populations in the modelling field.  
The model we propose in this chapter is more biologically relevant than the previous 
model defined in Chapter 2. Originally, we assumed that full and fragmented K18 
had similar mechanisms and acted as independent biomarkers. However, full and 
fragmented K18 are known to be effectively necrotic/apoptotic versions of the same 
biomarker [88]. Incorporating this into our model framework we confirmed that 
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necrosis was the pre-dominant form of cell death in mice APAP overdose cases 
[137]. Also, an identifiability analysis on the new model structure established an 
increased confidence in parameter estimates for the GSH, HMGB1, full and 
fragmented K18 components of the model structure. There are, however, some 
unidentifiabilities remaining, particularly within the HMGB1 and fragmented K18 
components of the model, indicating that additional data and model development is 
still required in order to have full confidence in the uniqueness of the chosen 
mechanistic parameter values. 
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Chapter 4: Pre-clinical systems 
toxicology approach to treating 
paracetamol overdose: predicting 
cell death dynamics and 
investigating antidote treatment 
regimens
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4.1. Background 
Up until this point in the thesis, we propose an in silico framework based on mouse 
data which can provide accurate predictions regarding whether or not an APAP 
overdose has taken place (by quantifying dose amount and time since 
administration), and whether an overdose is likely to progress into liver injury. There 
are, however, aspects of the model which require improvement prior to 
contemplating eventual translation to humans.  
Throughout the analyses until this point, HMGB1 outperforms all other biomarkers 
in predicting overdose and probability of liver injury, including the current clinical 
favourite ALT. As well as lacking in sensitivity, ALT is also considered sub-optimal 
in the APAP overdose case due to its non-liver specificity [138]. Although the novel 
biomarkers used in our in silico framework provide enhanced mechanistic 
information relating to the underlying basis of APAP toxicity [87], and our results 
thus far suggest that HMGB1 is particularly sensitive, the non-liver specificity issue 
remains for all biomarkers.  
An additional issue is that currently, the mathematical model is built assuming that 
cell death is one general mechanism. In fact, cell death can usually be described by 
one of two mechanisms: necrosis and apoptosis [31]. Necrosis is rapid and 
irreversible and occurs when an external trauma causes cells to quickly inflame and 
become damaged. Apoptosis, however, is a much slower physiological process and 
occurs when the external stimuli has not caused so much injury to the cell, that is 
has the energy (Adenosine Triphosphate, ATP) to programme its own demise, with 
cellular metabolism and membrane integrity being maintained until very late stages 
[32]. There is extensive research-based evidence to demonstrate that necrosis is 
the dominant form of APAP-induced hepatocellular death in overdose cases [33–
35]. However, mild levels of APAP toxicity can cause apoptosis [33] and, in both low 
and high APAP dose cases, there is evidence that these modes of cell death can 
simultaneously exist until ATP levels deplete, with necrosis dominating for higher 
doses [139]. Identifying the mode of cell death can therefore be beneficial in 
determining whether or not a patient is a mild toxicity/overdose case. Coupling this 
with our dose and time since administration predictions will strengthen our 
framework. Our framework can predict, for the mouse case, individuals likely to 
develop liver injury, and therefore those who may benefit from intervention with 
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antidote therapy. This project has the aim of providing a proof-of-concept framework 
which cannot only predict cases where intervention may be necessary, but also 
provide the optimal treatment strategy. By incorporating information regarding the 
mode of cell death at different doses/time points, the accuracy of the model with 
regard to predicting when to intervene may be improved.  
The PKPD model is currently developed based upon mice dosed with various 
amounts of APAP and no treatment with the antidote, N’acetylcysteine (NAC). This 
means that up until this stage, we propose a proof-of-concept framework for initial 
patient presentation, however the model may not be useful as a platform for 
monitoring changes in liver injury potential following an antidote. Since NAC is not 
initially included in the modelling framework (defined in Chapters 2 and 3), we 
require additional data and model development. 
The In vitro Toxicology Society (IVTS) provide Mini-Fellowship awards, which allow 
early-career scientists to learn techniques which are useful for their research aims, 
but are currently unavailable at their home institution. The aim is to promote further 
career development within the in vitro toxicology field, and also to build strong 
collaborations between in silico and in vitro researchers. In 2017 I was successful 
in winning the IVTS Mini-Fellowship award, and used the £1.5k to fund experimental 
work in collaboration with the University of Liverpool to fill the aforementioned data 
gap and allow further model refinement. As well as providing additional data, the 
fellowship allowed me to obtain hands-on experience of the wet-lab environment, 
and form collaborations with in vitro experimentalists. The experiments were carried 
out in collaboration with a University of Liverpool PhD student, Nathalie De Bois-
Brillant. To obtain the necessary data, we exposed primary mouse hepatocytes to 
a range of antagonist (APAP) and antidote (NAC) concentrations to investigate their 
interaction, whilst conducting experimental tests to understand their effect on cell 
dynamics and mode of cell death. 
In order to provide experimental insight into the cell dynamics, we provide results of 
an ATP assay used to quantify cell viability. In order to determine the mode of cell 
death we provide results from experiments based on Western Blotting for Caspase 
3 (an apoptosis marker) and quantitative polymerase chain reaction (qPCR) 
analysis for miR-122 (a necrosis marker). The necrosis marker is chosen to be miR-
122 due to its high level of liver-specificity, something the model is hitherto lacking. 
Additional to these experimental findings, we provide results from a fluorescence-
activated cell-sorting (FACS) analysis which compares the amount of apoptosis 
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versus necrosis present at 24h. In order to test the predictivity of biomarkers in an 
APAP overdose case, and also in an APAP plus antidote treatment (APAP+NAC) 
case, we apply multiple linear regression analysis. The mathematical model defined 
in Chapters 2 and 3 is extended within this chapter in order to simulate cell viability 
dynamics in both the APAP and APAP+NAC cases. Administration schedules of 
NAC are investigated and compared, determining the effects on biomarker output, 
probability of liver injury and severity of cell damage. 
Chapter aims 
 Generate and analyse in vitro experimental data to better understand the 
influence of NAC administration on biomarker concentrations and their 
subsequent predictivity. 
 Obtain greater understanding of liver injury at the cellular level. 
 Investigate the effects of NAC administration on defined APAP toxicity 
measures. 
4.2. Methods 
All experiments were carried out at the University of Liverpool under the supervision 
of Nathalie De Bois-Brillant. The protocols described were undertaken in 
accordance with criteria outlined in a license granted under the Animals (Scientific 
Procedures) Act 1986 and approved by the University of Liverpool Animal Ethics 
Committee. 
4.2.1. Experimental methods 
4.2.1.1. Mouse hepatocyte isolation 
Hepatocyte isolation was carried out by Nathalie De Bois-Brillant at the University 
of Liverpool. Again, methods are detailed here for completeness. 
Mice were ordered 7 days prior to the planned experiment to allow for 
acclimatisation. Wash, perfusion and digestion buffers were prepared one day prior 
to the planned experiment and stored in the fridge until required. When preparing 
perfusion and digestion buffers, HEPES was added first to aid salt dissolution. 
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The perfusion buffer was made by the following method: 
Mouse 250 ml perfusion buffer 
5 ml HEPES (1M) 
217.6 ml ddH2O 
25 ml 10X HBSS 
1.2 ml 7.5% (w/v) NaHCO4 
1.25 ml EDTA (50 mM) 
pH to 7.35-7.46 
The digestion buffer was made by the following method before being split into two 
bottles: 150 ml (referred to as DGI) and 100 ml (referred to as DGII) 
Mouse 250 ml digestion Buffer  
5 ml HEPES  
216.3 ml ddH2O  
25 ml 10X HBSS 
1.2 ml 7.5% (w/v) NaHCO4  
25 mg MgSO4  
1.25 ml CaCl2 
pH to 7.35-7.46 
DGI was kept on ice and used only after hepatocyte isolation. DGII was warmed in 
the water bath, as was 2.5 mg of 20X collagenase which was then added to DGII 
immediately before tissue digestion. DGI did not contain collagenase and could 
therefore be used to spin cells whereas DGII could be used for digestion. 
4.2.1.2. Liver Perfusion 
Liver perfusion was carried out by Nathalie De Bois-Brillant at the University of 
Liverpool. 
The centrifuge was set to a 4°C cycle. The perfusion pump was set up to run at a 
speed of 8 ml/min (14G tube). Pentobarbitone was taken out of the fridge and diluted 
down 1:3 in 0.9% saline from a 200 mg/ml stock solution to 50 mg/ml and left aside 
to reach room temperature. Mice were dosed into the peritoneal cavity 
(intraperitoneally, i.p), which is situated just below the abdomen, with 1 µl/g of diluted 
solution. The level of anesthesia was determined by loss of corneal reflex response 
and foot withdrawal response. Once the mouse was completely sedated, the 
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perfusion was quickly performed via cannulation of the inferior vena cava and the 
portal vein was cut to relieve pressure. The liver was perfused with wash buffer until 
cleared and then perfused with digestion buffer until digested. The liver was then 
transferred to a petri-dish for release of cells. 
4.2.1.3. Cell release 
Cell release was carried out by Nathalie De Bois-Brillant at the University of 
Liverpool. Methods are detailed here for completeness. 
The liver was placed into a 50 ml falcon tube containing ice cold 1X DGI. On ice, 
the liver hepatocytes were cleaned by stripping the capsule at the edges. Using 
curved forceps, holes were made in the four lobes of the liver. The liver was flipped 
to the underside and this process was repeated. The liver was punctured many 
times, before being gently shaken in buffer until the biliary tree became visible. The 
crude cell mixture was then put through a 100-micron filter to remove connective 
tissue and aggregates. The hepatocytes were collected and 50 g were spun for 2 
minutes. The supernatant was discarded and the hepatocytes were then re-
suspended using ice cold digestion buffer (without collagenase). The spin was then 
repeated. This process (discarding, washing and spinning) was repeated to obtain 
a pellet of pure hepatocytes. The hepatocytes were then cultured in the following 
medium 
Hepatocyte culture medium (/100 ml) 
1 ml P/S 
1 ml L-Glutamine 
1 ml ITS 
100 µl of 100 µM DEX 
96.9 ml Williams Medium E 
10% FBS omitted since performing ATP assay 
Once the liver was perfused and cells released, I was then involved in carrying out 
each of the experiments that follow, under the supervision of Nathalie. We first 
investigated the effects of APAP and NAC on cell viability. Secondly, we 
investigated the effects of APAP and NAC on the mode of cell death 
(apoptosis/necrosis).  
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4.2.1.4. Dosing 
All cells were incubated for 24 hours. Following this, the primary mouse hepatocytes 
were exposed to a range of concentrations of APAP (0-20 mM) and one hour later 
were further exposed to varying concentrations of NAC (0-5 mM).  
4.2.1.5. Cell viability – ATP 
Adenosine Triphosphate (ATP) is the main energy source for all cells [140]. 
Measuring cellular ATP levels is therefore often used to measure cell functionality; 
reduction in cellular energy levels can in turn be assumed to represent reduction in 
cell viability. We therefore carried out an ATP assay to determine how different dose 
combinations of APAP+NAC effected cell functionality over time. 
ATP content of the cells was measured using a kit ATP bioluminescent somatic cell 
assay kit (Sigma-Aldrich) following the manufacturer’s instructions. 20 µl of assay 
reagent was added to each well and shaken for one minute. 100 µl from each well 
was then plated onto a 96-well flat-bottomed plate and left to incubate for five 
minutes. Luminescence was measured using VarioSkan flash plate reader 
(Thermo-Fisher).  
4.2.1.6. Bradford Assay 
A Bradford assay was used to measure the total protein concentrations in the cells. 
Within our experiments, the Bradford protein quantification assay was performed in 
accordance with the manufacturer’s instructions (BioRad, UK). Six 500 ug/ml 
dilutions of a protein standard (bovine serum albumin, BSA) were prepared. 
Duplicates of each protein standard and sample (20 µl) were pipetted into separate 
microtitre wells. Following this, 200 µl of diluted dye reagent (prepared by diluting 1 
part dye reagent concentrate with 4 part DDI water) was added to each well. They 
were then incubated at room temperature for 10 minutes. A standard curve was 
constructed using BSA (Sigma-Aldrich) between the concentrations 0-1 mg/ml. 
Absorbance was measured at 595 nm. 
4.2.1.7. Gene quantification– Western blotting  
Western blotting is an experimental technique that can detect and quantify particular 
proteins among a mixture of proteins [141]. Firstly, all proteins are separated into 
their linear chains and then separated according to their size using a method called 
gel electrophoresis. Once separated, each protein is transferred onto a blotting 
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membrane. The membrane subsequently undergoes a blocking procedure which 
disables any non-specific reactions. A primary antibody is then used to incubate the 
membrane, which specifically binds to the protein of interest. Any unbound primary 
antibody is washed away and the membrane is then incubated with a secondary 
antibody. The secondary antibody not only specifically recognises and binds to the 
primary antibody, but is also linked to a reporter enzyme that produces colour or 
light, allowing for the detection of the protein of interest. We carried out Western 
Blotting analysis to detect levels of protein markers, actin and caspase. 
Sample preparation 
A master mix of lithium dodecyl sulfate (LDS) sample buffer and reducing agent 
(70:30) was created. Each sample was added to 5 µl of the master mix, centrifuged 
for 30 seconds and placed in a heating block at 80ºC for 10 minutes. 
Loading Precast Gel 
Precast 4-12% Bis-Tris gel was locked into the electrophoresis unit. 1X MOPS 
running buffer was created by diluting 50 ml of 20X MOPS in 950 ml dH2O. The 
MOPS running buffer was mixed and poured into the central chamber of the 
electrophoresis unit. The outside of the chamber was filled with MOPS running 
buffer to approximately half of the total volume. The heated samples were pulse-
spun and loaded into the appropriate wells of the gel. 5 µl of protein marker were 
loaded in the first well whilst 10 µl of protein marker were loaded into each sample 
well. The gel was then run for 10 minutes at 90V followed by 1 hour at 170V. 
Electrophoretic transfer 
1X transfer buffer was prepared by mixing 100 ml 10X transfer buffer + 200 ml 
MeOH + 700 ml dH20. Each gel had 3x sponges, 2x filter papers, 1x transfer buffer 
and 1x nitrocellulose membrane (GE Healthcare, Little Chalfont, UK). The plastic 
plates were opened using a spatula and the gel remained attached to one plate. 
The wells were cut away from the top of the gel, and the ridge cut away from the 
bottom of the gel. Pre-soaked filter paper and a nitrocellulose membrane were 
placed onto the gel, and the gel was carefully peeled off the plate with a spatula. 
The gel was placed onto the bench (filter-paper down) and the pre-soaked 
membrane was placed on top of the gel. An additional pre-soaked filter paper was 
placed on top of the membrane. The transfer cassette was then assembled and 
locked into the transfer chamber. Both the cassette and cool pack were inserted into 
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the transfer tank. The transfer tank was filled with 1x transfer buffer until almost full 
and stirred for 1 hour at 230mA. 
Protein detection 
The membrane was rinsed in 0.1% TBST and stained with ponceau red for 10 
seconds. The membrane was then cut at 37 kDa marker for ß-Actin (42 kDa) and 
for caspase 3 (35 kDa). The actin membrane was blocked in 10% milk blocking 
solution overnight whilst the caspase membrane was blocked for 1 hour. The 
primary caspase 3 antibody was then added at the required dilution of 1:2000 in 2% 
milk and incubated overnight at 4°C. The actin membrane was incubated in 10% 
milk blocking-solution on a rocker overnight at 4°C. The primary actin antibody was 
added at a dilution of 1:10,000 in 10% milk blocking-solution and the actin 
membrane was incubated on the rocker for 30 minutes at room temperature. Both 
actin and caspase 3 membranes were washed for 4 x 10 minutes in 0.1% T-TBS. 
The secondary antibody solutions were prepared (anti-mouse HRP at a dilution of 
1:10,000 in 2% milk for actin and anti-rabbit HRP at a dilution of 1:10,000 in 2% milk 
for caspase 3) and added to the necessary membrane, each being incubated on the 
rocker for 1 hour at room temperature. Both membranes were then washed for 4 x 
10 minutes in 0.1% T-TBS. 
Visualisation of immune reactivity was completed using Enhanced 
Chemiluminescence Plus (ECP) (Perkin Elmer, MA, U.S.A) according to the 
manufacturer’s instructions. Membranes were blotted dry and covered with a 
chemiluminescence reagent for 2 minutes. Membranes were then covered in Saran 
wrap and exposed to ECL film in a dark room for 1-15 minutes. All western images 
were scanned and analysed using Quantity One 1-D analysis software (Bio-Rad, 
Hercules, CA, USA). 
4.2.1.8. microRNA quantification– qPCR 
We aim to measure genetic changes over time in order to quantify protein markers. 
During Deoxyribonucleic acid (DNA) analysis, amplification is required in order for 
there to be enough DNA to provide a detectable signal for quantification [142]. 
Polymerase Chain Reaction (PCR) is a technique for amplifying DNA. Firstly, all 
double stranded DNA is “melted” into single strands, with each half representing a 
template for a new molecule. A polymerase enzyme then synthesises a 
complementary sequence of bases to each single strand of DNA. Adding small 
pieces of DNA, complimentary to the gene of interest (known as primers), prepares 
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the DNA sample, ensuring the polymerase can bind. This eventually results in a 
copy of the gene of interest. In order to quantify this reaction, probes (or 
fluorescently labelled DNA oligonucleotides) can be added to the mixture, which 
bind downstream to one of the primers and give a fluorescent signal during the 
reaction. As the number of gene copies increases, so too does the fluorescence. 
This real-time analysis is often referred to as “quantitative” PCR or qPCR.  
Within our study, measuring the number of gene copies over time allowed for 
quantification of an apoptotic marker (Caspase) and a necrotic marker (miR-122). 
miRNA extraction 
For amplification to occur, miRNA must first be extracted and “melted” into single 
strands, with each half representing a molecule template for copying. All samples 
were stored in frozen conditions to ensure all DNA information remained intact and 
to ensure no enzymatic reactions could take place. Therefore, before miRNA 
extraction could occur, the samples were firstly defrosted and spun down. The 
amount of supernatant used for the extraction was up to 200 µl. 700 µl of Qiazol 
reagent was added and then mixed by vortexing. The mixture was incubated at room 
temperature for 3 minutes to ensure thorough nucleo-disruption. 140 µl of 
chloroform was added and the tubes were shaken vigorously by hand for 15 
seconds, before being left at room temperature for a further 5 minutes. Once 
centrifuged at 12,000 rpm for 15 minutes at 4°C, the samples were allowed to 
equilibrate at room temperature. 350 µl of supernatant was transferred to RNeasy 
mini-spin columns which were then placed inside collection tubes and centrifuged 
at 8,000 rpm for 15 seconds at room temperature. The flow-through was then finally 
transferred to a 2 ml micro-tube.  
Purification 
Purification of RNA is central to any gene expression/regulation investigation; it is 
essential to reduce the chance of degradation which could dramatically affect the 
quality of the qPCR data. Once extracted from the samples, the miRNA was then 
able to be purified.  
Within our experiments, in order to purify the miRNA, 450 µl of 100% ethanol was 
added to the previously collected flow-through and mixed by vortexing. Samples 
were applied (700 µl at a time) to RNeasy MinElute columns until the there was no 
sample remaining. They were then centrifuged at 8,000 rpm for 15 seconds at room 
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temperature before the flow-through was discarded. 500 µl of RPE buffer was added 
to the MinElute column and then centrifuged at 8,000 rpm for 15 seconds at room 
temperature. The flow-through and collection tubes were then discarded. The 
column was then placed in a fresh collection tube ensuring MinElute column had no 
residual flow-through to avoid contamination. The columns were then centrifuged 
with their lids open at 8,000 rpm for 5 minutes to ensure they were completely dry. 
The MinElute column was placed into a 1.5 µl micro-tube and 14 µl of RNAse-free 
water was pipetted onto the spin column membrane and centrifuged at 8,000 rpm 
for 1 minute at room temperature to elute the purified miRNA fraction. 
Reverse Transcription 
The reverse transcription (RT) stage is critical for accurate and sensitive RNA 
quantification [142]. It is at this point that a polymerase enzyme then synthesises a 
complementary sequence of bases to each single strand of DNA.  Within our 
experiments, reverse transcription was performed using the TaqMan miRNA 
reverse transcription kit (Applied Biosystems) following manufacturer instructions. 
The primers (or small pieces of DNA complimentary to the gene of interest) used 
were miR-22 and U6 (endogenous control). A GeneAmp PCR9700 machine was 
used to carry out the analysis. 2 µl of purified miRNA was used to synthesise 
complementary DNA (cDNA) with a total reaction volume of 15 µl in a 96-well PCR 
plate which was held in an ice block. RT was performed via thermal cycling (30 min 
at 16°C, 30 min at 42°C, 5 min at 85°C and then held at 4°C).  
miRNA PCR 
Primers (or small pieces of DNA complimentary to the gene of interest) allow the 
polymerase enzymes to bind and form a copy of the gene. In PCR, probes are 
added to the mixture which provide a fluorescent signal during the reaction, so that 
the number of copies can be quantified. For the quantification to take place within 
our experiments, 1.33 μl of cDNA from the RT were used in duplicate, with the use 
of corresponding specific qPCR primers (Life Technologies) and Taqman PCR 
Master mix (Life Technology) according to manufacturer’s instructions. 1.33 µl of 
cDNA was used and plated by a QIAgility (Qiagen) machine for high-precision 
automated PCR setup and analysed on a ViiA7 machine (Life Technologies). After 
undergoing thermal cycling (40 cycles of 15 sec at 95oC and 60 sec at 60oC), levels 
of miRNA were measured by the fluorescent signal produced from the Taqman 
assay probes.  
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4.2.1.9. Cell sorting– FACS 
Flow cytometry is a powerful tool used for analysing complex cell populations within 
a short space of time [143]. The process works by suspending cells into a stream 
that creates a laminar flow, allowing each cell to pass an interrogation point, where 
a beam of monochromatic light intersects the cells. The directions in which the 
emitted light from the cells are given off allows the computer to conclude various 
things about the cell, with particular focus on its shape and size. A derivate of flow 
cytometry, fluorescence-activated cell sorting (FACS) allows a researcher to 
physically sort a heterogeneous mixture of cells into different populations due to the 
use of highly specific antibodies tagged with fluorescent dyes [144]. With this in 
mind, we used FACS to sort our cell population with regard to the mode of cell death 
(apoptosis or necrosis). 
The following method was adapted from eBiosciences staining protocol. 
Supernatant, including cell debris, was harvested and transferred into 1.5 ml EP 
tubes on ice. The cells were then rinsed with PBS to remove serum and the adherent 
cells were harvested by using trypsin in the same 1.5 ml EP tube. The cells were 
then spun twice, firstly for 5 minutes at 3000 rpm and secondly for 8 seconds at 
12,000 rpm. The supernatant was removed and the cell pellets were put on ice, re-
suspended in 200 µl of cold PBS and transferred to round bottom 96-well plates. 
The 96-well plates were spun at 2300 rpm for 3 minutes at 4°C. The PBS was then 
discarded and the cell pellets re-suspended in cold PBS. The spinning process was 
repeated but once the PBS was discarded, the cells were this time re-suspended in 
2.5 µl annexin-FITC per well. The cells were mixed with a multichannel pipette and 
incubated in the dark, whilst shaking, for 10 minutes at room temperature. Following 
incubation, the cells were washed in 200 µl of binding buffer and centrifuged at 2300 
rpm for 3 minutes at 4°C. The supernatant was discarded and the cell pellets were 
re-suspended in 190 µl of binding buffer. 200 µl of binding buffer was added to the 
FACS tube and then 190 µl of cell suspension was also transferred. The samples 
were kept on ice. Just prior to acquiring the samples in the FACS, 10 µl of propodium 
iodide-A (PI) per tube was added. The FACS machine then acquired information 
regarding cell survival; flow cytometry was used to sort any dead cells with regard 
to their mode of cell death (apoptosis vs necrosis).  
4.2.2. Statistical methods 
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4.2.2.1. Multiple linear regression: predicting cell viability 
To test the use of biomarkers in predicting cell viability, multiple linear regression 
analysis was applied. This method uses more than one predictor variable (in this 
instance, multiple biomarkers) to predict an outcome variable (in this instance, cell 
viability). In the linear regression setting, the outcome variable must be continuous 
rather than nominal/categorical. The observed data (𝑌, representing cell viability) is 
a linear function of the predictor variables (𝑋1, 𝑋2, 𝑋3, 𝑋4 and 𝑋5, representing 
biomarker concentrations APAP, ALT, HMGB1, Full K18 and Fragmented K18, 
respectively). If all of the predictor variables were significant, and therefore included 
in the model, the relationship between predictor and outcome variables can be 
represented using a generalised linear model: 
 𝑌 = 𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + 𝛽4𝑋4 + 𝛽5𝑋5. 
(4-1) 
The objective of multiple linear regression is to optimise the parameters, 𝛽𝑖  (𝑖 =
0…5), so that the model provides the best fit to the observed (cell viability) data. 
Since a generalised linear model is assumed, ordinary least squares is a sufficient 
fitting method (minimising the distance from the model output and the data points 
[145]). In order to apply multiple linear regression analysis, there are several data 
assumptions that must be tested in order to ensure the method is appropriate for 
use and therefore the results are interpretable. The key assumptions are: 
 The outcome variable is measured on a continuous level. This assumption 
holds since cell viability is measured on a continuous level. 
 One or more of the predictor variables are continuous, ordinal or nominal. 
The predictor variables in our model are represented by biomarker 
concentrations (APAP, ALT, HMGB1, Full K18 and Fragmented K18), all of 
which are measured on a continuous level. 
 Observations must be independent. The Durbin-Watson statistic was used to 
test independence of the observations. This statistic tests for autocorrelation 
in the residuals from a statistical regression analysis. The test statistic 
created by Durbin and Watson summarises how each of the residuals vary 
in comparison to one another and the formula can be found in their study 
[146]. For independence to be present, the Durbin-Watson value can range 
between 0-4 but should be approximately 2 to indicate that there are no 
correlations between residuals (values from [0,2) indicate positive 
autocorrelation and values more than (2,4] indicate negative autocorrelation). 
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The Durbin-Watson statistic resulting from this dataset is 2.048 and therefore 
the independence of observations can be assumed. 
 Multi-collinearity should not be present between any predictor variables. This 
assumption was tested using the Variance Inflation Factor (VIF) test. The VIF 
is indicative of the amount of variance an estimated regression coefficient is 
increased by due to multicollinearity. Since the VIF is representative of 
increased variance, the square root of this result would be indicative of the 
increased standard error. As an example, a variable with VIF = 16 has a 
standard error 4 times larger than it would be if the variable was uncorrelated 
with the other variables. A recommended reasonable range for the VIF is 
[1,10]. Predictor variables were tested and remained within this range (all 
values within [1,3]). Therefore, multicollinearity does not exist between the 
predictor variables and the assumption is valid. 
 Outliers/highly influential points should not be present in the observed data. 
No outliers were identified. 
 Residuals should be approximately normally distributed. A histogram and 
normal P-P plot of the standardized residuals were inspected, and the data 
was found to be approximately normally-distributed. 
 
Figure 4-1: Data diagnostic plots. (A) Histogram – Visualisation of how the standardized 
residuals are distributed. For data to be diagnosed as normally distributed, the mean value 
should be approximately 0 and the standard deviation should be approximately 1. (B) Normal 
P-P plot of regression standardised residual. The cumulative probability expected from the 
model is plotted against the observed cumulative probability. For the data to be diagnosed as 
approximately normally distributed, most results (circles) should lie along the diagonal line. 
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Various regression models were created for subsets of the dataset (no antidote, 
1mM NAC, 2mM NAC, 3mM NAC, 4mM NAC, 5mM NAC) and then a regression 
model was created for the whole dataset 
A forward stepwise approach was used for each regression model. This means that 
the method (employed in SPSS) creates iterative multiple linear regression models. 
At each iteration, only the most significant predictor is included. An additional 
predictor is only included in the model if it provides improvement to the overall 
significance of the model. The resultant predictive biomarkers for each model 
created can be found in Table 4-1. 
4.2.3. Mathematical modelling 
4.2.3.1. Formulation 
We extended the PKPD framework described in Chapters 2 and 3 to account for 
cell functionality following an APAP dose. We employed a mathematical model 
defined by Remien et al. [73] which describes how functional and damaged cells 
change over time. In our model, we assumed that functional cells could be 
represented by viable cells, and therefore optimised the parameters against the cell 
viability data obtained from the experiments I carried out with my IVTS fellowship 
prize.  
The model for functional and damaged hepatocytes defined by Remien et al. is 
given by 
 𝑑𝐻
𝑑𝑡
= 𝑟𝐻 (1 −
𝐻 + 𝑍
𝐻𝑚𝑎𝑥
) − 𝜂[N]𝐻, (4-2) 
 𝑑𝑍
𝑑𝑡
= 𝜂[N]𝐻 − 𝛿𝑧𝑍, 
(4-3) 
where 𝐻 is the number of functional hepatocytes, 𝑍 is the number of damaged 
hepatocytes, 𝑟 is the functional hepatocyte regeneration rate (h-1), 𝐻𝑚𝑎𝑥 is the 
maximum number of hepatocytes, 𝜂 is the functional hepatocyte damage rate 
(l/µmol/h), [N] is the NAPQI concentration (µmol/l) and 𝛿𝑧 is the damaged 
hepatocyte lysis rate (h-1). Since our experimental data is expressed in terms of 
proportional cell viability, we set 𝐻𝑚𝑎𝑥 = 1 and effectively rescale such that 𝐻 
becomes the proportional number of functional hepatocytes and 𝑍 becomes the 
proportional number of damaged hepatocytes relative to the maximum. In Chapter 
112 
 
2, we described how the dynamics of NAPQI are assumed to be short-lived and the 
associated reactions are rapid on the time-scale of APAP depletion. In the model 
framework described in Chapters 2 and 3, we assume that NAPQI is at a quasi-
steady state on the time-scale of APAP PK. We re-introduce our NAPQI model here 
in equation (4-4): 
 𝑑[N]
𝑑𝑡
= 𝜉𝑘𝑒𝑙[Cc] − 𝑘𝐺[N][gsh] − 𝑘𝑝[N], 
(4-4) 
where 𝜉 is the proportion of CYP-activated APAP that is transformed into NAPQI, 
𝑘𝑒𝑙 (h
-1) is the total rate of APAP elimination, 𝑘𝐺  (l/µmol/h) is the decay rate of GSH 
due to binding with NAPQI, and 𝑘𝑝 (h
-1) is the rate at which NAPQI binds to other 
non-GSH proteins. We can derive the expression for NAPQI concentration by 
making use of the quasi-steady state approximation, 𝑑[N]/𝑑𝑡 = 0. By substitution 
into equation (4-4), it follows that 
 
N =
𝜉𝑘𝑒𝑙[Cc]
𝑘𝐺[gsh] + 𝑘𝑝
. (4-5) 
In vivo, hepatocytes have the ability to regenerate, whereas in the in vitro 
environment, they do not. Our aim was to create a mathematical model describing 
cell functionality following APAP dose, for which the parameters were representative 
of the in vitro scenario. Bearing this in mind, we adjusted Remien’s in vivo functional 
hepatocyte model (equation (4-5)) to result in the model shown in equation (4-6): 
 𝑑𝐻
𝑑𝑡
= −𝜂[N]𝐻. (4-6) 
The dynamics of functional hepatocytes in vitro could now be described by the 
model defined in equation (4-6). The dynamics for damaged hepatocytes in vitro 
could be modelled in the same way as the in vivo scenario (equation (4-3)).  
As well as modelling the effects of APAP on cell functionality, it is also essential to 
model the effects of antidote (NAC) on cell functionality. The distribution of NAC 
throughout the body can be represented mathematically by a 3-compartment model 
[147], with one (central) compartment consisting of well-perfused tissues and two 
peripheral compartments that contain poorly perfused tissues such as fats and 
blood binding proteins for example. Whilst APAP quickly distributes to well perfused 
tissues (central compartment) and secondarily to poorly perfused tissues 
(represented as one peripheral compartment), the PK of NAC has been shown to 
require an additional peripheral compartment as physiological which accounts for 
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different affinity sequestrations (to peripheral tissues, binding proteins etc.). In line 
with these findings, we employed a 3-compartment model previously described by 
Shen et al. [148] (Figure 4-2). 
 
Figure 4-2: Schematic of N’acetylcysteine (NAC) dynamical model described by Shen et 
al. [148]. A dose of NAC is provided and instantaneously reaches the first compartment (nacA). 
There are then continual rates of transfer to and from other compartments, nacB (𝒌𝟏𝟐 and 𝒌𝟐𝟏) 
and nacC (𝒌𝟏𝟑 and 𝒌𝟑𝟏). NAC is eliminated at rate 𝒌𝒆𝒍 from the first compartment (nacA). 
 
The model schematic portrayed in Figure 4-2 can be mathematically described as 
follows, 
 𝑑[NA]
𝑑𝑡
=
𝑁𝐷𝑜𝑠𝑒
𝑉𝑁𝐴
+ 𝑘𝑁21[NB] (
𝑉𝑁𝐵
𝑉𝑁𝐴
) + 𝑘𝑁31[NC] (
𝑉𝑁𝐶
𝑉𝑁𝐴
)
− (𝑘𝑁12 + 𝑘𝑁13 + 𝑘𝑁𝑒𝑙)[NA],   
(4-7) 
 𝑑[NB]
𝑑𝑡
= 𝑘𝑁12[NA] (
𝑉𝑁𝐴
𝑉𝑁𝐵
) −  𝑘𝑁21[NB], 
(4-8) 
 𝑑[NC]
𝑑𝑡
= 𝑘𝑁13[NA] (
𝑉𝑁𝐴
𝑉𝑁𝐶
) −  𝑘𝑁31[NC], 
(4-9) 
 
where [NA] is the total NAC concentration in the central compartment (µmol/l), [NB] 
and [NC] are the total NAC concentration in either peripheral compartment B or 
peripheral compartment C (µmol/l), 𝑁𝐷𝑜𝑠𝑒 is the initial dose of NAC provided (µmol), 
𝑉𝑁𝐴 is the theoretical volume of the central compartment (l/kg), 𝑉𝑁𝐵 and 𝑉𝑁𝐶  are the 
theoretical volumes of peripheral compartments B or C respectively (l/kg), 𝑘𝑁12 is 
the rate of transfer of NAC from the central compartment to peripheral compartment 
B (h-1), 𝑘𝑁21 is the rate of transfer of NAC from peripheral compartment B to the 
central compartment (h-1), 𝑘𝑁13 is the rate of transfer of NAC from the central 
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compartment to peripheral compartment C (h-1),  𝑘𝑁31 is the rate of transfer of NAC 
from peripheral compartment C to the central compartment (h-1), 
and 𝑘𝑁𝑒𝑙 represents the overall elimination rate of NAC (summation of excretion and 
metabolism processes) (h-1). 
These equations are applicable when a bolus dose of NAC is assumed, with the 
dose amount being converted to a concentration as described in equation (4-7) but 
redefined here for completeness, 
 
𝑁𝐴𝐶 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑏𝑜𝑙𝑢𝑠 = 
𝑁𝐷𝑜𝑠𝑒
𝑉𝑁𝐴
. (4-10) 
 
However, NAC regimens are typically administered via intravenous infusion, and 
therefore an infusion rate 𝑘𝑖𝑛𝑓 (μmol/kg/h) needed to be defined in the model based 
upon both dose amount and infusion time. For example, if a dose of 50 mg/kg is 
administered over 4 hours, 𝑘𝑖𝑛𝑓 = 12.5 mg/kg/h. In this scenario the infusion 
parameter, 𝑘𝑖𝑛𝑓, replaces the bolus parameter, 𝑁𝐷𝑜𝑠𝑒, such that the initial 
concentration term of equation (4-7) becomes, 
 
𝑁𝐴𝐶 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝐼𝑉𝑖𝑛𝑓 = 
𝑘𝑖𝑛𝑓
𝑉𝑁𝐴
. (4-11) 
For the conventional NAC regimen (initial administration of 150 mg/kg over 1 hour, 
followed by 50mg/kg over 4 hours, followed by a final infusion of 100 mg/kg over 16 
hours) the infusion rate (𝑘𝑖𝑛𝑓 , mg/kg/h) was defined as follows: 
 
𝑘𝑖𝑛𝑓 =
{
 
 
 
 
150 0 ≤ 𝑡 < 1
50
4
1 ≤ 𝑡 < 5
100
16
5 ≤ 𝑡 < 21
 (4-12) 
For the shortened NAC (SNAP) regimen (initial administration of 100 mg/kg over 2 
hours, followed by 200 mg/kg over 10 hours, the infusion rate (𝑘𝑖𝑛𝑓 , mg/kg/h) was 
defined as follows: 
 
𝑘𝑖𝑛𝑓 = {
100
2
 0 ≤ 𝑡 < 2
200
10
 2 ≤ 𝑡 < 12
 (4-13) 
Regardless of whether administered as a bolus dose or intravenous dose, NAC is 
an effective pre-cursor of GSH [149], provided in the APAP overdose case to 
increase GSH levels and subsequently increase the rate of detoxification of NAPQI. 
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With this in mind, we amended the GSH model described in Chapters 2 and 3, 
assuming that GSH production is a function of NAC concentration in the central 
compartment: 
 𝑑[gsh]
𝑑𝑡
= 𝑘𝑜(𝑔𝑠ℎ𝑜 − [gsh]) + 𝜁[NA] −
𝜉𝑘𝑒𝑙[Cc][gsh]
[gsh] + 𝑘𝑝𝑟
 (4-14) 
Where 𝑔𝑠ℎ is the GSH concentration (µmol/l), 𝑘𝑜 is the basal removal rate of GSH 
(including background usage) (h-1), 𝑔𝑠ℎ𝑜 is the baseline concentration of GSH in the 
APAP-free steady state (µmol/l), 𝜁 is the NAC-induced production rate of GSH (h-1), 
[NA] is the NAC concentration in compartment nacA (µmol/l), 𝜉 is the proportion of 
eliminated APAP that is transformed into NAPQI, 𝑘𝑒𝑙 is the total elimination rate of 
APAP (h-1), [Cc] is the APAP concentration and 𝑘𝑝𝑟 is the ratio of NAPQI forming 
other protein adducts relative to being detoxified by GSH. It should be noted that 
NAC and GSH will have different apparent volumes of distribution because of their 
different chemistries. 
Parameters for the all of the APAP PK and some of the PD (ALT, HMGB1, full and 
fragmented K18) elements of the model remained fixed at the optimised values used 
in our framework in Chapter 3. Parameters for the NAC PK model were equal to the 
values provided by Shen et al. [148]. Since we aimed to provide parameter values 
that could describe cell functionality changes following APAP/NAC doses, and 
provide profiles replicative of the cell viability data found from our experiments, we 
optimised the following parameters: from the cell functionality component of the 
model, the functional hepatocyte damage rate (𝜂) and the damaged hepatocyte lysis 
rate (𝛿𝑧); from the NAPQI component of the model, the GSH decay due to binding 
with NAPQI rate (𝑘𝐺); and from the GSH component of the model, the NAC-induced  
production rate of GSH (𝜁). All parameters were optimised by fitting the 
aforementioned (cell functionality, NAPQI and GSH) models to the cell viability time-
course data from my experiments (ATP assay).  
Parameters within the cell functionality component of our model were optimised by 
fitting to our in vitro cell viability time-course data. When using the model to simulate 
for the in vivo scenario, we assumed these parameters (found from fitting to in vitro 
data) would be similar in the in vivo scenario. However, in vivo, hepatocytes have 
the ability to regenerate, and therefore we did not assume that the cell functionality 
model for the in vivo scenario should be completely identical to the in vitro scenario. 
The in vivo model structure for functional hepatocytes over time was identical to 
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equation (4-2). The functional hepatocyte damage rate, 𝜂, was optimised from our 
in vitro data, but since no additional in vivo data was available, the functional 
hepatocyte regeneration rate,  𝑟, remained fixed as the value provided in Remien’s 
in vivo study [73]. The in vivo model employed for damaged hepatocytes is 
described by equation (4-3), with the functional hepatocyte damage rate, 𝜂, and the 
damaged hepatocyte lysis rate, 𝛿𝑧 , optimised based on our in vitro study. 
4.2.3.2. Simulation 
The model was simulated for various NAC doses provided at 1h post-APAP dose to 
visualise any effects on the thresholds (APAP dose and time since administration) 
required for our probability of liver injury toxicity measure. This toxicity measure was 
defined by our previous framework, details of which are described in Chapter 3, 
section 3.2.9. Using the extended framework defined within this chapter, we also 
assessed how amending the dose of NAC impacted the thresholds for an additional 
toxicity measure, APAP-induced loss of cell functionality. Loss of cell functionality 
was defined as any simulated proportion of functional cells lower than 20%; Acute 
liver failure is thought to take place beyond 80% hepatocyte loss [150]. The exact 
threshold for when a liver should be deemed “healthy” or “unhealthy” is currently 
unknown and of particular clinical interest [151].  
4.3. Results 
4.3.1. Wet-lab experiments 
4.3.1.1. Microscopic images of hepatocyte culture 
Microscopic images of the hepatocyte culture were taken to visualise the viability of 
the cells. Images were taken at 24h, 48h and 72h (Figure 4-3). A lower and higher 
dose of APAP was compared (1 mM and 20 mM respectively), as well as the effects 
of providing antidote treatment 1 hour post-APAP dose. For the control images (No 
APAP or NAC) the cells became more confluent as time progressed, with little 
indication of any cell death. 
The smaller dose of APAP (1 mM) was comparable to the control images. For the 
higher dose of APAP (20 mM), however, negative effects upon the hepatocytes 
could be clearly be visualised. At the 24 h time-point, dead hepatocytes were visible 
and identified by dark brown masses. As time progressed, so too did loss of 
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hepatocyte functionality, with the 72 h time-point providing a clear visualisation of 
hepatocyte death. Providing antidote treatment (5 mM) to the 1 mM APAP case 
provided no real positive/negative effect, i.e. both the 1 mM APAP case and the 
1mM APAP + 5 mM NAC case were visually comparable to the control case. 
Providing antidote treatment to the 20 mM APAP dosed cells did, however, provide 
a positive visual effect on the cells. At the 24 h and 48 h time-points in the 20 mM 
APAP dose without antidote case, the cells were already dying/dead. In comparison, 
at these time-points the cells treated with antidote were visually healthy and 
comparable to the 1 mM APAP dose and control cases. Although the cells were 
visibly dying at 72 h in the 20 mM APAP + 5 mM NAC case, the amount of time 
taken for the cells to die was longer in the antidote case (72 h compared with 24 h 
in the no antidote case).  
4.3.1.2. Cell viability – ATP assay 
In order to quantify cell viability, we measured the intracellular ATP and calculated 
the changes relative to baseline ATP. We see in (Figure 4-4) how varying doses of 
APAP and NAC affected the cell viability of each case as time progressed.  
Figure 4-4(F) shows that the average proportion of viable cells decreased over time 
in all cases (± NAC). At 6 h, the NAC treated data had 80% of the hepatocytes in a 
viable state, reducing to approximately 10% at 72 h. For the hepatocytes which were 
not treated with the antidote, approximately 70% were viable at 6 h, reducing to 
around 10% at 72 h. At all time-points, the cells which had 0 mM NAC treatment 
provided (shown by the blue line) had reduced viability when compared to the cells 
who were given a dose of NAC (green line). At 72 h, regardless of whether the cells 
were provided with NAC treatment, cell viability was low, around 10%. This result 
was consistent with that found by visualising the microscopic hepatocytes (Figure 
4-3); NAC appears to slow down the onset of cell death, but not completely prevent 
it. 
At the 6-hour time-point (Figure 4-4(A)), cell viability was reasonably high for the 
1mM and 5mM APAP dose cases, averaging around 80% across all NAC doses. 
Providing 1 mM and 3 mM NAC in both of these cases seemed to protect the cells 
and allowed the cells to remain at full viability (100%) 6 h post-dose. For the higher 
APAP doses, 10 mM and 20 mM, viability was reduced to an average of 
approximately 60% and 40% respectively. In both of these instances, NAC did not 
seem to provide any clear protection, regardless of the dose. 
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Figure 4-3. Microscopic images at various time-points for various doses of APAP/NAC, 
visualising the effects of both the toxin (APAP) and antidote (NAC) on primary mouse 
hepatocyte viability. Live cells are indicated by pale coloured shapes with visible nuclei. Dead 
cells are represented by shapes of a much darker brown shade, with less visible nuclei. Images 
which show a high population of condensed live cells are representative of cell confluence, 
whilst images with distinct empty spaces represent wells where cell loss has occurred. 
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Figure 4-4: The effect of varying APAP/NAC doses on hepatocyte viability. The primary 
hepatocytes were dosed with four APAP doses, [1, 5, 10, 20] mM. Each scenario was given a 
varying dose of NAC [0,1,2,3,4,5] mM 1 hour post-APAP dose Proportion of viable cells for each 
scenario was measured and represented as a score [0,1]: 1 for 100% viable (white); 0 for 0% 
viable (black). (A) shows the effect of varying APAP/NAC doses on hepatocyte viability 6 hours 
post-APAP dose, (B) shows the effects 10 hours post-APAP dose, (C) shows the effects 24 
hours post-APAP dose, (D) shows the effects 48 hours post-APAP dose, (E) shows the effects 
72 hours post-APAP dose and (F) shows the average proportion of viable cells across the whole 
time course, for scenarios given no NAC (green), and for scenarios provided with NAC treatment 
(blue).  
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At the 10 h time point (Figure 4-4(B)), a general reduction in cell viability could be 
clearly seen. At this time-point, no cases were completely viable (viability in all cases 
is less than 1). However, NAC did seem to have some sort of protective effect. For 
the [1, 5, 10] mM APAP dose cases treated with NAC, cell viability on average was 
approximately 70%. For the highest APAP dose (20 mM) cell viability was 
approximately 40% across all NAC dosed cases. Providing no NAC in the 1 mM and 
5 mM APAP cases reduced viability from approximately 70% in the NAC dosed case 
to approximately 20%. For the 10 mM and 20 mM APAP cases, cell viability was 
completely reduced to 0% if no NAC was provided.   
At 24 hours (Figure 4-4(C)), cell viability was reduced to 0% for the 5 mM, 10 mM 
and 20 mM APAP cases which were not given NAC. For the highest APAP dose (20 
mM), regardless of the amount of NAC provided, cell viability remained at 0%. For 
the 10 mM APAP case, cell viability was measured to be up to 50% at 24 h if 3 mM 
NAC treatment was provided. Providing the same dose of NAC in the 1 mM APAP 
case allowed cells to be measured as completely viable (100%) at 24 h, this was an 
increase of 40% from the 10 h time-point. For all of the cells dosed with 1 mM APAP, 
whether dosed with NAC or not, cell viability had recovered to above 90%, 
suggesting that for the 1 mM dose of APAP, NAC may not be required for ATP 
recovery to occur. However, we did begin to see the protective effects of NAC for 
other cases. There was no improved viability at 24 h for the higher doses of APAP 
([10, 20] mM) without NAC protection; for these doses, viability was 0% at 10 h and 
remained 0% at 24 h. For the 5 mM APAP case, providing NAC between 1-3 mM 
improved the viability almost completely at 24 h, increasing the viability from an 
average of 70% at 10 h to above 90% at 24 h. However, higher doses of NAC did 
not protect the viability of the cells at 24 h as viability was reduced from 
approximately 70% at 10 h to 20% at 24 h. For the 10 mM APAP case, NAC did not 
protect the cells at this time-point; for the NAC-dosed cases, viability reduced from 
an average of 70% at 10 h to approximately 30% at 24 h. Interestingly, providing 
the highest NAC dose (5 mM) resulted in 0% viability at 24 h, an identical result to 
cell viability at 24 h following no NAC dose at all.  
At the 48-hour time point, viability started to generally decrease again (Figure 
4-4(D)). The positive effects of NAC for the 1 mM APAP case at 24-hours were no 
longer seen here. If a NAC dose was provided, viability was measured at 100% at 
24 h, whereas at 48 h the maximum measured cell viability was approximately 70%. 
Although there was generally a decrease in viability for the 5 mM APAP case (an 
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average decrease of around 20% from the 24 h measurements), at 24 h, the cells 
were measured to be completely viable. Subsequently, a decrease to 80% cell 
viability at 48 h, when compared to a measurement of 40% viability for the case 
without antidote, suggests that the protective effects of NAC are still seen at 48-
hours for the 5 mM APAP case. For the 1 mM and 5 mM APAP cases, cell recovery 
was identified (40% and 20% increase in cell viability respectively) between 10 and 
24 h, but this recovery was not seen for the 10 mM and 20 mM APAP cases. At 48 
hours, we began to see recovery for the 10 mM APAP case (increase of 
approximately 80% cell viability from 24 h to 48 h). This increase was only seen for 
cells provided with the highest doses of NAC, [4, 5] mM, and this late recovery 
suggests it takes longer for the positive effects of NAC to be seen as the dose of 
APAP increases. This could correspond to the severe depletion of GSH stores in 
high APAP dose cases that would take longer to restore. For the 20 mM case, cell 
viability remained at 0%, regardless of the NAC dose given.  
At the 72-hour time point, the protective effects of NAC could not be seen (Figure 
4-4(E)). Cell viability completely reduced for the 10 mM and 20 mM APAP dose 
cases. Whilst providing a high NAC dose allowed cells to be measured as 100% 
viable at 48 h, at 72 h, regardless of whether NAC was provided or not, there were 
0% viable cells for the 10 mM and 20 mM APAP cases. For the 5 mM APAP case, 
all NAC-dosed cases had cell viability measurements less than 20%, with most at 
0%.  Even for the lowest APAP case (1 mM), cell viability reduced by an average of 
40% from 48 h to 72 h, regardless of the NAC dose initially provided. 
4.3.1.3. Cell sorting - FACS 
FACS analysis was carried out to investigate the mode of cell death (apoptosis or 
necrosis (Figure 4-5)). The clearest result from this analysis was that in almost all 
APAP dose cases, providing no NAC treatment resulted in the percentage of dead 
cells being greater than live cells. This result is reflected by the summation of the 
black and white (necrotic and apoptotic regions) in Figure 4-5, for the 0 mM NAC 
dose in all APAP cases being greater than 50%. Comparing the amount of necrosis 
against apoptosis when no NAC was provided, for the 1 mM APAP case (Figure 
4-5(A)), 42% of cells were necrotic whilst 8% were apoptotic. For the 5 mM APAP 
case (Figure 4-5(B)), 54% were necrotic whilst 2% were apoptotic. For the 10 mM 
and 20 mM APAP case, (Figure 4-5(C-D)) 56% of cells were necrotic whilst 0% were 
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apoptotic. The amount of necrotic cells dominated the amount of apoptotic cells in 
each of these cases. 
For the 1 mM APAP dose case with no NAC, approximately half of the cells died 
with around 42% of the cells being necrotic and 8% apoptotic. Providing any dose 
of NAC and comparing this to the case with no NAC, showed an increased amount 
of apoptosis and decreased amount of necrosis: 2 mM NAC decreased the necrotic 
percentage to 20% and increased the apoptotic percentage to 10%, 3 mM NAC 
decreased the necrotic percentage to 20% but increased the apoptotic percentage 
to 22%, 4 mM NAC decreased the necrotic percentage to 22% but increased the 
apoptotic percentage to 12% and 5 mM NAC decreased the necrotic percentage to 
8% but increased the apoptotic percentage to 22%. When providing 2 mM, 3 mM 
and 4 mM NAC, the proportion of apoptosis and necrosis were similar. Providing 
the highest dose of NAC (5 mM) resulted in apoptosis dominating with reduced 
levels of necrosis. 
For the 5 mM APAP case, when no NAC was provided, there was a greater amount 
of necrosis (52% versus 3% apoptosis) than seen in the 1 mM APAP case (40% 
necrosis versus 10% apoptosis). Providing the antidote in this 5 mM APAP case 
caused a distinctive switch to apoptosis for all doses of NAC. Specifically, providing 
2 mM NAC resulted in an almost negligible amount of necrosis (2%). The cases 
dosed with 3 mM and 4 mM NAC provided similar results to one another – 
approximately 10% of the cells were necrotic whilst approximately 25% were 
apoptotic. For the highest dose of NAC however, whilst apoptosis still dominated 
(25% of cells), it was to a lesser extent since the amount of necrosis had increased 
from 10% to 15%.  
Providing no antidote in the 10 mM APAP case did not allow any apoptosis to occur, 
with around 57% of the cells being necrotic. Providing 2, 3 or 4 mM NAC allowed a 
decreased percentage of necrotic cells (10%, 15% and 17% respectively), and 
increased percentage of apoptotic cells (22%, 22% and 25% respectively). 
Apoptosis remained the main form of cell death until the 5 mM NAC dose, where 
the percentage of apoptosis was very similar to necrosis, at approximately 30% 
each. 
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Figure 4-5: Quantifying the mode of cell death 24 hours post-APAP dose through FACS 
analysis. The mode of cell death (apoptosis vs necrosis) was compared for four APAP doses 
[1, 5, 10, 20] mM, at 24 hours post-dose. Additionally, the effect of NAC on this mode of cell 
death was analysed. Varying doses of NAC were applied and compared, [0, 2, 3, 4, 5] mM, 1 
hour post-APAP dose. Apoptotic cells are indicated by white regions on each bar, whilst necrotic 
cells are represented by black regions on each bar. 
Providing no antidote in the 20 mM case provided similar results to the 10 mM case 
with no antidote; around 57% cells were necrotic with no visible apoptosis. When 
providing 2 mM NAC in the 20 mM APAP case, the apoptotic and necrotic forms of 
cell death were identical (20% each). Interestingly, providing a 3 mM NAC dose 
seemed to completely reduce the number of necrotic cells, whilst 20% of the cells 
remained apoptotic. Increasing the NAC dose beyond 4 mM in the 20mM APAP 
case, however, did result in necrotic cells, however, he apoptotic dominance was 
not apparent; both apoptosis and necrosis levels were similar (20% each in the 4 
mM NAC case and 25% each in the 5 mM NAC case). 
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4.3.1.4. Gene quantification - qPCR 
qPCR was carried out in order to quantify and compare the amount of an apoptotic 
marker (caspase) and a necrotic marker (miR-122) following two different doses of 
APAP (5 mM and 20 mM), and how various doses of NAC ([0,1,2,3,4,5] mM) 
affected this subsequent output. 
Figure 4-6(A) clearly shows that apoptosis levels were higher for the 5 mM APAP 
case, and lower for the 20 mM APAP case. This was expected, since a higher dose 
of APAP is likely to result in relatively higher levels of necrosis, and therefore lower 
levels of apoptosis. NAC treatment did not cause a distinctive difference to the 
apoptosis levels except for the 20 mM APAP dose case, where NAC > 4 mM 
seemed to increase the amount of apoptosis. 
 
 
Figure 4-6: Comparing mode of cell death through quantification of apoptotic 
and necrotic markers. The effects of 5 mM and 20 mM doses of APAP (black and red lines 
respectively) in combination with various doses of NAC, [0,1,2,3,4,5] mM (1 hour post-APAP 
dose) were analysed at 24 hours post APAP dose. Firstly, with respect to the quantification of 
an apoptotic marker, (caspase, A) and secondly, a necrotic marker (miR-122, B). 
The levels of necrosis were higher for the 20 mM APAP case than they were for the 
5 mM case, as expected (Figure 4-6(B)). For the 5 mM APAP case, NAC did not 
seem to have any effect on necrosis levels. However, for the 20 mM case, it seemed 
that increasing the amount of NAC from 0-4 mM had a negative effect, increasing 
the amount of necrosis, until beyond 4 mM when necrosis levels started to decrease. 
Although this decrease in necrosis for the 20 mM case is mirrored by an increase in 
the caspase apoptosis marker in Figure 4-6(A), the overall results in Figure 4-6 are 
not consistent with the results from the FACS analysis carried out above in Figure 
4-5. When quantifying apoptosis by analysing changes in caspase for the 5 mM 
APAP case (Figure 4-6(A)), NAC seemed to have no impact. The FACS analysis 
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(Figure 4-5(B)) showed minimal levels of apoptosis for the 0 mM NAC case, but an 
increased level for NAC [2, 5] mM. This protection is not mirrored in the caspase 
quantification results. For the 20 mM APAP case, caspase remained stable and 
increased when NAC >4 mM. Again, this result does not reflect the result from the 
FACS analysis (Figure 4-5(D)), where the increase in apoptosis was seen only at 2 
mM, and then remained stable for all higher doses of NAC. 
With regards to the 5 mM APAP dose, the FACS analysis showed high necrotic 
levels when 0mM NAC was provided, with reduced levels when a dose of [2, 5] mM 
NAC was provided. Again, this result is not mirrored with the results from the miR-
122 quantification; miR-122 was low when 0 mM NAC was provided and remained 
stable throughout all doses of NAC. For the 20 mM APAP dose, Figure 4-6(B) shows 
that NAC did not impact on miR-122 as we may have expected – increasing the 
NAC dose also increased the amount of the miR-122 necrosis marker. This result 
is contrary to the result found in the FACS analysis, Figure 4-5(D), where high 
necrotic levels were found for the 0 mM NAC case, with a reduced amount for higher 
NAC doses. Carrying out more repeats of the experiments may help to explain this 
disparity. 
4.3.2. Multiple linear regression - predicting cell viability 
All biomarkers (APAP, ALT, HMGB1, full K18 and fragmented K18) were initially 
employed in the statistical analysis. Significant predictors from the forward stepwise 
multiple linear regression analysis for each subset of data are detailed in Table 4-1. 
Table 4-1: Table of significant biomarkers for predicting cell viability for various subsets 
of data. 
For the subset of data which had not been dosed with any antidote, cell viability 
could be significantly predicted by the full and fragmented versions of biomarker 
K18. For each subsequent NAC dosed subset, the combination of biomarkers 
APAP, HMGB1 and fragmented K18 could significantly predict cell viability. For the 
Dataset Significant predictors P-value 
0 mM NAC subset Full K18, Fragmented K18 0.001 
1 mM NAC subset APAP, HMGB1, Fragmented K18 <0.001 
2 mM NAC subset APAP, HMGB1, Fragmented K18 <0.001 
3 mM NAC subset APAP, HMGB1, Fragmented K18 <0.001 
4 mM NAC subset APAP, HMGB1, Fragmented K18 0.001 
5 mM NAC subset - - 
Full dataset ALT, Full K18, Fragmented K18 <0.001 
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subset of data that was dosed with 5 mM NAC, none of the biomarkers could 
significantly predict viability of the cells. When all of the subsets of data were 
combined into one full dataset (± NAC) viability of cells could be significantly 
predicted by ALT, full and fragmented K18 biomarker concentrations.  
Interestingly, currently used clinical biomarkers (APAP/ALT) were predictive of cell 
viability when NAC dosed data was tested. However, if the analysis was tested on 
data with no NAC provided, these clinical biomarkers were not significant, and only 
the novel biomarkers could significantly predict cell viability. 
4.3.3. Modelling the effect of NAC dosing regimen on the 
functionality of hepatocytes, and the probability of liver 
injury 
4.3.3.1. Model optimisation 
By extending our mathematical model within this chapter, our framework now has 
the ability to account for APAP, APAP toxicity biomarkers, and cell functionality 
profiles over time. For parameters affecting the cell functionality component of the 
model, so that model output could replicate our cell viability time-course data, the 
parameters were optimised by fitting the models to the cell viability data (resulting 
from the ATP assay). Optimised parameters affecting the cell functionality 
component of the model were as follows: from the functional hepatocyte model, 
functional hepatocyte damage rate, 𝜂 = 3.584 l/μmol/h; from the damaged 
hepatocyte model, damaged hepatocyte lysis rate, 𝛿𝑧 = 2.1891 h
-1; from the NAPQI 
model, decay of GSH due to NAPQI, 𝑘𝑔 = 7.1437 l/μmol/h; and from the GSH model, 
increasing factor of GSH due to NAC, 𝜁 = 165.1162 h-1. The in vivo functional 
hepatocyte regeneration rate was fixed as the value from Remien’s study [73], 𝑟 = 
0.0417 h-1. The predictive output versus the data used for optimisation can be seen 
in Figure 4-7. 
127 
 
 
Figure 4-7: Predicted model output versus experimental data used for optimisation. (A) 
Proportional cell viability over time (in vitro) following a dose of 1 mM APAP. (B) Proportional 
cell viability over time (in vitro) following a dose of 5 mM APAP. (C) Proportional cell viability 
over time (in vitro) following a dose of 10 mM APAP. (D) Proportional cell viability over time (in 
vitro) following a dose of 20 mM APAP. In each instance, stars represent the experimental data 
used for optimisation and dashed lines represent the predicted model output. 
4.3.3.2. The effect of NAC administration time on biomarker 
profiles 
The optimal timing of NAC administration for the best protective effects is currently 
heavily debated within the clinic. Therefore, we used our model to simulate various 
scenarios, with differing times of NAC administration, and analysed subsequent 
effects on biomarker and cell functionality profiles (Figure 4-8). Note that the model 
was simulated to provide time-courses over a 24-hour period, since this was the 
latest time point observed in the biomarker data that was originally used for 
biomarker-related parameter optimisation. 
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For an APAP overdose of 350 mg/kg, providing no NAC at all resulted in very 
different predicted profiles compared to when 150 mg/kg NAC 1-hour-post-APAP is 
provided. These results can be seen in Figure 4-8. When no NAC was provided, the 
predicted GSH profile (Figure 4-8(B)) remained low for the entire time-course, 
whereas providing a dose of NAC at 1 hour caused great increases in the GSH 
concentration. The benefits of providing NAC can also be seen by the NAC dosed 
cases having lower predicted biomarker (ALT, HMGB1, NAPQI) concentrations than 
if no NAC was provided. While biomarkers ALT and HMGB1 began to increase 
following an APAP dose of 300 mg/kg, a slightly higher APAP dose (350 mg/kg) was 
required to see full and fragmented K18 profiles perturbed. However, at APAP doses 
higher than 350 mg/kg, all biomarkers followed a similar pattern– lower 
concentrations for the NAC-dosed case and higher concentrations when no NAC 
was provided. We report the findings for a 350 mg/kg APAP dose since this is the 
dose thought to induce toxicity in mice (predicted by our previous framework in 
Chapters 2 and 3). NAC dose is predicted to also have a positive effect on cell 
functionality: Figure 4-8(H) shows that when provided with a 350 mg/kg APAP dose 
and no NAC protection, the predicted proportional cell viability reduced to around 
10%, and only began to slightly recover at late time-points (beyond 24 hours). In the 
case where 150 mg/kg NAC was provided 1 hour post-APAP-dose however, the 
proportion of viable cells did not decrease beyond approximately 50%, and 
immediately after NAC intervention the cells began to recover. 
NAC is usually administered beyond 4 hours of the initial APAP overdose, and so 
therefore we simulated the administration of 150 mg/kg NAC 5 hours post APAP-
dose to visualise the effects on biomarker concentrations and cell functionality 
(Figure 4-9). 
Providing the NAC dose 5-hours-post-APAP-dose still provided favourable 
biomarker concentration/cell functionality profiles when compared to the cases 
where no NAC was provided. This is reflected firstly in Figure 4-9(B) where the GSH 
concentration profile in the NAC-dosed scenario (green) is much higher than the 
non-NAC-dosed scenario (red). These positive results are also mirrored by ALT and 
HMGB1 concentrations being lower for the NAC dosed case than the non-NAC 
dosed case Figure 4-9(C,D); and also the proportion of viable cells being slightly 
higher in the NAC case compared to the non-NAC case Figure 4-9(H). Generally 
though, NAC was predicted to provide less improvement if administered 5 hours 
post-dose (Figure 4-9) than if it is administered 1 hour post dose (Figure 4-8). 
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It is thought that NAC is no longer beneficial if provided longer than 8 hours post-
overdose [23]. We therefore simulated the administration of 150 mg/kg NAC 15-
hours-post-APAP-dose to investigate the effects on biomarker concentrations and 
cell functionality (Figure 4-10). 
Although Figure 4-10 (B) shows the expected positive effects of NAC administration 
on GSH concentration (the NAC-dosed profile is much higher than the non-dosed 
profile) beyond 15 hours, NAC administration only very slightly lowered ALT and 
HMGB1 concentrations (Figure 4-10(C,D)). Providing NAC 15-hours-post-APAP 
dose was predicted to have no protective effects on cell viability Figure 4-10 (H,I). 
 
Figure 4-8: Effect of administering antidote (NAC) 1-hour-post-APAP overdose on 
predicted biomarker and cell functionality profiles. Red lines show the simulated output if 
no NAC dose is provided, while green shows the simulated output if 150 mg/kg NAC is provided. 
If only a green simulation is present, this indicates it overlaps the non-NAC simulation, and 
therefore they are identical. (A) Predicted APAP concentration over time, (B) predicted GSH 
concentration over time, (C) predicted ALT concentration over time, (D) predicted HMGB1 
concentration over time, (E) predicted full K18 concentration over time, (F) predicted fragmented 
K18 concentration over time, (G) predicted NAPQI concentration over time, (H) proportion of 
healthy cells over time, (I) proportion of damaged cells over time. 
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Figure 4-9: Effect of administering antidote (NAC) 5-hours-post-APAP overdose on 
predicted biomarker and cell functionality profiles. Red lines show the simulated output if 
no NAC dose is provided, while green shows the simulated output if 150 mg/kg NAC is provided. 
If only a green simulation is present, this indicates it overlaps the non-NAC simulation, and 
therefore they are identical. (A) Predicted APAP concentration over time, (B) predicted GSH 
concentration over time, (C) predicted ALT concentration over time, (D) predicted HMGB1 
concentration over time, (E) predicted full K18 concentration over time, (F) predicted fragmented 
K18 concentration over time, (G) predicted NAPQI concentration over time, (H) proportion of 
healthy cells over time, (I) proportion of damaged cells over time. 
 
131 
 
 
Figure 4-10: Effect of administering antidote (NAC) 15-hours-post-APAP overdose on 
predicted biomarker and cell functionality profiles. Red lines show the simulated output if 
no NAC dose is provided, while green shows the simulated output if 150 mg/kg NAC is provided. 
If only a green simulation is present, this indicates it overlaps the non-NAC simulation, and 
therefore they are identical. (A) Predicted APAP concentration over time, (B) predicted GSH 
concentration over time, (C) predicted ALT concentration over time, (D) predicted HMGB1 
concentration over time, (E) predicted full K18 concentration over time, (F) predicted fragmented 
K18 concentration over time, (G) predicted NAPQI concentration over time, (H) proportion of 
healthy cells over time, (I) proportion of damaged cells over time. 
4.3.3.3. The effect of NAC dose amount on toxicity thresholds 
As well as investigating effects of the administration time of NAC, the effects of NAC 
dose alone (without changing the time of administration) was investigated with 
regard to the effect on both of our toxicity measures: probability of liver injury and 
proportion of healthy cells. Each NAC dose under investigation, [0, 150, 400] mg/kg, 
was administered 1-hour post-dose, and we calculated which APAP dose would 
indicate probable liver injury and severe reduction in the proportion of healthy cells. 
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If the NAC administration was beneficial, then a higher dose of APAP would be 
required to result in probable liver injury/severe reduction in cell viability. 
NAC resulted in protecting against much higher APAP doses when using the 
probability of liver injury based on biomarker concentrations as a toxicity measure, 
in comparison to using loss of cell functionality as a toxicity measure. This can be 
clearly visualised in Figure 4-11 by the order of magnitude difference in the scale of 
APAP doses reaching up to 10,000 mg/kg in the probable liver injury cases (Figure 
4-11(A,C,E)) and reaching only 1,000 mg/kg in the cell functionality cases (Figure 
4-11(B,D,F)). If no NAC was provided, the APAP dose threshold for toxicity was of 
the same order of magnitude. Using probability of liver injury as a toxicity measure 
(Figure 4-11(A)), toxicity was predicted for any APAP dose above approximately 
550 mg/kg. This is shown by the black contour – any observation above this contour 
is predicted to be highly probable to progress into liver injury. When using loss of 
cell functionality (or the percentage of dead/damaged cells being greater than 80%) 
as a toxicity measure (Figure 4-11(B)), toxicity was predicted for any APAP dose 
above approximately 400 mg/kg, with any APAP dose above approximately 500 
mg/kg predicted to result in 100% of cells being dead/damaged. 
Providing a dose of NAC (either 150 mg/kg or 200 mg/kg) appeared to make a slight 
change to the predictions when using cell functionality as a toxicity measure (Figure 
4-11(D,F)). The contour increased to a slightly higher APAP dose, and the 
progression from 80% to 100% hepatocyte death/damage was more gradual as the 
APAP dose increased, rather than any APAP dose above 500 mg/kg resulting in 
100% death/damage. When providing NAC and using biomarker-based-probable 
liver injury as a toxicity measure, the antidote benefits could be clearly seen. 
Treatment with the recommended 150 mg/kg dose of NAC increased the APAP 
dose predicted to cause liver injury from approximately 550 mg/kg (Figure 4-11(A)), 
to a much greater 7000 mg/kg (Figure 4-11(B)). This APAP dose was even further 
increased when 200 mg/kg NAC is provided (Figure 4-11(C)). 
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Figure 4-11: Effect of administering different doses of antidote (NAC) 1-hour-post-APAP 
overdose on the predicted probability of liver injury and proportion of healthy cells for 
various APAP doses. Black contours are thresholds where any observation above such would 
be predicted to have a high probability of liver injury (A,C,E) or a severe loss of cell functionality 
(B,D,F). Red regions are representative of 1 and blue regions are representative of 0. Therefore, 
in the liver injury probability plots (A,C,E) the red regions are representative of a predicted 
probability of liver injury of 100% and therefore severe toxicity. The red region in the cell 
functionality plots (B,D,F), is representative of cells being 100% dead/damaged, and therefore 
indicative of severe toxicity. (A,B) show the effects of providing no NAC dose on the APAP dose 
thresholds for probability of liver injury and cell functionality, respectively. (C,D) show the effects 
of providing a 150 mg/kg NAC dose on the APAP dose thresholds probability of liver injury and 
cell functionality, respectively. (E,F) show the effects of providing 200 mg/kg NAC dose on the 
APAP dose thresholds for probability of liver injury and cell functionality, respectively. 
The benefits of providing NAC at 1-hour-post-APAP dose (when using probable liver 
injury as a toxicity measure) is clearly represented in Figure 4-12(A) by the large 
difference in thresholds for the “No NAC” case (black contour) when compared to 
the NAC cases (blue and orange contours). 
The APAP dose predicted to induce severe loss of cell functionality when no NAC 
was provided was approximately 400 mg/kg (Figure 4-11(B)). Providing a NAC dose 
of 150 mg/kg slightly increased the APAP dose predicted to induce severe loss of 
cell functionality, however increasing the NAC dose from 150 mg/kg to 200 mg/kg 
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did not have any additional effect (Figure 4-12(B)). Our results suggest although 
NAC may slightly increase the APAP dose required to cause toxicity, this effect may 
be limited for cell functionality and increasing the NAC dose will not necessarily 
increase the APAP dose likely to cause toxicity. 
 
Figure 4-12: NAC dose effects on the APAP dose threshold for inducing liver toxicity 
based on two different measures: (A) probable liver injury based on HMGB1 
concentration (probability greater than 0.5) and (B) severe loss of cell functionality (80% 
reduction of cell viability). Any observation above any of the thresholds is predicted to be a 
toxic case. The black contour represents the toxic threshold when no NAC is provided. The blue 
dashed contour represents the toxic threshold when 150 mg/kg NAC is provided. The orange 
dotted contour represents the toxic threshold when 200 mg/kg NAC is provided. 
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4.3.3.4. Comparing the effects of two NAC regimens on biomarker 
profiles 
The current NAC regimen [24] (providing an initial dose of 150 mg over 1h, followed 
by a second dose of 50 mg over 4h, followed by a final dose of 100 mg over 16h) 
was compared to a NAC regimen in which the NAC is administered over a shorter 
time period (100 mg over 2h followed by 200 mg over 10h). This shorter NAC 
regimen is often referred to as SNAP and is proposed by Bateman et al. [152]. Both 
NAC protocols were applied and corresponding biomarker outputs were simulated 
(Figure 4-13). 
 
Figure 4-13: The effect of different NAC regimens on various time-course profiles (black 
profile – no NAC provided, red profile – current NAC regimen, blue dashed profile – SNAP 
regimen). (A) NAC concentration profile, (B) GSH concentration profile, (C) NAPQI 
concentration profile, (D) HMGB1 concentration profile, (E) Proportional cell viability profile. 
Of course, the NAC concentration remained at 0 throughout the whole time-course 
when no NAC was provided (Figure 4-13(A)). The current regimen allowed a high 
peak concentration which quickly declined. The SNAP regimen allowed a peak 
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concentration around half of that provided by the current regimen, but the 
concentration remained around this level for around 17 hours before declining. Both 
NAC regimens allowed the GSH concentration to far exceed its baseline (Figure 
4-13(B)) before decreasing to its baseline after approximately 24 hours. NAPQI 
concentration rapidly decreased following administration of both NAC regimens 
(Figure 4-13(C)). When no NAC was provided, as expected, HMGB1 increased from 
baseline, before returning to baseline around 50 hours post APAP-dose. When 
either NAC regimen was introduced, the biomarker decreased below the baseline 
value, before returning at around 50 hours. Both regimens maintained HMGB1 
concentration at around the same value for the first 20 hours post-dose, however, 
since the shorter NAC regimen did not continue beyond this point, HMGB1 
concentrations returned to baseline at a faster rate than the conventional regimen. 
If no NAC was provided, cell viability was predicted to almost completely diminish 
before starting to slowly recover beyond approximately 20 hours. Both NAC 
regimens were predicted to protect the function of cells, with viability reducing to 
approximately 40% in both scenarios, and recovering quicker than the case in which 
no NAC was provided. 
4.3.3.5. Comparing the effect of two NAC regimens on toxicity 
thresholds 
Both regimens (conventional and SNAP) were simulated and compared to 
investigate any differences in APAP dose threshold predicted to induce probable 
liver injury probability and severe loss of cell functionality (Figure 4-14). 
NAC administration had a much greater influence on the toxicity measure based on 
probable liver injury in comparison to the toxicity measure based on loss of cell 
functionality (Figure 4-14). This is reflected by APAP doses likely to induce toxicity 
being on a much greater scale (up to 10,000 mg/kg) in the probable liver injury plots 
(Figure 4-14(A,C)) when compared to the lower scale (up to 800 mg/kg) on the cell 
functionality plots (Figure 4-14(B,D)). This result (NAC having a greater effect on 
probable liver injury as a toxicity measure, rather than loss of cell functionality) 
mirrors the result found in (Figure 4-11). Our results suggest that if cell functionality 
is used as the toxicity measure, (Figure 4-14(B,D)), both NAC regimens have similar 
protective effects, with severe loss of cell functionality apparent for any APAP dose 
above approximately 450 mg/kg. When using probable liver injury based on HMGB1 
concentration as a measure however (Figure 4-14(A,C)), the NAC regimens 
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provided clearly different results. The current regimen only indicated probable 
toxicity when an APAP dose above 8,000 mg/kg had been taken, and this probability 
was only around 0.5. The SNAP regimen however, identified potential for cases 
where the APAP dose was above a much lower threshold of 4,000 mg/kg, with most 
cases having a probability greater than 0.8.  
Whilst the differences in the NAC effects on both toxicity measures can be seen in 
Figure 4-14, we looked more closely at comparing each regimen against the 
measures individually, with Figure 4-15(A) showing the regimen effects if probable 
liver injury based on HMGB1 was used as a toxicity measure, and Figure 4-15(B) 
showing the regimen effects if loss of cell functionality was used as a toxicity 
measure. 
When using probable liver injury based on HMGB1 concentration as a toxicity 
measure (Figure 4-15(A)), both NAC regimens were predicted to be highly 
protective (toxicity not predicted to occur for any APAP dose below 3,500 mg/kg). 
However, the protective effects were predicted to be much greater for the current 
regimen. Simulating the current regimen (black threshold) identified HMGB1 
concentrations that resulted in probable liver injury levels for APAP doses above 
8,000 mg/kg. It appears that the maximum APAP dose the SNAP regimen (blue 
dashed threshold) could protect against was 3,500 mg/kg APAP, although this is 
still a very high threshold.  
When cell functionality was used as a toxicity measure (Figure 4-15(B)), both NAC 
regimens were predicted to have similar protective potential, especially at early time-
points following the APAP dose. The current regimen (black threshold) enabled 
functionality to recover at a slightly faster rate than the proposed regimen (blue 
dashed threshold). For example, if two individuals were to take 430 mg/kg, with one 
being administered NAC according to the current regimen, and the other being 
administered NAC according to the SNAP regimen, at 2 hours-post APAP dose, 
both would be deemed toxic, since more than 80% cells would be predicted to be 
dead/damaged. At 25-hours-post-APAP-dose however, whilst the person following 
the SNAP schedule would remain in the toxic region (above the blue dashed 
threshold), the person following the current NAC regimen would no longer be 
deemed toxic. 
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Figure 4-14: Effect of two comparative NAC dosing regimens on the predicted probability 
of liver injury and proportion of damaged/dead cells for various APAP doses. Black 
contours are thresholds where any observation above such would be predicted to have a high 
probability of liver injury or a severe loss of cell functionality. Red regions are representative of 
1 and blue regions are representative of 0. Therefore, in the liver injury probability plots (A, C) 
the red regions are representative of a predicted probability of liver injury of 100% and therefore 
severe toxicity. The blue region in the cell functionality plots (B, D), is representative of cells 
being 100% damaged/dead, and therefore indicative of severe toxicity. (A,B) show the effects 
of providing the conventional NAC dosing regimen on the APAP dose thresholds for probability 
of liver injury and cell functionality, respectively. (C,D) show the effects of providing the proposed 
SNAP dosing regimen on the APAP dose thresholds for probability of liver injury and cell 
functionality, respectively. 
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Figure 4-15: NAC dosing regimen effects on the APAP dose threshold for inducing liver 
toxicity based on two different measures: (A) probable liver injury based on HMGB1 
concentration (probability greater than 0.5) and (B) severe loss of cell functionality (80% 
reduction of cell viability). Any observation above the thresholds is predicted to have a 
HMGB1 concentration indicating probable liver injury. The black contour represents the 
threshold when the current clinical NAC regimen is provided. The blue dashed contour 
represents the proposed shorter NAC (SNAP) regimen is provided. 
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4.4. Discussion 
In previous Chapters (2 and 3), we have been interested in the relationship between 
APAP and toxicity biomarkers and their subsequent predictive potential. Should the 
interest be to make predictions upon initial investigation of a suspected APAP 
overdose case, this may be sufficient. However, if we aim to use the toxicity 
biomarkers throughout a patient’s hospital admission, the relationship between 
APAP dose and these novel biomarkers requires extension to include the antidote 
(NAC). The aim with this chapter was to generate and analyse my own experimental 
data to better understand the influence NAC had on these biomarker concentrations 
and their subsequent predictivity, and also to obtain a further understanding of liver 
injury at the cellular level (cell death via necrosis or apoptosis). We firstly discuss 
whether NAC shows protective effects, and if so, how this changes the mechanism 
of cell death. 
Looking at the cell-viability time-course (Figure 4-4), as expected, there was a 
general decrease in viability as time progressed following an APAP dose. Also, the 
protective effects of NAC could be seen, especially for lower doses of APAP. 
Providing a high dose of NAC (5 mM) had similar effects as providing no antidote 
treatment at all, this was an interesting result. This may give further justification for 
the requirement to better optimise NAC treatment; our results suggest that providing 
too much antidote could cause as much damage as not intervening at all. This result 
was further justified by the conclusions from our FACS analysis; NAC provided a 
protective switch, where we observed the dominant form of cell death change from 
necrosis to apoptosis. However, the amount of NAC required to cause this switch 
was different for different APAP doses, and the relationship between NAC and 
APAP dose with regards to this switch was not clear from these experiments. It must 
be noted that these experiments have not yet been repeated; further repeats could 
help to understand the relationship between NAC and APAP dose and the switch 
from necrosis to apoptosis. 
Although an attempt was made to further investigate the relationship between 
APAP, NAC and mode of cell death by comparing quantification of apoptosis marker 
(caspase) and necrotic marker (miR-122), the results were inconsistent with our 
FACS analysis. These opposing results could be due to interference when the 
assays were carried out, and since we only have n=1, more repeats are required in 
order to clarify this discrepancy. At present, since NAC is known to have protective 
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effects in the APAP overdose case, the FACS analysis results are in line with what 
would be expected, and therefore can be included in the model with more 
confidence than the caspase/miR-122 quantification data, until more repeats are 
carried out. 
With the aim of further model development, note that the frameworks identified in 
the two previous chapters may only be applicable for a patient at initial hospital 
presentation with a suspected APAP overdose. However, following hospital 
admission, patients will likely be given NAC treatment. Additional to investigating 
NAC effects on hepatocyte functionality, we used multiple linear regression analysis 
to determine if introduction of therapy could alter the predictivity of the biomarkers. 
When looking at the subset of data which was not given any NAC therapy, 
biomarkers full and fragmented K18 could significantly predict cell viability. Upon 
initial presentation, before a patient has been given the antidote, these biomarkers 
may prove useful to predict how well the cells are functioning. Measuring these two 
values would make sense since they are necrotic/apoptotic versions of the same 
biomarker; quantifying both levels could therefore give insight into cell damage – 
high levels of necrosis compared to low levels of apoptosis for example may indicate 
the functionality of the cell is diminishing. For each NAC dose (other than 5 mM) the 
same biomarkers – APAP, HMGB1 and fragmented K18 could significantly predict 
cell viability. The fact that no biomarkers could significantly predict cell viability for 
the 5 mM NAC dosed subset could be due to the fact that the dose of NAC is too 
high and could have interaction effects with APAP.  
Combining all datasets (no antidote and various antidote dosed subsets) resulted in 
biomarkers ALT, full and fragmented K18 being significant predictors for cell 
viability. ALT is a biomarker already utilised clinically which gives credence to the 
proposal of our panel. Therefore, measuring these biomarkers (ALT, full and 
fragmented K18), whether previously given a dose of the antidote or not, could 
predict the level of cell viability and therefore give insight into cell functionality 
following an APAP dose. The fact that current clinical biomarkers only became 
significant in cases where the analysis was applied to data which included NAC 
doses, may suggest that these biomarkers are only useful for monitoring purposes 
following antidote treatment. However, if cell functionality is of interest at initial 
presentation when no NAC therapy has been provided, our analysis predicts that 
the novel biomarkers outperform those currently used in the clinic. 
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Whilst in previous Chapters (2 and 3) we describe a predictive framework for the 
probability of liver injury based on biomarker concentrations, we here provide an 
extension to this framework, which additionally uses severe loss of cell functionality 
as a marker for potential toxicity. Remien et al. [73] published a mathematical model 
which describes the dynamics of functional and damaged hepatocytes in the APAP 
overdose setting. Whilst their parameters are representative of cell functionality 
following APAP overdose, parameters within our model can describe cell 
functionality when both APAP plus NAC antidote are provided, rather than APAP 
alone.  
Simulating the administration of NAC at 1-hour-post-APAP dose provided lower 
predicted biomarker concentrations than the case that was simulated without any 
NAC administration. The longer the time period between APAP dose and NAC dose, 
the lower the effect NAC had on subsequent biomarker concentrations, which could 
further support the idea that NAC is no longer beneficial beyond 8 hours post-APAP 
dose [23]. When investigating how thresholds for probable liver injury (based on 
biomarker concentrations) differed, the effects of providing no antidote versus 
providing antidote could be clearly seen. This investigation was carried out by 
supplying different NAC doses at 1-hour-post-APAP dose and determining the 
resultant APAP dose threshold for probable liver injury. When no NAC was provided, 
liver injury was predicted to be probable following any APAP dose above 
approximately 550 mg/kg. Providing a 150 mg/kg dose of NAC increased the toxic 
APAP threshold to 7,000 mg/kg while providing a 200 mg/kg NAC dose increased 
the threshold even further to 9,000 mg/kg. Whilst this result supports the benefits of 
NAC intervention, it must be noted that this framework is based on the concentration 
of one biomarker (HMGB1). Further validation of the biomarker’s predictivity should 
be carried out. Should cell functionality be the preferred measure of toxicity, much 
lower APAP dose thresholds were predicted, even following administration of NAC 
at 1-hour-post-APAP-dose. Although increasing the amount of NAC did not greatly 
increase the toxic threshold, the distinction was still clear between no antidote, and 
antidote cases, as can be seen in Figure 4-12; the non-NAC case provided a lower 
APAP dose threshold than both of the NAC dosed cases.  
There has been much discussion around the uncertainty of the optimal combination 
of both NAC dose amount and time since administration. The current NAC regimen 
[24] was simulated and compared with a recently proposed shorter NAC protocol 
(SNAP regimen) [152] to visualise their effects on biomarker time-course profiles, 
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and also the predicted toxic APAP thresholds (for both probable liver injury and 
severe loss of cell functionality). As expected, providing NAC (following either 
regimen) caused large increases in peak NAC and GSH concentrations. The current 
regimen provided higher peaks which declined at a faster rate, whilst the SNAP 
regimen provided a lower peak, but with increased concentrations remaining for a 
longer time period. When using the probability of liver injury (based on HMGB1 
concentration) as a toxicity measure, the current regimen had better protective 
capability than the SNAP regimen; the current regimen was predicted to protect for 
APAP cases up to 8,000 mg/kg and the SNAP regimen was predicted to protect for 
APAP cases up to 3,500 mg/kg. However, the lower threshold (3,500 mg/kg) is still 
a really high APAP dose, and therefore the protective effects of this regimen should 
not be discounted.  
If loss of cell functionality was used as a toxicity measure, both regimens were 
predicted to provide a similar level of protection (for APAP cases up to 
approximately 450 mg/kg). Using cell functionality as a toxicity measure, our model 
predicted severe toxicity occurrence for any APAP dose beyond 400 mg/kg when 
NAC was not provided. Currently, the clinic suggest that any individual having taken 
an APAP dose above 250 mg/kg is likely to experience potentially fatal liver toxicity 
[8]. Our preliminary results suggest that this clinical threshold may have the potential 
to be increased, possibly leading to huge savings on unnecessary transplantations. 
However, since there are no repeats of this study, further investigation would be 
required before such suggestions could be confirmed. The initial results are 
promising though, and warrant further investigation.  
The fact that results differed greatly depending on the toxicity measure used 
(probability of liver injury based on HMGB1 concentration, or loss of cell functionality 
based on in vitro data) in each scenario when NAC was provided, supports the 
requirement for better understanding of the relationship between the two measures. 
Results from our investigation could be used to guide in vitro experiments to improve 
this understanding. Potential experiments could focus on monitoring multidrug 
resistance proteins (MRPs) over time following different APAP/NAC doses. These 
transporters are reported to transport GSH and also bind to ATP [153]. Further 
experimental repeats of the cell viability study would also be required to ensure 
confidence in the accuracy of the optimised parameters used in our cell functionality 
model. It must be noted however, that whilst the biomarker in our predictive liver 
injury framework is heavily dependent on GSH depletion, and although our cell 
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functionality model is also based on NAPQI accumulation (which is itself dependent 
on GSH depletion), we have optimised against cell viability data which is 
representative of intracellular ATP depletion. Our model framework could benefit 
from optimisation against more diverse cell functionality data such as albumin 
changes or ability to metabolise MTT. Albumin is the most abundant protein in the 
blood and decreased levels are widely used to indicate severely ill individuals [11], 
while MTT is a compound that viable cells with active metabolism can convert into 
a purple coloured formazan product [154]. When cells die, they lose the ability to 
convert MTT into formazan and therefore colour formation can serve as a 
convenient marker for cell viability. 
The results from our investigation have provided further insight and confirmation into 
the benefits of NAC administration in the overdose case. Although the results from 
our preliminary investigation are promising, the in vitro experiments used in the 
analysis were not repeated due to time and cost limitations. Therefore, before these 
results can be concluded with confidence, more repeats are highly recommended. 
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Chapter 5: Clinical paracetamol 
overdose model 
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5.1. Background 
Ultimately, this research has the aim of making predictions to better inform human 
safety. The current clinical treatment framework for APAP overdose is known to be 
highly sub-optimal, mainly due to its dependency on APAP dose amount; and time 
since overdose, information which is often highly inaccurate. In Chapters 2 and 3, 
we provide a pre-clinical framework that, once extrapolated to human, could have 
the potential to improve this current APAP clinical decision-making framework. 
Although APAP metabolism in mice is similar to that in human [155], humans are 
known to have much larger inter-individual variability in the metabolism processes 
in comparison to mice [77]. The modelling approach in the human case must 
therefore be more extensive than the pre-clinical case, ensuring this inter-
individuality is accounted for. In this chapter, we extend our mathematical modelling 
approaches described in previous chapters to the clinical case.  
Through collaboration with Dr. James Dear (Consultant and Honorary Senior 
Lecturer in Clinical Pharmacology at the Royal Infirmary Edinburgh, Edinburgh 
University) we obtained access to a database of approximately 3,600 APAP 
overdose patients, providing data for the optimisation of model parameters. We take 
a non-linear mixed effects modelling approach to account for both known and 
unknown errors in model predictions due to physiological differences between 
humans. The issues with the APAP toxicity framework can be further complicated 
by these physiological differences. Even though we are able to provide more 
accurate predictions of overdose amount and time since overdose, there are certain 
individuals that may respond to treatment differently for matters which are currently 
not accounted for within our modelling framework. For example, there is an apparent 
distinct global increase in accidental pediatric overdoses [156], and there have 
subsequently been many toxicological studies that have tried to understand 
metabolic differences in younger people versus older people, and whether these 
potential differences are linked to the increase in pediatric overdoses [157]. 
Additionally, there have been many cases where APAP toxicity has been apparent 
although APAP was prescribed and taken appropriately at the recommended 
therapeutic dosage [158,159], particularly for individuals of low weight (<50 kg) 
[160,161]. Identifying individuals that are particularly susceptible to APAP-induced 
liver injury has been heavily debated in the literature (for a review, see Caparrotta 
et al. [157]). Briefly, individuals are deemed ‘high-risk’ in the APAP overdose 
147 
 
scenario if they are known to have factors which may impair their ability to 
synthesise or maintain sufficient GSH levels [10]. Such factors may include pre-
existing liver disease, concurrent use of alcohol and/or other liver-metabolised 
medications, genetic predispositions and acuity/chronicity of APAP use [5]. The 
debate has been such that the threshold for providing NAC treatment (found by 
plotting measured APAP concentration against time since overdose) has been 
lowered by 25% from the original threshold to take into account individuals with 
potential risk factors and also to account for the possibility of measurement errors 
[20]. However, this of course bears the risk of treating more patients unnecessarily.  
In silico models are being increasingly used to make drug toxicity predictions, with 
focus on liver toxicity specifically. For a review, see Yang et al. who review in silico 
models for DILI prediction that were published between 2000-2015 [162]. In this 
chapter, we describe a nonlinear mixed effects modelling approach to 
pharmacokinetic modelling, which allows us to make population-pharmacokinetic 
(Pop-PK) predictions for individuals outside the region of the dataset used in 
optimisation. The APAP Pop-PK model is optimised against clinical data provided 
by Dr. James Dear at Queens Medical Research Institute Edinburgh and the focus 
of the modelling at this stage is firstly identifying and investigating any relationships 
between patient demographics and model parameters. Once the model is 
formulated and relationships identified, we conduct a model evaluation, 
emphasising its predictive utility in both acute and multiple dosing scenarios. 
Additional to this, numerical approaches are used with the aim of investigating of a 
current clinical problem, APAP toxicity in young, low-weight individuals.  
Chapter aims 
 Identify relationships between patient demographics and Pop-PK model 
parameters. 
 Investigate the effects of altering administration schedule on therapeutic 
effects. 
 Investigate the effects of age and weight on maximum tolerable dose, with 
particular focus on young, low-weight individuals. 
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5.2. Methods 
Detailed within this section is the mathematical modelling approach taken to 
computationally represent APAP metabolism in human. In order to ensure the 
parameters within the model were representative of the human APAP overdose 
case, we optimised the model parameters by fitting the model to data from over 
3,600 APAP overdose patients. A description of the data is provided within this 
section. During model development, we tested multiple variations of PK models to 
identify the most predictive model framework. The model selection criteria used at 
each stage during the model development are also defined within this section.  
5.2.1.  Clinical data description 
Clinical data was obtained from approximately 3,600 patients from 3 UK hospitals – 
Newcastle, Edinburgh and London. Data from 1,000 of these patients was published 
in the Lancet in 2017, within a study carried out by Clarke et al. [136]. The group 
aimed to determine whether novel biomarkers HMGB1 and K18 could accurately 
predict the requirement for prolonged hospital treatment, using ALT measurements 
as their predictive endpoint. This published data did not include all of the patient 
information. The full raw dataset was provided by our clinical collaborator, Dr. James 
Dear. For example, for each patient, the following information was obtained: 
Covariate/demographic information (namely, age, sex, and weight); APAP dose 
taken; time since APAP dose; and initial APAP concentration measurement (mg/l). 
The following observations were removed from the data set prior to analysis: 
patients with missing initial dose information; patients with missing time since dose 
information; patients with a missing initial APAP measurement; and patients with an 
initial APAP measurement below the lower limit of detection (LLOD), 10 mg/l [163]. 
5.2.2. Model selection criteria 
Various Pop-PK models were tested throughout the model development process to 
determine the most predictive. These variations included both one and two 
compartmental models (Figure 5-2), and models which included different 
combinations of potential parameter/demographic correlations. Further details of 
these models can be found in sections 5.2.5 and 5.3.1. In order to determine the 
most suited model, the Akaike Information Criteria (AIC) and Bayesian Information 
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Criteria (BIC) were compared at each stage of the development process. Within this 
analysis, model parameters (within the Pop-PK model structure) were obtained by 
maximizing their likelihood, in relation to the observational data provided (Maximum 
likelihood estimation) [164]. The parameter estimation methodology is explained in 
further detail in section 5.2.4 of this chapter, however we also mention it here briefly. 
AIC and BIC are defined by: 
𝐴𝐼𝐶 =  −2𝐿𝐿(𝑦; 𝜃) + 2𝑃, 
𝐵𝐼𝐶 =  −2𝐿𝐿(𝑦; 𝜃) + log(𝑁)𝑃, 
where 𝐿𝐿 is the log-likelihood function. Minimising minus two times the log-
likelihood, −2𝐿𝐿, is equivalent to maximizing the log-likelihood function, 𝐿𝐿 [82]. 
Minus two times the log-likelihood, −2𝐿𝐿, is a function of 𝑦 and 𝜃 which are 
representative of the observational data and the estimated parameter, respectively. 
The total number of parameters to be estimated is represented by 𝑃, while 𝑁 is the 
number of subjects. Both AIC and BIC measures were investigated at each stage 
in the model development process, and the model with the lowest combination was 
chosen to be best suited.  
5.2.3. Mixed effects modelling background 
If we assume that a sample dataset is quantitatively representative of the true 
population (for example, genetically homogeneous populations of mice  are often 
bred for medical research purposes, making results of medical trials more uniform 
[165]), then simple regression models may be sufficient. This would allow the 
modelling approaches applied in previous chapters to be suitable. These type of 
models contain leading order parameters that can be assumed to remain constant 
across individuals (fixed effects). However, if we have reason to believe that certain 
individuals may respond differently to others (as we do with the human population 
[166]), this model should be extended to include so-called higher-order random 
effects. These random effects account for the fact that there may be significant 
differences between the observations in the subset of data at hand, and the general 
population. Mixed effects models are necessary for clinical population modelling due 
to the requirement of both fixed (population averages) and random (individual 
variation) effects. Fixed effect variables are those that cause differences in 
observations for reasons of which we are aware, for example, different doses of 
drug, different time-point measurements of concentration, different weights and 
150 
 
heights of individuals [167]. Random effect variables are necessary to account for 
the fact that there will be additional differences between individuals in the general 
population for reasons of which we are unaware. These unknown differences cannot 
be accounted for solely by the residual error of the dataset that the model is based 
upon. 
Mixed effects modelling generally uses a two-stage hierarchical process [168], firstly 
creating the model at a population level and secondly at an individual level. This 
approach formalizes knowledge and assumptions about variation in outcomes and 
mechanisms both between (stage 1) and within individuals (stage 2) [169]. Once 
the model describing individual trajectories is embedded within the statistical 
population model, this then provides a suitable framework for inference of covariate 
effects (namely, obtaining a greater understanding of how much variance in model 
output may be attributable an individual’s covariate information) [170] .  
5.2.4. Model optimisation 
Monolix is an advanced computational software programme that provides robust, 
global solutions for even the most complex pre-clinical and clinical population PKPD 
models [171]. We used Monolix [172] to estimate parameter values that can 
represent the clinical human population. Subsequently, parameters were also 
estimated on an individual level for individuals within this population. Here, I 
describe how the parameters within our model were estimated, firstly at a population 
level and secondly at an individual level. 
5.2.4.1. Stage 1: Population level model 
The parameter component of the population model aims to quantify average values 
for the whole population: 
 𝜃𝑖 = 𝑑(𝛽, 𝑎𝑖, 𝑏𝑖),               𝑖 = {1,2, … ,𝑚}, (5-1) 
where 𝜃𝑖 is the population parameter estimate; a function of the fixed parameter, 𝛽 
(fixed effects) is given by 𝑑; parameter variation due to systemic association with 
individual attributes is given by 𝑎𝑖; and parameter variation that cannot be explained 
in the population is given by 𝑏𝑖.  The total number of population parameters to be 
estimated is represented by 𝑚. In our Pop-PK model (equation (5-23)), we have 
𝑚 = 5 parameters to be estimated: 𝑡𝑙𝑎𝑔, 𝑘12, 𝑘21, 𝑉, 𝑘𝑒𝑙. 
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5.2.4.2. Parameter estimation – Stochastic Approximation 
Expectation-Maximisation (SAEM) Algorithm 
Estimating the unknown population parameter estimates is a key task in non-linear 
mixed effect modelling. When faced with an incomplete dataset (clinical data is a 
perfect example – the data is clearly a subset and does not represent how the whole 
population behaves), from which unknown parameter estimates are to be estimated, 
expectation maximisation (EM) methods are particularly useful for parameter 
optimisation [173]. The key idea that underlies EM methods and differentiates them 
from other optimisation techniques is the introduction of a latent variable, 𝑍, which 
is representative of a “complete-data space”. This allows the enhancement of 
incomplete data by making reasonable guesses of any missing information. EM 
methods are used for solving maximum likelihood estimation problems (maximising 
the likelihood function of parameters over a given search space given observational 
data). EM algorithms are also iterative, meaning they maximize successive local 
approximations of the likelihood function.  
Each iteration 𝑘 has two phases, an exploratory phase and a smoothing phase.  
Exploratory phase – this searches the entire given parameter space to find the 
neighbourhood of maximum likelihood. 
During the exploratory phase, parameters for each individual within the dataset are 
generated from the conditional distribution first, and then the population parameters 
are generated based upon these. The conditional distribution is the probability 
distribution of the individual parameters and is defined for each iteration 𝑘 as follows: 
 𝑝(𝜓𝑖|𝑦𝑖, 𝜃
𝑘), (5-2) 
where the individual parameter estimate of individual 𝑖 is represented by  𝜓𝑖, the 
observation or data point for individual 𝑖 is represented by 𝑦𝑖 and the population 
parameter estimate from the previous iteration is represented by 𝜃𝑘. For the first 
iteration, this parameter estimate will be equal to the initial guess. 
There is no analytical solution to (5-2). Instead, Kuhn and Lavielle proposed 
combining the SAEM algorithm with a Markov-Chain Monte Carlo (MCMC) 
procedure [174]. When an estimated value is required but is difficult to obtain (in our 
instance individual parameter estimates, 𝜓𝑖), simulation approaches such as 
Metropolis-Hastings can sample from likely distributions to obtain the best estimate 
possible in the following way [175]. Firstly, the Markov-Chain Monte-Carlo approach 
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takes a random walk from a user defined initial point within the distribution, to 
another (more probable) point within the distribution. Then, at each iteration, the 
probability of the newly proposed point is only dependent on the one point previous, 
not every point previous. This general definition is applicable in our case, since the 
probability of the individual parameter, 𝜓𝑖, is only dependent on the population 
parameter from the previous iteration, 𝜃𝑘, and not all of the parameter estimates 
from all of the previous iterations. As seen in equation (5-2), the probability of the 
individual parameter also has a dependency on the data point for that individual, as 
this helps to pull the search closer to the true maximum likelihood [176]. Multiple 
iterations then allow the most probable value from the whole distribution to be 
obtained [177]. The general Metropolis Hastings algorithm described by Robert et 
al. [175] can therefore be altered to represent the concepts underlying the estimation 
of our population parameter estimates, as follows. 
1. Provide an initial estimate for the individual estimate value, 𝜓𝑖. 
2. Choose a nearby point within the parameter space to represent the newly 
proposed individual parameter estimate, 𝜓∗. 
3. Use the Metropolis Hastings algorithm as follows to determine whether the 
proposed point should be accepted/rejected 
I. Sample 𝑢 from a distribution 𝑈(0,1]. 
II. If 𝑢 < min {1,
𝑝(𝑦𝑖 |𝜓∗; 𝜃
𝑘
)
𝑝(𝑦𝑖 |𝜓𝑖; 𝜃
𝑘
)
} 
i. 𝜓𝑖+1 = 𝜓∗ 
else,  
ii. 𝜓𝑖+1 = 𝜓𝑖. 
4. The process is then repeated, choosing a different nearby point each time, 
until the most probable value is found. 
Once the most probable values are found for each individual, the average of the 
individual parameter estimates from this iteration is then taken to represent the 
proposed population parameter estimate, 𝜃𝑘+1, as 
 
𝜃𝑘+1 =
1
𝑁
∑𝜓𝑖
𝑁
𝑖=1
, (5-3) 
where 𝑁 is the total number of individuals within the dataset. This whole process is 
repeated 𝑘 times until results from iterations begin to converge and a resultant local 
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neighbourhood is found. This concludes the exploratory phase of this iteration of the 
EM algorithm. 
Following the exploratory phase, is the final (smoothing) stage of the EM algorithm. 
Smoothing phase – Once the local neighbourhood is found, this subsection of the 
parameter space is further explored. 
Individual parameter estimates are generated using MCMC as previously described 
(5-3). 
This time, the population parameter estimates are not taken to be the average of 
the individual parameter estimates at the current iteration, but instead the average 
across all previous iterations. This can be mathematically described as follows 
 
𝜃𝑘+1 =
1
𝑘
[
1
𝑁
∑𝜓𝑖
1
𝑛
𝑖=1
+
1
𝑁
∑𝜓𝑖
2
𝑛
𝑖=1
+⋯+
1
𝑁
∑𝜓𝑖
𝑘
𝑛
𝑖=1
], (5-4) 
Where 𝜓𝑖
1 is the individual parameter for individual 1, and 𝜓𝑖
2 is the individual 
parameter 2.This can be equivalently written as, 
 
𝜃𝑘+1 =
1
𝑘
[(𝑘 − 1)𝜃𝑘 +
1
𝑁
∑𝜓𝑖
𝑘
𝑛
𝑖=1
], (5-5) 
which simplifies to, 
 
𝜃𝑘+1 = 𝜃
𝑘 +
1
𝑘
[
1
𝑁
∑𝜓𝑖
𝑘 − 𝜃𝑘
𝑛
𝑖=1
]. (5-6) 
This process is continued until there is negligible change in the objective function. 
5.2.4.3. The simulated annealing SAEM algorithm 
SAEM convergence can strongly depend on the initial guess if the likelihood 
possesses several local maxima [178]. To try to improve convergence towards the 
global maximum, the simulated annealing version of SAEM is introduced [179]. This 
simulated annealing version fixes the residual error variance to a large value when 
initially trying to optimise the model parameters. The large values of the variance 
allow the estimated values to be less concentrated around its mode. This allows the 
sequence (𝜃𝑘) to escape from the local maxima and converge to a neighbourhood 
of the global maximum. Once this initial process is complete, the usual MCMC-
SAEM algorithm is used [176]. 
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5.2.4.4. Stage 2: Individual level model 
Once average population (fixed effect, and corresponding error) parameters have 
been estimated, estimates for a new individual from that given population can be 
estimated: 
 𝑌𝑖𝑗 = 𝑓(𝑋𝑖𝑗; 𝜓𝑖) + 𝑒𝑖𝑗 ,               𝑗 = {1,2, … , 𝑛𝑖}, (5-7) 
where the outcome, 𝑌𝑖𝑗  (for each individual 𝑖 at each time point 𝑗) is a function of the 
variables, 𝑋𝑖𝑗 (for example, time); and fixed regression parameters, 𝜓𝑖; with the 
addition of some intra-individual error, 𝑒𝑖𝑗. The total number of observations for each 
individual 𝑖 is represented by 𝑛𝑖 . 
5.2.4.5. Parameter estimation – conditional distribution 
In order to calculate the most probable value of the individual parameter estimates, 
the conditional parameter distribution is firstly calculated, which is described by (5-2) 
but detailed here for completeness. In this case, the parameter definition is defined 
bty 
 𝑝(𝜓𝑖|𝑦𝑖, 𝜃), (5-8) 
where 𝜓𝑖 are the individual parameters for individual 𝑖, 𝜃 are the estimated 
population parameters and 𝑦𝑖 are the observations for individual 𝑖. This distribution 
is representative of the uncertainty in an individual’s parameter value taking into 
account the following: 
1. Information available for the individual, which includes: 
a. Observed data for the individual; and 
b. Covariate (or demographic) values for them 
2. The fact that the individual belongs to a population (for which the parameters 
have already been estimated). 
Within Monolix, there are two possible methods for estimating the most probable 
value arising from this distribution, either calculating Empirical Bayes Estimates 
(EBEs) or Markov Chain Monte Carlo (MCMC) sampling from a conditional 
distribution. I will now summarize both approaches. 
5.2.4.6. Empirical Bayes Estimates  
Empirical Bayes Estimates (EBEs) are alternatively referred to as the conditional 
mode, 𝜓𝑖
𝑚𝑜𝑑𝑒, which represents the most common individual parameter; they are 
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found by maximising the aforementioned conditional distribution and therefore 
represent the most likely value of the individual parameter, 𝜓𝑖 , given the 
observations, and a given population distribution: 
 𝜓𝑖
𝑚𝑜𝑑𝑒 = arg𝜓max𝑝(𝜓𝑖|𝑦𝑖; 𝜃). (5-9) 
It is therefore necessary to maximize the conditional probability with respect to the 
individual parameter value, 𝜓𝑖. In Monolix, the Nelder-Mead search algorithm is 
used to find this maximum. Since 𝑝(𝜓𝑖|𝑦𝑖; 𝜃) cannot be easily solved for a given 𝜓𝑖, 
this means that the conditional distribution does not have a closed form solution, 
and therefore Bayes’ Law is used to rewrite the conditional distribution in the 
following way: 
 
𝑝(𝜓𝑖|𝑦𝑖) =
𝑝(𝑦𝑖|𝜓𝑖)𝑝(𝜓𝑖) 
𝑝(𝑦𝑖)
. (5-10) 
If the individual parameter values 𝜓𝑖 are known, then the conditional density function 
of the data given these parameter values (𝑝(𝑦𝑖|𝜓𝑖)) is simple to calculate, as is the 
density function for the individual parameters (𝜓𝑖), since they both have closed form 
solutions. However, the denominator of (5-10) (the density function of the 
observations, 𝑝(𝑦𝑖)), has no closed form solution. Since the solution of 𝑝(𝑦𝑖) will 
have no dependency on 𝜓𝑖 however, this value would remain the same in each 
calculation of 𝑝(𝜓𝑖|𝑦𝑖), having no direct effect on the maximum value. This element 
𝑝(𝑦𝑖) is therefore removed from equation (5-10) for the optimisation procedure, and 
only 𝑝(𝑦𝑖|𝜓𝑖)𝑝(𝜓𝑖) is optimised. 
Once the most probable individual parameter values, 𝜓𝑖
𝑚𝑜𝑑𝑒 are known, using the 
population parameters and the covariates, the corresponding individual random 
effects can then be calculated using 
 𝜂𝑖 = 𝜓𝑖
𝑚𝑜𝑑𝑒 −𝜓𝑝𝑜𝑝 − 𝛽𝑐𝑖, (5-11) 
where 𝜂𝑖 is the individual random effect, 𝜓𝑖
𝑚𝑜𝑑𝑒 is the estimated conditional mode,  
𝜓𝑝𝑜𝑝 and 𝛽 are population parameters, and 𝑐𝑖 is covariate data for individual 𝑖. 
For each individual, then, we have a fixed effect and random effect. An individual’s 
parameter value is found by randomly sampling from a normal distribution with the 
mean value equal to the fixed effect and the standard deviation value equal to the 
random effect. 
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5.2.4.7. MCMC sampling of conditional distribution 
MCMC methods can be used to obtain samples from the previously predicted 
conditional distribution, when direct sampling is difficult for individual parameter 
optimisation. This approach involves a stochastic procedure which yields the most 
likely value from the probability distribution of interest. 
We can use this approach to conclude the most probable value of the individual 
parameter estimate as the mean value from all of the accepted MCMC draws, 
 𝜓𝑖
𝑚𝑒𝑎𝑛 =
1
𝛺
∑ 𝜓𝑖
𝛺𝛺
𝛺=1 , 
(5-12) 
where 𝜓𝑖
𝑚𝑒𝑎𝑛 is the average individual parameter value over all of the samples, 𝜓𝑖
𝛺 
is the individual parameter value for the current MCMC draw, and 𝛺 is the number 
of accepted MCMC draws. 
5.2.5.  Covariate model  
An individual’s covariate (or demographic) information such as age, gender and 
weight may affect one or more of that individual’s structural parameters. If this is the 
case, the individual parameter affected should be a function of this continuous 
covariate. Initially, no covariates were included within model optimisation, but all 
covariate relationships with individual parameters were tested to determine whether 
or not inclusion would improve the model fitting criteria. The Pearson correlation co-
efficient is calculated to determine the relationship between demographic 
(covariate) information, and the parameter value under investigation. For continuous 
covariates, the null hypothesis for this test is as follows, 
𝐻0: The Pearson correlation coefficient between the individual parameter and the 
covariate (demographic) value is zero. A small p-value indicates that the null 
hypothesis can be rejected, in which case a correlation is present and the covariate 
should be included within the model. 
Once it is determined that a significant correlation is present, the Wald test is then 
used to analyse whether including the covariate relationship brings enough change 
to the model output to validate its inclusion. The null hypothesis of the Wald test is 
as follows, 
𝐻0: The approximated beta parameter (from the Pearson correlation test) is equal 
to zero. A small p-value indicates that the null hypothesis can be rejected, and 
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therefore the estimated beta parameter is significantly different from zero, 
subsequently warranting inclusion within the model. 
5.2.6. The non-linear mixed effects model 
Now that we have described how an individual’s fixed effects and random effects 
can be approximated, we define a general non-linear mixed effects model for 
continuous outputs: 
 𝑌𝑖𝑗 = 𝑓(𝑋𝑖𝑗; 𝜓𝑖) + 𝑔(𝑋𝑖𝑗; 𝜓𝑖; 𝜉)𝑒𝑖𝑗, 1 ≤ 𝑖 ≤ 𝑁, 1 ≤ 𝑗 ≤ 𝑛𝑖 , (5-13) 
where 𝑌𝑖𝑗  is the 𝑗th observation of subject 𝑖; the structural model 𝑓(𝑋𝑖𝑗; 𝜓𝑖) depends 
on both the regression variables 𝑋𝑖𝑗, and a vector of individual parameters 𝜓𝑖, the 
residual error model 𝑔(𝑋𝑖𝑗; 𝜓𝑖; 𝜉) depends on both the regression variables and 
individual parameters but also an additional vector of parameters, 𝜉, the residual 
error for individual 𝑖 is represented by 𝑒𝑖𝑗, the number of subjects is represented by 
𝑁; and 𝑛𝑖 is representative of the number of observations for subject 𝑖. 
As mentioned, the vector 𝜓𝑖 is a vector of individual parameters: 
 𝜓𝑖 = (𝜇, 𝑐𝑖, 𝜂𝑖), (5-14) 
where 𝑐𝑖 is a known vector of covariates, 𝜇 is an unknown vector of fixed effects, 
and 𝜂𝑖 is an unknown vector of normally distributed random effects. 
The residual errors (𝑒𝑖𝑗) are random variables with mean 0 and variance 1, and the 
residual error model is defined by the function 𝑔. This residual error model is further 
explained in the section below. 
5.2.6.1. Residual error model 
There are various potential reasons for which a model may not predict the exact 
observed paracetamol concentration. The structural model used for prediction may 
only be an approximation of the biology, or the PK responses may have been 
measured with some level of assay error, for example. The observed difference 
between actual values and predicted values is known as residual error. Each 
individual prediction (inclusive of model predictions and residual error predictions) 
can be described by equation (5-13). 
 With focus on the error component of the model, 𝑔(𝑋𝑖𝑗; 𝜓𝑖; 𝜉)𝑒𝑖𝑗, we are reminded 
that the residual errors are standardized Gaussian random variables with mean 0 
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and standard deviation 1. It follows then, that 𝑓(𝑋𝑖𝑗; 𝜓𝑖) is the conditional mean, 
𝐸(𝑦𝑖𝑗|𝜓𝑖) =  𝑓(𝑋𝑖𝑗; 𝜓𝑖). It also follows that 𝑔(𝑋𝑖𝑗; 𝜓𝑖; 𝜉) is the standard deviation, 
𝑠𝑑(𝑦𝑖𝑗|𝜓𝑖) =  𝑔(𝑋𝑖𝑗; 𝜓𝑖; 𝜉). 
In Monolix, the function 𝑔 is considered to be a function of the structural model, i.e., 
 𝑔(𝑋𝑖𝑗; 𝜓𝑖; 𝜉) = 𝑔(𝑓(𝑋𝑖𝑗; 𝜓𝑖); 𝜉), (5-15) 
which leads to an expression of the observation model of the form 
 𝑌𝑖𝑗 = 𝑓(𝑋𝑖𝑗; 𝜓𝑖) + 𝑔(𝑓(𝑋𝑖𝑗; 𝜓𝑖); 𝜉)𝑒𝑖𝑗 . (5-16) 
There are many functions that can be chosen to represent the residual error model 
𝑔. A constant error model assumes that the  𝑓(𝑋𝑖𝑗; 𝜓𝑖) element of 𝑔 is eliminated, 
resulting in the residual error function, 𝑔, being constant and the observation model 
can then written in the form  
 𝑦 = 𝑓 + 𝜉𝑒, (5-17) 
where 𝑦 is the predicted observation, 𝑓 is the structural model, 𝜉 is an error related 
parameter, and 𝑒 is the residual error. As a reminder, the structural model is 
dependent upon the model variables, 𝑋𝑖𝑗, the individual parameters, 𝜓𝑖.  
Alternatively, a proportional error model assumes that the residual error function, 𝑔, 
is proportional to the structural model, 𝑓, meaning that this element is no longer 
eliminated from 𝑔. The observation model can then be written in the form  
 𝑦 = 𝑓 + 𝜉𝑓𝑒. (5-18) 
However, in our analysis, we chose to model the residual error as a linear 
combination of a constant error term and a term proportional to the structural model. 
The observational model can therefore be written in the form 
 𝑦 = 𝑓 + (𝜉1 + 𝜉2𝑓)𝑒, (5-19) 
where 𝑦 is the predicted observation, 𝑓 is the structural model and 𝑒 is the residual 
error. In this case, there are two error related parameters 𝜉1, a constant error related 
parameter and 𝜉2, a proportional error related parameter. We chose this combined 
residual error model to firstly account for any error that may appear due to the 
structural model being only an approximation of the biology of APAP metabolism in 
human (proportional error), and secondly to account for any observations near to 
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the lower limit of detection to ensure that bioassay error is considered (constant 
error). 
Prior to optimisation, the data and parameters were transformed to the log-normal 
distribution, to ensure the Gaussian assumption is met, and to also ensure that no 
negative values could be predicted, since negative blood concentrations are not 
possible. The logit error model was extended to assume that observational 
concentrations, 𝑦, were bounded. Namely, A < 𝑦 < B, with A= 0 mg/l being the lowest 
possible concentration and B= 50,483 mg/l being the maximum observed 
concentration in the dataset.  
The transformed model can therefore be represented by 
 𝑇(𝑦𝑖𝑗) = 𝑇 (𝑓(𝑥𝑖𝑗, 𝜓𝑖)) + 𝑔(𝑥𝑖𝑗 , 𝜓𝑖 , 𝜉)𝑒𝑖𝑗 , 
(5-20) 
Where 𝑇 is the transform function, 𝑓 is the structural model and 𝑔 is the error model. 
In order to ensure strictly positive results ranging between A and B, the transform 
function can be represented by 
 
𝑇(𝑦) = log (
𝑦 − 𝐴
𝐵 − 𝑦
), (5-21) 
Applying this transformation to our model, we obtain: 
 𝑦 = 𝐴 + (𝐵 − 𝐴) (
𝑓−𝑎
𝑓−𝐴+(𝐵−𝑓)𝑒−𝑔𝑒
). (5-22) 
 
5.3. Results 
5.3.1. APAP Pop-PK model formulation 
To understand how to effectively model the clinical APAP dynamics, the observed 
APAP concentrations were transformed into log-space and plotted over time (Figure 
5-1).  
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Figure 5-1: Log-transformed paracetamol concentration versus time. The highest trend 
represents the 90th percentile, meaning that 90% of the observed data falls below this line at 
these time points. The middle trend is the 50th percentile, meaning that 50% of the observed 
data falls below this line. The bottom-most line is the 10th percentile, meaning that 10% of the 
observed data falls below this line. 
Since it was not clear whether the distribution/elimination phase of APAP occurs 
over one or two phases (Figure 5-1), we trialled both one and two-compartmental 
models. In a one-compartment model, all tissues within the body are assumed to be 
contained within one compartment [92]. A two-compartmental model assumes that 
tissues within the body can be separated into two different compartments [92]. The 
first compartment can be thought of as consisting of well-perfused tissues such as 
heart, liver and brain. The secondary compartment could represent poorly perfused 
tissues such as fat and bone. [93]. Schematics of both the one-compartment and 
two-compartment models can be seen in Figure 5-2. Models representing APAP 
concentration over time (𝐶𝑐𝑡) were built based on the laws of mass action, following 
a similar methodology as in our pre-clinical APAP model developed in section 2.2.1. 
Parameters from these models were optimised using the methodology defined in 
section 5.2.4 and models were selected based on their AIC/BIC values (a 
description of this criteria is defined in section 5.2.2). Model selection criteria for 
both the one-compartment and two-compartment models are described in Table 
5-1. 
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Figure 5-2: Pharmacokinetic model schematic. (A) One-compartment PK model 
representing the distribution of APAP. A dose of APAP is transferred to the central compartment 
but the rate of this transfer is limited by a parameter, 𝒕𝒍𝒂𝒈. APAP is then eliminated from the 
central compartment at a rate 𝒌𝒆𝒍. The central compartment has a theoretical volume, 𝑽. (B) 
Two-compartment PK model representing the distribution of APAP. A dose of APAP is 
transferred to the central compartment (well perfused tissues) but the rate of this transfer is 
limited by a parameter, 𝒕𝒍𝒂𝒈. The central compartment has a theoretical volume, 𝑽. APAP is 
secondarily transferred to the peripheral compartment (poorly perfused tissues) at a rate 
𝒌𝟏𝟐, and transferred back from the peripheral compartment to central compartment at a rate 𝒌𝟐𝟏. 
APAP is eliminated from the central compartment at a rate 𝒌𝒆𝒍. 
 
Compartmental model Akaike 
Information 
Criteria (AIC) 
Bayesian 
Information 
Criteria 
(BIC) 
-2LL 
One 2.67x105 2.67x105 2.67x105 
Two 2.64x105 2.65x105 2.65x105 
Table 5-1: Model fitting criteria for population pharmacokinetic models. AIC, BIC, and -
2LL are all compared for one- and two-compartment models. 
As can be seen in Table 5-1, the two-compartmental model provided marginally 
lower values for all three metrics, AIC, BIC and -2LL, and therefore was the PK 
model taken forward to represent the data. The chosen model is almost identical to 
the pre-clinical mechanistic APAP model defined in Chapters 2 and 3 (sections 2.2.1 
and 3.2.3 respectively), with the difference being that IP administration is not 
assumed and therefore an absorption rate from the peritoneal cavity is not required. 
Instead, we assumed an oral dose with absorption from the stomach, with a time 
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delay representing digestion/lag time. The corresponding model for APAP 
concentration over time in the central compartment (𝐶𝑐𝑡) can be written as follows: 
𝐶𝑐𝑡 = {
0, 𝑡 < 𝑡𝑙𝑎𝑔,
𝐷(𝐴𝑒−𝛼𝜔 + 𝐵𝑒−𝛽𝜔 − (𝐴 + 𝐵)𝑒−𝑘𝑎𝜔 ), 𝑡 ≥ 𝑡𝑙𝑎𝑔,
 (5-23) 
where 
𝛼 = 𝛽 (
𝑘21
𝑘𝑒𝑙
), 
𝛽 = 0.5(𝑘12 + 𝑘21 + 𝑘𝑒𝑙) + √(𝑘12 + 𝑘21 + 𝑘𝑒𝑙)2 − (4𝑘21𝑘𝑒𝑙), 
𝜔 = 𝑡 − 𝑡𝑙𝑎𝑔, 𝐴 =
𝑘𝑎
𝑉
(
𝑘21 − 𝛼
𝑘𝑎 − 𝛼
) (𝛽 − 𝛼), 𝐵 =
𝑘𝑎
𝑉
(
𝑘21 − 𝛽
𝑘𝑎 − 𝛽
) (𝛼 − 𝛽). 
The dose amount of APAP (mg) is represented by 𝐷, the parameter that limits 
transfer of the oral dose to the central compartment due to, for example, digestion 
is represented by tlag . The theoretical volume of the central compartment (l/kg) is 
represented by 𝑉,  the rate at which APAP is transferred to the peripheral 
compartment (poorly perfused tissues) (h-1) is represented by 𝑘12, the rate at which 
APAP transferred from the peripheral compartment to central compartment (h-1) is 
represented by  𝑘21, the rate at which APAP is eliminated from the central 
compartment (h-1) is represented by 𝑘𝑒𝑙  and 𝑡 represents the current time point (h). 
5.3.2. Identifying relationships between patient 
demographics and model parameters 
Multiple variations of the population PK model were fitted to the clinical dataset with 
the aim to optimise the APAP PK parameters such that computational simulations 
could mimic the clinical dataset provided. During initial model development, no 
demographic/parameter relationships were included in the model, although all 
possible combinations were statistically tested to determine whether their inclusion 
could improve the model fitting criteria. Results from the Pearson and Wald tests 
suggested that the final correlations to be included in the model should be between 
𝑡𝑙𝑎𝑔 and age (negative correlation); 𝑘12 and age (positive correlation); and 𝑘21and 
sex (positive correlation), where 1=male and 2=female. Literature searches were 
carried out to try and understand/confirm these potential relationships. Mian et al. 
reviewed 27 PK studies [180]. Of those defined within the review (that investigated 
a possible link between 𝑡𝑙𝑎𝑔 and age), none found a significant result. It must be 
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noted, however, that only a small number of studies investigated this correlation 
(n=3) and none of these studies incorporated inter individual variability.  
5.3.3. Model parameterisation 
The mixed-effects Pop-PK model resulted in optimised parameter values 
representative of the population, a random individual, and the level of correlation 
between an individual subject’s parameter estimate and their demographic 
information. Optimised population parameter values are provided in Table 5-2. 
Parameter Description Value 
𝑡𝑙𝑎𝑔𝜃 Parameter limiting the rate of transferring an APAP dose 
to the central compartment due to, for example, 
digestion 
3.16 
𝑘𝑎𝜃 APAP absorption rate 0.381 
𝑉𝜃 Theoretical volume of central compartment 0.0213 
𝑘12𝜃 Rate of APAP transfer from central to peripheral 
compartment 
0.929 
𝑘21𝜃 Rate of APAP transfer from peripheral to central 
compartment 
1.2 
𝑘𝑒𝑙𝜃 APAP elimination rate from central compartment 0.000479 
Table 5-2: Optimised population parameter estimates for clinical APAP Pop-PK model. 
Individual values, 𝜂𝑖, were randomly sampled for each individual and were assumed 
to be normally distributed, with mean of 0 and variance of 𝜔2. The variance for each 
parameter is provided in Table 5-3. 
Parameter Description Value 
𝑡𝑙𝑎𝑔𝜔 Variance of the parameter limiting the rate of 
transferring an APAP dose to the central compartment 
due to, for example, digestion 
1 
𝑘𝑎𝜔 Variance of the APAP absorption rate 1.24 
𝑉𝜔 Variance of the theoretical volume of central 
compartment 
1.75 
𝑘12𝜔 Variance of the rate of APAP transfer from central to 
peripheral compartment 
1.28 
𝑘21𝜔 Variance of the rate of APAP transfer from peripheral to 
central compartment 
1.02 
𝑘𝑒𝑙𝜔 Variance of the APAP elimination rate from central 
compartment 
4.17 
Table 5-3: Optimised variance of parameter values for each individual Pop-PK parameter. 
As detailed in Section 5.3.2, some parameter estimates were correlated with an 
individual’s demographic information. Coefficients for these correlations are detailed 
in Table 5-4. 
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Parameter Description Value 
𝛽_𝑡𝑙𝑎𝑔𝑎𝑔𝑒 Coefficient of the correlation between the APAP lag time 
in absorption into the central compartment, and an 
individual’s age 
-0.00585 
𝛽_𝑘12𝑎𝑔𝑒 Coefficient of the correlation between the rate of APAP 
transfer from central to peripheral compartment, and an 
individual’s age 
0.0163 
𝛽_𝑘21𝑠𝑒𝑥 Coefficient of the correlation between the rate of APAP 
transfer from peripheral to central compartment, and an 
individual’s gender 
0.5 
Table 5-4: Optimised coefficients of significant correlations between Pop-PK parameters and 
an individual’s demographic information. 
Assuming a log-normal distribution, to allow positive values only for predicted APAP 
concentration, the individual and population parameter values were combined to 
provide a parameter value for the 𝑖𝑡ℎ subject as follows: 
𝑘𝑎𝑖 = 𝑘𝑎𝜃𝑒
𝑘𝑎𝜂, 
𝑉𝑖 = 𝑉𝜃𝑒
𝑉𝜂, 
𝑘𝑒𝑙𝑖 = 𝑘𝑒𝑙𝜃𝑒
𝑘𝑒𝑙𝜂. 
For those parameters with significant correlations, the parameter values for the 𝑖𝑡ℎ 
subject were as follows: 
𝑡𝑙𝑎𝑔𝑖 = 𝑡𝑙𝑎𝑔𝜃𝑒
𝑡𝑙𝑎𝑔𝜂 + 𝛽_𝑡𝑙𝑎𝑔𝑎𝑔𝑒(𝐴𝐺𝐸) , 
𝑘12𝑖 = 𝑘12𝜃𝑒
𝑘12𝜂 + 𝛽_𝑘12𝑎𝑔𝑒(𝐴𝐺𝐸) , 
𝑘21𝑖 = 𝑘21𝜃𝑒
𝑘21𝜂 + 𝛽_𝑘21𝑠𝑒𝑥(𝑆𝐸𝑋), 
where 𝐴𝐺𝐸 and 𝑆𝐸𝑋 were the actual demographic values for the 𝑖𝑡ℎ subject. 
5.3.4. Model evaluation 
We tested the predictivity of the non-linear mixed effects model by plotting simulated 
output against the observed clinical data (Figure 5-3). For each individual observed 
data point, the corresponding individual model output is plotted as a blue circle. As 
a point of reference, in a model that was 100% predictive, these blue circles would 
fall along the black solid diagonal line. If observations fall above the diagonal line, 
this would be an example of model under-prediction, since the observed value would 
be higher than the predicted value. Conversely, if observations fall below the line, 
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this would be an example of model over-prediction, since the observed value would 
be lower than the predicted value.  
Additionally, individual weighted residuals (IWRES) were plotted versus both 
predicted time and APAP concentrations (Figure 5-4). In order for the model to be 
deemed predictive, predictions are required to remain within approximately +/-1.96 
standard deviations [181]. As can be seen in Figure 5-4, for the most part, this 
requirement is met, with only very few predictions falling outside of this range 
(approximately 1.05% in the IWRES versus time case and approximately 0.5% in 
the IWRES versus APAP concentration case). 
 
Figure 5-3: Observational data versus individual predictions. The black solid line is the 
reference 𝒚 = 𝒙 line. The black dotted lines define the region containing 95% of the data. 
 
Figure 5-4: Individual weighted residuals (IWRES) comparison. (a) IWRES versus time and 
(b) IWRES versus APAP concentration (Cc). The black dashed line is a reference line at 
IWRES=0. Observations should ideally fall between +/-1.96 standard deviations. 
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In Figure 5-5, we provide a Visual Predictive Check (VPC) of the predictivity of our 
population pharmacokinetic model. If our model was completely predictive of the 
real clinical environment, we would expect the predicted percentiles (--) to directly 
overlap with the empirical percentiles (-). Additionally, the prediction intervals 
(shaded regions) would ideally encase the empirical percentiles. The upmost 
percentile and prediction intervals are representative of the 90th percentile, meaning 
that 90% of the data is either observed (clinically) below this line (-) or are predicted 
by the model to fall below this line (--). The upmost prediction interval (blue shaded 
area) means that there is a 95% chance that the 90% predicted percentile will fall 
within this range. Following these descriptions then, we can see that although our 
model slightly over predicted the peak APAP concentration, the predicted outputs 
were reasonably similar to the observational outputs. 
 
Figure 5-5: Visual Predictive Check (VPC). Empirical percentiles are represented by blue solid 
lines. Predicted percentiles are represented by black dashed lines. The highest trend is the 90th 
percentile, central trend is the 50th percentile and the bottom-most trend is the 10th percentile. 
The blue shaded region around the 90th percentile is the 95% prediction interval, meaning there 
is a 95% chance the simulated prediction interval will fall within this range. The 95% prediction 
interval for the 50th percentile is indicated by a red shaded region. 
5.3.5. Model simulation 
5.3.5.1. Acute dosing 
Individual simulations 
The population-pharmacokinetic model was firstly used to simulate an individual 
taking acute doses of paracetamol. In the first instance, paracetamol concentration 
profiles were explored for a 25-year-old, 45kg female taking two different doses, 
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1,000 mg (2 tablets) and 336,000 mg (672 tablets, which was the maximum amount 
defined in the clinical data used within this investigation). Results of the simulations 
can be seen in Figure 5-6. 
Figure 5-6(A) shows the predicted APAP concentration profile following a 
therapeutically recommended dose of APAP (1,000 mg). Considering the 
therapeutic window for the maximum APAP concentration (Cmax) is predicted to be 
between 5-20 mg/l, and APAP is recommended to be taken every four hours, the 
predicted profile for an acute dose was as expected; almost reaching the therapeutic 
threshold a few hours-post-dose, but indicating that an additional dose may be 
required for full therapeutic effects. If a dose much higher than the recommended 
dose was taken acutely by the same individual, the predicted difference in profiles 
was clear (Figure 5-6(B)). The threshold for toxicity is thought to be any APAP Cmax 
above 25 mg/l. As expected, for a dose 336 times the recommended amount, the 
predicted peak concentration far exceeded this, at almost 3,000 mg/l. 
 
 
Figure 5-6: Simulated concentration over time for an individual taking two different acute 
APAP doses. Simulated APAP concentration over time for a 25-year-old female weighing 45kg 
following an APAP dose of 1,000 mg (A) and 336,000 mg (B). 
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Multiple individual simulations 
Although a patient may have similar demographics, e.g. weight, age and gender, 
their physiological parameters (e.g. rate of APAP absorption, rate of APAP 
elimination) will differ due to inter-individual variability. Taking this inter-individual 
variability into account, the model was used to simulate three individuals with the 
same demographic information (gender - female, age - 25 weight - 45kg) receiving 
a high APAP dose (336,000 mg) to see how their paracetamol concentration profiles 
differed. 
The clear differences between simulated individuals (with the same demographic 
information) receiving the same highly toxic APAP dose, can be seen in Figure 5-7. 
Although, as expected, all simulated individuals had predicted concentrations that 
far exceeded the toxic threshold (25 mg/l), the predicted profile shapes appeared to 
be very different for the three simulations. While two of the simulations showed fairly 
similar absorption and clearance of APAP, the third simulation had a much more 
rapid absorption of APAP, leading to a much higher maximum APAP concentration 
(Cmax), although the clearance was also much quicker, resulting in the APAP being 
cleared by around the same time as the other two simulations. The visual 
differences in profiles for only three simulations, shows the importance of 
accounting for this inter-individual variability when making population predictions. 
 
Figure 5-7: Simulation of APAP concentration over time for multiple individuals with the 
same demographic information taking the same 336,000 mg dose. Portrayal of the variation 
in simulated outputs when inter-individual variability of parameters is taken into account. 
Population simulations 
Since differences in APAP concentration profiles could be clearly seen in individuals 
with the same demographics, it was clear that simulations of a high number of 
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individuals would be necessary to make predictions for a more representative 
population. For this reason, acute dosing was simulated for 1,000 individuals, each 
having the same covariate/demographic information (gender, age, weight) but 
taking into account inter-individual variability in their physiological parameters. From 
these 1,000 simulations, predicted population profiles were calculated (Figure 5-8). 
Predicted population profiles were visually as expected. For example, in Figure 
5-8(A) we see that for an acute therapeutic dose of 1,000 mg, 95% of females who 
weigh 45kg were predicted to have a Cmax that was within the therapeutic range 
(5-20 mg/l). Figure 5-8(B) shows that by increasing this dose to 4,000 mg (a daily 
recommended dose in one acute instance), 95% of females were predicted to have 
a Cmax above the toxic threshold (25 mg/l). If this dose was increased even further, 
to an amount chosen to represent the maximum dose recorded in the clinical dataset 
(336,000 mg/672 tablets), visually, we see in Figure 5-8(C), that 95% of the 
population were predicted to far exceed the toxic threshold. 
 
 
Figure 5-8: Predicted population APAP concentration profiles for varying doses. For 25-
year-old women weighing 45kg, there is a 95% chance that their profile will be within the upper 
and lower bound (palest purple bounds). There is a 55% chance that their profile will be within 
the inner-most band (darkest purple). The therapeutic index for the maximum of the 
concentration profile (Cmax) is bounded by the green horizontal lines (5-20 mg/l). The threshold 
for toxicity is indicated by the red horizontal line (25 mg/l). If the Cmax is above this threshold, 
toxicity is predicted by the model.  (A) shows the population predicted profiles for individuals of 
this demographic taking an acute dose of 1,000 mg APAP. (B) shows the population predicted 
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profiles following a 4,000 mg dose. (C) shows the population predicted profiles following a 
36,000 mg dose. 
5.3.5.2. Multiple dosing 
Although the simulated output was as expected for the acute dosing situation, 
paracetamol is therapeutically advised to follow a multiple dosing regimen. Prior to 
using the model for further investigation, the model was exposed to a multiple dosing 
regimen for validation. 
Test population introduction 
To test the predictive capacity of the model in the multiple dosing scenario, three 
test subjects were exposed to the recommended APAP dose (1,000 mg) 4 times 
daily. Test subjects were created by providing demographic information on three 
known individuals – namely myself, Chantelle Mason (gender – female, age – 25 
years, weight 47 kg), and my supervisory team, Dr Steven Webb (gender – male, 
age – 44 years, weight 92 kg), and Dr Joseph Leedale (gender – male, age – 32 
years, weight 86 kg).  
Recommended dosing 
The recommended dose (1,000 mg, 4 x daily) was firstly assumed to be taken at 
times typical of breakfast (7am), lunch (12pm), dinner (5pm) and bedtime (9pm). 
Resultant paracetamol concentration profiles can be seen in Figure 5-9 for each test 
individual.  
In Figure 5-9 we see that for all test individuals, concentrations did not appear to 
reach the therapeutic window following the first dose. However, following a second 
dose, the therapeutic window was reached. Profiles appeared to be generally similar 
for all three individuals, the main difference being Chantelle (orange) had a greater 
lag time (parameter limiting the transfer of the oral dose to the central compartment) 
than both Steven (purple) and Joseph (green). While it took longer for Chantelle’s 
oral dose to enter the central circulation, Chantelle also took the longest to 
completely clear the APAP.  If this one-day approach to dosing was taken, 
therapeutic effects were predicted to diminish while each of the subjects were 
sleeping (beyond around 1am). If the targeted pain was short-lived (e.g. a 
headache), this may have been a sufficient schedule. However, if post-operative 
pain relief was required, for example, it may have been necessary for the therapeutic 
effects to remain for longer than a one-day period. For this reason, the model was 
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used to simulate a repeated administration schedule, the outputs of which can be 
seen in Figure 5-10. 
In this simulation scenario, the recommended dose (1,000 mg 4 x daily) was 
provided to all three test individuals, this time for two consecutive days. Figure 5-10 
shows that predicted concentration profiles for all three test individuals 
predominantly remained within the therapeutic window as expected. Similar to the 
one-day-dosing simulation scenario, for all test individuals, taking the first dose of 
APAP did not result in predicted therapeutic effects.  However, taking the first dose 
of APAP on the second day resulted in almost immediate therapeutic effects. This 
is likely due to the non-cleared APAP from the previous day having an accumulating 
effect on the total concentration. Consecutive doses (2nd, 3rd and 4th) on day 2 
resulted in similar peak concentrations to the previous day for all three test 
individuals.  
 
Figure 5-9. Predicted APAP concentration profiles for three test individuals following the 
recommended APAP dosing schedule – 1,000 mg administered at 7am,12pm,5pm,9pm. 
Purple - Concentration profile for test individual Steven Webb (44-year-old male weighing 92kg). 
Green - Concentration profile for test individual Joseph Leedale (32-year-old male weighing 
86kg). Orange – Concentration profile for test individual Chantelle Mason (25-year-old female 
weighing 47kg).  Green horizontal lines bound the therapeutic window (a peak APAP 
concentration within this window would be assumed to represent an efficacious case). The red 
horizontal line defines the toxic threshold (a peak APAP concentration reaching this level would 
be assumed to represent a toxic case). 
172 
 
 
Figure 5-10: Predicted APAP concentration profiles for three test individuals following 
the recommended APAP dosing schedule, repeated for 2 days – 1,000 mg administered 
at 7am, 12pm, 5pm and 9pm. Purple - Concentration profile for test individual Steven Webb 
(44-year-old male weighing 92kg). Green - Concentration profile for test individual Joseph 
Leedale (32-year-old male weighing 86kg). Orange – Concentration profile for test individual 
Chantelle Mason (25-year-old female weighing 47kg). Green horizontal lines bound the 
therapeutic window (a peak APAP concentration within this window would be assumed to 
represent an efficacious case). The red horizontal line defines the toxic threshold (a peak APAP 
concentration reaching this level would be assumed to represent a toxic case). 
An interesting result in both the one-day and two-day scenarios, was the time-period 
of drug holiday (time periods in which no therapeutic effects are caused by the drug). 
That is, with reference to the one-day dosing scenario for Chantelle (Figure 5-9), if 
the recommended dose was taken at 7am, 12pm, 5pm and 9pm, there are 8 hours 
throughout this period where no pain relief was achieved. Since no effective therapy 
was seen following the first dose (reflected by peak concentration resulting in a 
value lower than the therapeutic window requirement, 5-20 mg/l), this resulted in no 
therapeutic effects between 7am-12pm. Additionally, a drug holiday was seen 
between 2.30pm-5pm and finally between 8.30pm-9pm.  
Differing demographic combination responses to varying doses of APAP  
One important current clinical question is whether responses to the same APAP 
dose are different in younger, lighter individuals when compared to either older, 
average-weight or heavy-weight individuals. Once concentration profiles were 
confirmed to be as expected by our clinical collaborator (Dr. James Dear), for both 
the acute and multiple recommended dosing scenarios, we used the model to 
investigate differences in responses for the demographic groups of interest.  
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For this investigation a 15 years old was chosen to represent a “young” individual 
since “young” overdose cases are usually classed as those occurring in individuals 
aged between 15-24 [182]. 90-years-old was chosen to represent an “old” individual 
since this is beyond the general elderly age threshold of 75 [183]. Low weights were 
chosen to be below the average for the age group of interest [184] and heavy 
weights were chosen to be representative of obese/class 3 obese [185].  With this 
approach, a young, light weight individual was assumed to be aged 15, weighing 35 
kg. A young, heavy individual was assumed to be aged 15, weighing 90 kg. This 
weight (90 kg) was chosen since this is the threshold for obesity for an individual of 
average height [185]. An old, light individual was assumed to be aged 90, weighing 
40 kg. For elderly individuals, a weight beyond the class 3 obesity threshold was 
used [185]. An old, heavy individual was assumed to be aged 90, weighing 135 kg. 
For each of these demographic combination groups, an acute dose of 1,000 mg was 
provided, and simulated concentration-time profiles were compared (Figure 5-11). 
 
Figure 5-11: Predicted population APAP concentration profiles for various demographic 
groups following administration of a 1,000 mg APAP dose at 7am, 12pm, 5pm and 9pm. 
For each demographic group, there is a 95% chance that their concentration profile will be within 
the upper and lower bound (palest purple bounds). There is a 55% chance that their profile will 
be within the inner-most band (darkest purple). (A) predicted population APAP concentration 
profiles of young, low weight individuals. (B) predicted population APAP concentration profiles 
of young, heavy weight individuals. (C) predicted population APAP concentration profiles of old, 
light weight individuals. (D) predicted population APAP concentration profiles of old, heavy 
weight individuals. 
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For the recommended APAP dose, Figure 5-11 shows that all demographic groups 
were exposed to therapeutic effects, as expected. Interestingly though, individuals 
in the older groups (Figure 5-11(C-D)) were predicted to only see therapeutic effects 
following a third dose of APAP, whilst younger individuals (Figure 5-11(A-B)) were 
predicted to see therapeutic effects following the first dose.  The group with the 
highest variance in their profile were the young, light group of individuals (Figure 
5-11(A)), meaning that there was less certainty in predicting exact results for these 
individuals. This is a key result. For the younger group, if the weight was increased 
(Figure 5-11(B)), this seemed to improve confidence in the predictions, although any 
uncertainty in predictions was reduced further in the older population (Figure 
5-11(C-D)). Generally, there was a greater variance in model predictions for lower 
weight individuals. As both age and weight increased, there was an improvement in 
the confidence of predictions. 
The dose was then increased from the recommended 1,000 mg to 2,000 mg for an 
investigation into a higher dose in the same demographic groups. Resultant 
simulated concentration profiles are shown in Figure 5-12. 
 
Figure 5-12: Predicted population APAP concentration profiles for various demographic 
groups following administration of a 2,000 mg APAP dose at 7am, 12pm, 5pm and 9pm. 
For each demographic group, there is a 95% chance that their concentration profile will be within 
the upper and lower bound (palest purple bounds). There is a 55% chance that their profile will 
be within the inner-most band (darkest purple). (A) predicted population APAP concentration 
profiles of young, low weight individuals. (B) predicted population APAP concentration profiles 
of young, heavy weight individuals. (C) predicted population APAP concentration profiles of old, 
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light weight individuals. (D) predicted population APAP concentration profiles of old, heavy 
weight individuals. 
The main difference in the concentration profiles when increasing the dose, was the 
therapeutic effects being seen earlier for the older populations (Figure 5-12(C-D)). 
The younger populations (Figure 5-12(A-B)) were predicted to have therapeutic 
concentrations for the whole duration of the dosing schedule. For the older 
populations (Figure 5-12(C-D)), although there was a small drug holiday window 
between around 10h post-dose and 12h post-dose, the situation seemed to have 
improved for this higher dose, with therapeutic effects predicted following the first 
2,000 mg dose, rather than the third 1,000 mg dose.  
Differences in toxic responses for the demographic groups were investigated by 
simulating two highly toxic doses, 5,000 mg, and 10,000 mg.  
 
Figure 5-13: Predicted population APAP concentration profiles for various demographic 
groups following administration of a 5,000 mg APAP dose at 7am, 12pm, 5pm and 9pm. 
For each demographic group, there is a 95% chance that their concentration profile will be within 
the upper and lower bound (palest purple bounds). There is a 55% chance that their profile will 
be within the inner-most band (darkest purple). (A) predicted population APAP concentration 
profiles of young, low weight individuals. (B) predicted population APAP concentration profiles 
of young, heavy weight individuals. (C) predicted population APAP concentration profiles of old, 
light weight individuals. (D) predicted population APAP concentration profiles of old, heavy 
weight individuals. 
The predicted concentration-time profiles of individuals following 4x 5,000 mg doses 
can be seen in Figure 5-13 and the predicted concentration over time profiles of 
individuals following 4 x10,000 mg doses can be seen in Figure 5-14. 
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For a toxic acute APAP dose of 5,000 mg, as shown in Figure 5-13(A-B), toxicity 
(represented by concentrations higher than 25 mg/l) was predicted to be apparent 
almost immediately in the younger individuals. For the older individuals (Figure 
5-13(C-D)), following administration of one 5,000 mg dose, therapeutic 
concentrations were predicted, but following the third consecutive dose, toxic 
concentrations were predicted. As in previous results, the younger individuals 
(Figure 5-13(A-B)), particularly those who were also light-weight (Figure 5-13(A)), 
had the highest variance and least certainty in their predictions. 
 
Figure 5-14: Predicted population APAP concentration profiles for various demographic 
groups following administration of a 10,000 mg APAP dose at 7am, 12pm, 5pm and 9pm. 
For each demographic group, there is a 95% chance that their concentration profile will be within 
the upper and lower bound (palest purple bounds). There is a 55% chance that their profile will 
be within the inner-most band (darkest purple). (A) predicted population APAP concentration 
profiles of young, low weight individuals. (B) predicted population APAP concentration profiles 
of young, heavy weight individuals. (C) predicted population APAP concentration profiles of old, 
light weight individuals. (D) predicted population APAP concentration profiles of old, heavy 
weight individuals. 
For the highest dose of 10,000 mg (Figure 5-14), as expected, toxic concentrations 
were predicted in all demographic groups. There did appear to be a difference 
however, with regard to the extent of toxicity when comparing the younger (Figure 
5-14(A-B)) and older individuals (Figure 5-14(C-D)). For the younger individuals, 
(both light and heavy in weight) the predicted concentrations far exceeded the toxic 
threshold. For the older population (both light and heavy in weight), the toxic 
threshold was only just exceeded after the first dose. 
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5.3.5.3. Investigating the effects of demographic information on 
APAP tolerance 
Influence of age and weight 
Our clinical collaborator (Dr. James Dear) requested an investigation into the effects 
of a patient’s age and weight on APAP tolerance. This is of particular interest 
currently due to an increasing amount of toxicity cases being identified in young, 
low-weight individuals. These demographic factors were investigated in terms of 
their effect on maximum tolerated dose. For each age/weight combination for an 
individual, doses were increased until the toxic APAP Cmax threshold was reached. 
This process was repeated for 10 different virtual humans per age/weight class, with 
the average and standard deviation recorded.  The results can be seen in Figure 
5-15. The figure represents results for simulated females. The approach was 
repeated for males, however the visual difference in results was negligible and 
therefore to avoid repetition, the figures for males are not provided. 
On average, younger lighter people were predicted to have a lower tolerance to 
APAP (Figure 5-15(A)). This is indicated by the blue region, in the bottom left-hand 
corner of the plot, mainly accounting for individuals below age 40 and weight 80 kg 
(approximately). On average, individuals aged between 40-60 years and weighing 
between 80-100 kg had a slightly higher predicted tolerance to APAP dose 
compared to the younger, light-weight individuals. Individuals aged between 60-75 
years and weighing between 100-120 kg had an even higher tolerance, whilst 
individuals above 75 years old and also weighing above 120 kg were predicted to, 
on average, have the highest tolerance to APAP dose. 
The results from Figure 5-15(B) suggest that if a younger person has a higher 
weight, there is less variance in their predictions. This means that for these 
age/weight classes, we could predict their maximum tolerance with more certainty. 
This is indicated by the dark blue region in the bottom right-hand corner of the figure. 
This figure also shows that for any individual weighing less than 80 kg, the predicted 
maximum tolerable dose had a high potential to vary, with lower weight individuals 
over the age of 60 years having the highest variance in predictions.  Visualising the 
data in terms of relative standard deviation (Figure 5-15(C)) however, we see that 
regardless of age, there was predicted to be a higher variance in tolerance for low 
weight individuals. Both Figure 5-15(B and C) suggest that for older people (above 
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approximately 65 years), an increased weight does not necessarily reduce the 
variability in maximum dose tolerance. 
 
Figure 5-15: Maximum tolerated dose (the dose at which a toxic APAP Cmax is reached) 
for females with various age and weight combinations. Lowest values are indicated by a 
dark blue colour; as the value increases, the colour becomes green and eventually yellow at the 
highest values. (A) Average predicted maximum tolerated dose. (B) Standard deviation of 
predicted maximum tolerated doses. (C) Relative standard deviation of predicted maximum 
tolerated doses.  
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Age differences 
We investigated age-related differences in maximum tolerated APAP dose with 
particular focus on young individuals, regardless of weight. Whilst previously, we 
analyse APAP concentration (mg/l), upon arrival at the clinic, often an APAP dose 
(mg/kg) is the initial information provided to the clinician to aid in their decision of 
whether or not intervention is necessary. For this reason, our analysis is now 
conducted in terms of APAP dose (mg/kg) rather than APAP concentration (mg/l). 
We compared the predicted maximum tolerated doses with current thresholds used 
in the clinic which may deem a patient “unnecessary for intervention”, “potentially 
toxic” or “requiring transplant”. The aim of this was to determine whether or not “one-
size fits all” thresholds are predictive, or whether further accountability for age 
should be considered. Results of which can be seen in Figure 5-16. 
 
Figure 5-16: Predicted age effect on maximum tolerated APAP dose. Black lines indicate 
the average maximum tolerated dose predicted by the model, with error bars representing 
standard error mean in predictions. The green horizontal line represents a currently used clinical 
threshold (75 mg/kg) for which any patient reporting an ingested dose below this would be 
deemed unnecessary for intervention. The blue horizontal line represents a currently used 
clinical threshold (100 mg/kg) for which any patient reporting an ingested dose above this would 
be deemed potentially toxic and therefore would require treatment. The red horizontal line 
represents a currently used clinical threshold (150 mg/kg) for which any patient reported to have 
ingested a dose above this would be thought to require a liver transplant. 
The results from Figure 5-16 show that although the currently used potentially toxic 
dose threshold may be suitable for individuals above 40 years of age, keeping the 
threshold this high may mean that toxicity could potentially be missed for individuals 
below this age. For the youngest individuals in our investigation, the average dose 
at which toxic concentrations were present was 85 mg/kg. Should a young individual 
ingest a dose of approximately 85 mg/kg, clinically, they would currently be assumed 
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to be a non-toxic case. However, our predictions suggest that toxic concentrations 
may in fact be present in this scenario. Conversely, if a 75-year-old individual reports 
an ingested dose of 100 mg/kg, currently, they would be treated with 
N’Acetylcysteine. However, our results suggest that individuals of this age could 
tolerate a maximum dose of 120 mg/kg, and therefore this individual could 
potentially be unnecessarily treated under the current recommendations. The 
threshold currently used to advise transplant requirement (reported dose above 150 
mg/kg) lies above the average maximum tolerated dose predicted for all age ranges, 
and therefore our results suggest this threshold may be sufficient for this purpose. 
The threshold used to deem a patient unnecessary for intervention is 75 mg/kg. For 
all age ranges, the average maximum tolerated dose was predicted to be higher 
than this, and therefore this threshold may also be considered suitable.  
5.4. Chapter discussion 
The current clinical framework for treating paracetamol overdose is known to be sub 
optimal [10]. In previous chapters, specifically Chapters 2 and 3, we proposed a 
framework to improve the accuracy of predictions for initial dose and time since 
ingestion, and subsequently, the probability of liver injury. The mathematical 
approach we detailed is a proof-of-concept pre-clinical framework, which shows 
potential for translation to human and subsequent clinical application. Within this 
chapter, we provide a predictive framework applicable to humans. However, since 
biomarker data was unavailable at the time of investigation, within this chapter we 
detailed initial investigations on the PK aspect of the model only. The interesting 
results from these initial investigations provide additional support for further 
developing the model to include the pharmacodynamic aspect and strengthen the 
utility of the framework.  
Large differences in inter-individual susceptibility to APAP overdose have been 
reported, but the specific reasons for this variability remain unknown [77]. To 
account for this variability in responses we employed a mixed effect modelling 
approach. This modelling approach takes into consideration parameters that are 
representative of the average population, but additionally considers how much an 
individual may potentially deviate from this average, providing a range to sample for 
individual in silico investigations.  The parameters within our mixed effects model 
were optimised by fitting to data from approximately 3,600 APAP overdose patients. 
The optimised parameters (based on the clinical data) that varied greatest between 
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individuals were the APAP absorption rate (𝑘𝑎) and the theoretical volume of 
distribution (𝑉). There are many reasons which may justify variability in the 
absorption of a drug such as an individual’s nutritional state, gastrointestinal health, 
or necessity for drug co-administration [186]. Since the theoretical volume of 
distribution is associated with the weight of an individual, it is no surprise that this 
varies greatly within the population. The PK parameters predicted to vary the 
greatest were therefore those as expected.  
Simulating the model for three test individuals with different demographic 
information (gender, age and weight) allowed for the visualisation of differing 
concentration versus time profiles. There is persisting confusion regarding whether 
or not the weight of an individual should influence their oral APAP dose requirement. 
This has resulted in many independent clinics choosing to reduce the oral dose for 
low-weight individuals as a precautionary measure [157]. For just three test 
individuals, differences were identified in their predicted APAP concentration 
profiles, suggesting that profiles may vary greatly for a large amount of individuals 
with differing demographic information.   It must be recollected however, that the 
model parameters used for simulation were optimised based on overdose data, and 
further optimisation with non-overdose data would be necessary to make 
therapeutic predictions with improved confidence.  
With the potential effects of demographic information in mind, we investigated 
further the relationship between age and weight for large ranges which were not 
beyond the scope of the clinical dataset used for optimisation (10-90 years, 35-135 
kg), with the aim of determining how this information affected the maximum tolerated 
dose. Results from this more extensive analysis suggest that, on average, younger 
lighter people are predicted to have a lower tolerance to APAP. It must be noted, 
however, that there was also predicted to be a high level of variability in the 
maximum tolerated dose for the young, low-weight group of individuals. For heavier, 
younger individuals, the variability in profiles was predicted to be less, suggesting 
that we can have more confidence that a younger person can tolerate less than an 
older person, specifically if they are of a higher weight.  
Results suggest that regardless of age, there is much more variability in predictions 
for low-weight individuals, supporting the idea that some clinics take precautionary 
measures for these individuals. Since our findings thus far suggested that age was 
an important factor in differing responses to APAP, we used our model to compare 
predicted toxic thresholds for individuals ranging from 10-90 years with currently 
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used clinical thresholds. The key prediction from this analysis was that individuals 
below the age of 40 may not be investigated for potential toxicity under current 
clinical guidance (where 100 mg/kg is the considered toxic threshold). Results from 
our analysis suggest that individuals younger than 40 years old could have toxic 
APAP concentrations following a dose of 85 mg/kg. When simulating various four 
times daily doses and comparing how the concentration profiles differed for varying 
demographic groups, in every dosing scenario ([1,000; 2,000; 5,000; 10,000] mg) 
the group with the highest predicted variability in profiles were young, light weight 
individuals. Again, it must be noted that this model has been optimised against 
overdose data and therefore extrapolating predictions for therapeutic purposes may 
require additional optimisation against therapeutic data.  
Clinically, there has been much discussion around this demographic group with 
regards to their differing toxicity when compared with other demographic groups, 
although there is currently little evidence to guide clinicians on how to appropriately 
treat this group. Our study highlights the necessity for further investigation into this 
demographic group. Better understanding should be sought in terms of why this 
specific demographic group has such variability in APAP response, which should in 
turn be used to try and better guide clinicians to amend treatment. 
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Chapter 6: Discussion 
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6.1. Conclusions 
Paracetamol (APAP) overdose is a concerning global health issue [5]. Considered 
safe at therapeutic doses, this drug is also the most commonly used in overdose 
situations, accounting for 40% of all drug poisoning cases in the UK [3]. APAP 
overdose is the leading cause of acute liver failure (ALF) in the western world [4], 
with ALF being responsible for approximately 56,000 emergency room visits, 2,600 
hospitalisations and 500 deaths per year in the USA [6]. Considering the severity 
level of this public health concern, the current clinical treatment framework for APAP 
overdose is criticised for being sub-optimal. The two main issues with the current 
framework are: decisions to administer NAC are currently heavily dependent on the 
patients’ knowledge of time elapsed since overdose [10]; and, decisions to continue 
NAC treatment are heavily based on biomarkers ALT and INR, which are criticised 
for lacking sensitivity and specificity [11,17]. Further complexities arise as some 
individuals are more susceptible to toxicity from APAP overdose than others, 
particularly those with a weakened ability to synthesise or maintain sufficient 
glutathione (GSH) levels [10]. Such high-risk individuals may be of a particular age, 
suffer from pre-existing liver disease, concurrently use alcohol, or be malnourished, 
for example [5].  
While the decision of whether or not to administer NAC is currently sub-optimal, so 
too is the ideal treatment regimen (i.e. NAC dose amount and administration time), 
resulting in recent trials of newly proposed treatment protocols [136]. As well as 
known risk-factors that cause individuals to have a higher susceptibility to toxicity 
following overdose, there are also variations in the physiology of humans which may 
cause increased susceptibility [77], and more work is needed to try and quantify 
these effects in order to improve the treatment framework. Whilst pre-clinical animal 
testing remains an important element of toxicity identification methodology, 
quantitative systems toxicology (QST) modelling is a recently well-employed tool in 
modern toxicity testing, providing useful predictions efficiently and reducing the 
dependency on animal tests [43]. Within this thesis, we describe a QST modelling 
approach with the aim of improving the current APAP clinical treatment framework. 
Chapter 2 describes a pre-clinical proof-of concept framework representing APAP 
metabolism and corresponding toxicity biomarkers in mice. The biomarkers used 
within the investigation include the conventional (ALT), as well as the novel 
biomarkers (HMGB1, full and fragmented K18) that are thought to have improved 
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sensitivity over those currently used in the clinic [87]. We identified pharmacokinetic 
(PK) parameters for APAP in mice, which were previously undocumented within the 
literature. These values can now form a basis for other researchers within the field 
aiming to undertake similar pre-clinical APAP toxicity modelling investigations. All 
biomarkers were tested for their ability to predict potential liver injury against in vivo 
animal histology data via binomial logistic regression analysis. Although the 
biomarkers have been previously investigated individually [39], the biomarkers were 
tested in combinations within this study to better understand their relationship in the 
APAP toxicity setting. Although the current clinical combination of APAP and ALT 
turned out to be predictive for liver injury, HMGB1 alone was found to be the most 
significant predictor. This result formed the basis of our proposed liver injury 
identification framework.  
Whilst Remien et al. [73]  proposed a predictive liver injury framework based on a 
single measurement of biomarker concentrations, their study was focused upon 
conventional biomarkers e.g. alanine aminotransferase (ALT) and international 
normalised ratio (INR). Our study combined conventional and novel biomarkers with 
the aim of predicting the initial APAP dose, and how much time had elapsed since 
the dose was taken. The initial dose and time since administration predictions were 
found by combining PKPD modelling and simulation with statistical (visualisation 
and classification) techniques. The PKPD model was used to simulate a virtual 
population, with each individual receiving a random dose of APAP. Conventional 
and novel biomarker concentrations were extracted at a random time point to mimic 
the clinical situation. Measuring biomarker concentrations and combining with our 
proposed statistical framework allows the following to be predicted for each 
individual: initial APAP dose amount; time since overdose; and most importantly, a 
quantitative probability of liver injury (based solely on HMGB1 concentration).  
Currently, the clinical treatment framework is heavily dependent on knowledge of 
time since administration [10], information which is often unknown or highly 
inaccurate. We have developed a framework that can predict the time elapsed since 
overdose, based on biological information rather than verbal. The decision to 
continue NAC treatment is currently based on monitoring levels of biomarkers such 
as international normalised ratio (INR) and alanine aminotransferase (ALT), both of 
which are criticised for their lack of sensitivity and specificity [11,17]. An additional 
issue is the requirement of multiple invasive biomarker measurements, which has 
the potential to lead to incomplete results. Our proposed framework predicts the 
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probability of liver injury based on HMGB1 concentration (a biomarker defined to 
have improved sensitivity over those currently used [39]). Additionally, our 
framework requires only one measurement of biomarkers, eradicating the 
requirement for multiple invasive measures.  
Although QST models are being increasingly employed in the field of drug toxicity, 
skepticism around their utility still exists due to the necessity of underlying 
assumptions within the models. Therefore, any uncertainties that exist within the 
model should be explicitly defined to ensure the model may be used to its highest 
potential [46]. In Chapter 3, an identifiability analysis technique was defined with the 
aim to identify and quantify parameter uncertainty within the model. The technique 
was developed following a two-week award training placement at Freiburg Institute 
for Advanced Studies (FRIAS). In order to quantify any uncertainties in the model 
framework described in Chapter 2, we applied an identifiability analysis to the PKPD 
model which resulted in the identification of several model parameters that were 
unidentifiable. Structural unidentifiabilities (associated with the mechanistic 
structure of the model) were dominant in the HMGB1 and fragmented K18 
components of the model. Practical unidentifiabilities (associated with a lack of 
experimental data used during parameter optimisation) were dominant in the GSH 
component of the model, with additional practical unidentifiabilities in the full and 
fragmented K18 components.  
Chapter 3 describes the refinement of the model described in Chapter 2, adjusting 
the structure of the mechanistic framework and subsequently fitting the model to 
additional data to optimise the parameters. Since one of the complexities in APAP 
overdose treatment is that some individuals are more susceptible (“high-risk”) with 
regard to toxicity than others [10], we chose to extend our model framework to also 
predict toxicity in these “high-risk” individuals. We achieved this by modifying our 
pre-clinical PKPD model to represent both a fed and fasted state (fasted mice are 
known to have depleted GSH stores) and optimised parameter values by fitting to 
additional fed and fasted mouse data.  
The extended model can be used to make toxicity predictions for either healthy, 
high-risk or mixed populations. Prediction accuracy for time since APAP 
administration and initial APAP dose were similar for the healthy and mixed 
populations, with a 3-4 h error for time since administration and a 65-75 mg/kg error 
for initial dose. The initial dose was much harder to predict in the high-risk population 
(184.1 mg/kg error). This result is unsurprising since a much larger range of doses 
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may have a toxic effect if the liver is already impaired. Time since administration, 
however, could be predicted in the high-risk group more accurately than in a 
healthy/mixed population (2.118 h error). It has already been found that amending 
treatment thresholds  to account for high-risk individuals can better protect those 
with greater liver injury susceptibility [5].  
Results from this pre-clinical study further endorse the idea that there are likely very 
different outcomes with respect to liver injury potential for healthy and high-risk 
individuals. This was concluded from the visualisation of in silico individuals from 
both “healthy” and “high-risk” populations, with each observation being 
discriminated by their probability of liver injury. For the healthy population, most of 
the observations were predicted to have less than around 35% chance of DILI 
progression. In stark contrast, however, most of the observations in the high-risk 
population were predicted to have almost 100% chance of liver injury progression. 
More informed decisions could therefore be made regarding optimal treatment if 
clinicians can identify those who are more susceptible to overdose. This would 
significantly improve patient outcomes while reducing the cost and burden of 
unnecessary antidote treatment.  
In order to create a framework that has the potential to improve current APAP 
toxicity treatment in the clinic, it is important to include the antidote 
(N’acetylcysteine, NAC) and its effects on toxicity potential. In Chapter 4, we 
included in vitro experimental data showing the effects of APAP and NAC on cell 
functionality obtained through a laboratory experimental training placement at the 
University of Liverpool. The results of a multiple linear regression analysis 
concluded that, if biomarker measurements are taken throughout treatment, ALT, 
full and fragmented K18 could significantly predict cell viability. This insight was 
made possible by modelling full and fragmented K18 as separate necrotic and 
apoptotic versions of the same biomarker, suggesting its critical role in quantifying 
cell functionality. 
There has been much discussion around the uncertainty of the optimal combination 
of NAC dose amount and time of administration. In Chapter 4, we compared two 
NAC treatment regimens [24,136], the first, being the regimen currently used in the 
clinic, and the second being a proposed regimen that administers NAC over a 
shorter time period (SNAP) regimen. We assessed the regimens’ effects on the 
amount of APAP exposure allowed before toxicity was predicted. We used the 
thresholds defined by our framework: probable liver injury; and severe loss of cell 
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functionality. We found that when using probable liver injury as a marker of toxicity, 
the current NAC regimen was predicted to have better protective effects than the 
proposed SNAP regimen (protecting against APAP doses of 8,000 mg/kg compared 
to the SNAP regimen which protects against 3,500 mg/kg). When using loss of cell 
functionality as a measure, however, both regimens were predicted to provide 
similar protective effects. If cell functionality is used as a toxicity measure, our 
framework predicted toxicity occurring for any APAP dose beyond 400 mg/kg. 
Currently, the clinical expected fatal toxicity dose is thought to occur at APAP doses 
beyond 250 mg/kg [8]. Our preliminary results suggest that this clinical threshold 
may have the potential to be increased, possibly leading to huge savings on 
unnecessary interventions. However, further investigations would be required 
before such predictions could be confirmed. 
In Chapters 2 to 4, we have provided a proof-of-concept framework that is based on 
pre-clinical in vivo/in vitro scenarios. Chapter 5 describes a population-
pharmacokinetic (Pop-PK) model that can be applied to the human clinical case. 
The framework has parameters that were optimised by fitting the Pop-PK model to 
a clinical dataset of 3,616 patients (provided by our clinical collaborator, Dr. James 
Dear). The APAP overdose patients were from 3 UK hospitals – Newcastle, 
Edinburgh and London. For each patient, we had the following information: 
Covariate (demographic) information (age, sex, weight); APAP dose taken (mg); 
time since APAP dose (h); and APAP measurement upon hospital admission (mg/l). 
Once confident that the simulations from our Pop-PK framework were 
representative of the clinical data, we used the modelling framework to investigate 
some concerns which are currently of clinical interest.  
Firstly, large differences between inter-individual susceptibility to APAP overdose 
have been reported. However, specific reasons for this variability remain unknown 
[77]. We used modelling and simulation approaches to obtain a better quantification 
of this variability. Namely, the parameters that varied greatest between individuals 
were the APAP absorption rate, 𝑘𝑎, and the theoretical volume of distribution, 𝑉. 
There are many reasons which may explain differences in the absorption of a drug, 
such as an individual’s nutritional state, gastrointestinal health or polypharmacy 
[186].  
Secondly, within the clinic, there has been much discussion around a specific 
demographic group (young, lower weight individuals) with regards to their differing 
toxicity when compared to other demographic groups. At present, there is little 
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quantitative evidence to guide clinicians on how to appropriately treat this specific 
group. Through various simulations of our model, we were able to compare APAP 
concentration profiles for individuals in different demographic classes. We 
compared predicted population profiles from four different classes of individuals; 
young, light weight; young, heavy weight; old, light weight; and old, heavy weight.  
A consistent result, throughout testing various APAP doses, was that the 
concentration profiles for the young, light weight individuals were predicted to have 
much greater variance compared to the other demographic groups, suggesting less 
certainty in their predicted APAP profiles. We also simulated over 2,000 different 
age and weight combinations with the aim of investigating any differences in the 
APAP dose threshold predicted to induce toxicity. The results from this analysis 
clearly suggest that on average, younger, light weight individuals may have a lower 
tolerance to APAP. Something important to note, however, is that there was a high 
level of variability in the predicted maximum dose for this demographic group. As 
the weight of the young individuals increased, the relative variability in their 
predictions was much lower. This suggests that we can have more confidence that 
young individuals may have a lower APAP tolerance than an older person, if they 
are of a higher weight.  
One of the key highlights from our study suggests that under the current clinical 
guidelines, some patients who are deemed unnecessary for investigation, may in 
fact require treatment for APAP toxicity. An APAP dose of 100 mg/kg is thought to 
be the toxic APAP threshold at present. Results from our analysis suggest that 
individuals below the age of 40 years old could have toxic APAP concentrations 
following a dose of 85 mg/kg. Missing potential toxicity cases upon arrival at the 
hospital can have several detrimental downstream effects. For example, a 
nationwide study of over 12,000 subjects conducted by Huang et al. found that 
APAP poisoning is associated with increased long-term mortality and early referral 
for intensive after-care is essential [187]. 
In summary, this thesis aims to show the utility of mathematical modelling in toxicity 
predictions, with the particular objective of making improvements to the clinical 
APAP overdose treatment framework. We provide a proof-of-concept framework 
that, from a single measurement of conventional and novel biomarker 
concentrations, predictions about the amount of APAP taken and how long it has 
been since the overdose took place can be made. We also have the capability of 
predicting the probability of liver injury for each individual, and the severity of the 
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loss of cell functionality. We investigated the effects of NAC treatment and propose 
potential adjustments to the current framework which may improve the clinical 
situation. Finally, we provide a fully-optimised Pop-PK clinical model that has 
provided a better understanding of which physiological parameters could have the 
greatest influence on inter-individual susceptibility to APAP overdose. Whilst our 
clinical framework in its Pop-PK form has provided insight to the APAP overdose 
problem, once extended to include the biomarker dynamics (such as those 
investigated in Chapters 2-4), our hope is that our framework would have the utility 
to make toxicity predictions in the human case based on biomarkers that are more 
sensitive and specific than those currently used. 
There have been some mathematical approaches to improving the APAP overdose 
problem to date. For better understanding of APAP metabolism, mechanistic models 
often take the form of systems of ordinary differential equations (ODEs). These kind 
of mathematical models are useful for representing and making predictions of 
biological processes over time. Examples of such studies are defined by the DILI-
sim-initiative and Geenen et al.  [69,83]. We have taken a similar ODE modelling 
approach to represent APAP metabolism and the corresponding toxicity biomarkers. 
However, considering the limitation of data dependence, we define an identifiability 
analysis technique, which following application to the model defined in Chapter 2, 
enabled us to determine areas of uncertainty within our model structure that required 
refinement/additional data during optimisation. We were subsequently able to define 
the uncertainty within our predictions, and improve confidence in our framework.  
The key novelty of this study is the combination of mathematical and statistical 
modelling approaches. Simulations of the mechanistic models are combined with 
statistical visualisation and classification techniques to provide key mechanistic 
information that can be utilised by experimentalists, whilst additionally providing 
results from statistical analysis that can be easily interpreted and used by a clinician.  
6.2. Future work 
While the results of this research are promising, with additional time and resources, 
the utility of the model predictions could clearly be improved. With regard to the 
proof-of-concept framework defined in Chapters 2 and 3, although the results from 
the T-SNE method for visualisation showed clear separation, particularly with 
regards to the probability of liver injury, there was a slight overlap in the time-since-
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administration and dose plots. This result supports the possibility of defining further 
classes through unsupervised methodologies in future investigations. Also, the 
classification techniques used provided incredibly high accuracy levels considering 
the nature of the problem. However, a further investigation of interest could be the 
rate of misclassiﬁcation between the classes with regard to critical errors at the 
edges of the variable ranges. 
Better understanding of the relationship between probability of liver injury (based on 
HMGB1 concentration) and loss of cell functionality is required. This is supported 
by our APAP tolerability results in Chapter 4 varying greatly depending on the 
toxicity measure used. Results from our investigation could be used to guide in vitro 
experiments to improve this understanding. For example, potential experiments 
could focus on monitoring multidrug resistance proteins (MRPs) over time following 
different APAP/NAC doses; these transporters are reported to transport GSH (which 
will affect HMGB1 concentration) and also bind to ATP (which will affect hepatocyte 
viability) [153]. Further experimental repeats of our cell viability study would also be 
necessary to ensure confidence in the accuracy of the optimised parameters used 
in our cell functionality model, and therefore the cell functionality metric.  
For QST models to be useful, relevant human biomarkers are essential [188]. During 
the time this research was carried out, the novel biomarkers used in our pre-clinical 
framework were unavailable within the clinical setting. Since this time, human 
biomarker data has been made available for HMGB1, full and fragmented K18 [136]. 
The next stage in this research will be to extend the currently developed APAP Pop-
PK model (Chapter 5) to include the pharmacodynamic components of the pre-
clinical novel biomarkers. A crucial investigation will be determining whether the 
predictions made from our framework defined in Chapters 2 and 3 are translatable 
to the clinical setting. Results from our pre-clinical analysis suggest that biomarkers 
ALT and full K18 are particularly sensitive to perturbations in parameters, and 
therefore sufficiently dense data will be required when translating the work to the 
clinical context. Dr. James Dear has expressed his interest in continuing our 
collaborative research. He and his team at the Queens Medical Research Institute, 
Edinburgh, predict that if translated to the clinic, our framework has the potential to 
save approximately 20,000 hospital bed days per year in the UK. This equates to 
an approximate saving of £8 million. Dr. Dear suggests that if translatability potential 
is deemed successful, their team could employ the framework within their clinic 
within a matter of months. 
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Appendices 
 
Model equations – Dynamic equations for the full pre-clinical systems toxicology 
model: APAP, corresponding toxicity biomarkers, NAC and hepatocyte functionality. 
Models for toxicity biomarkers are provided for the fed and fastedf cases (note that 
we use subscript f to denote parameters and variables in the fasted case). Note that 
for Full and Fragmented K18, 𝐻(𝑥) is the Heaviside function where 𝐻(𝑥) = 1 when 
𝑥 ≥ 0 and 𝐻(𝑥) = 0 when 𝑥 ≤ 0. 
PK 
 APAP central [𝐶𝑐]: 𝑑[𝐶𝑐]
𝑑𝑡
=
𝑘𝑎𝐷0𝑒
−𝑘𝑎𝑡
𝑉𝑐
+ 𝑘21[𝐶𝑝]
𝑉𝑝
𝑉𝑐
− 𝑘12[𝐶𝑐] − 𝑘𝑒𝑙[𝐶𝑐] (A-1) 
 APAP peripheral 
[𝐶𝑝]: 
𝑑[𝐶𝑝]
𝑑𝑡
=  𝑘12[𝐶𝑐]
𝑉𝑐
𝑉𝑝
− 𝑘21[𝐶𝑝] (A-2) 
GSH 
 Fed GSH [𝑔𝑠ℎ]:  𝑑[𝑔𝑠ℎ]
𝑑𝑡
= 𝑘𝑜(𝑔𝑠ℎ0 − [𝑔𝑠ℎ]) + ζ[NA] −
𝜉𝑘𝑒𝑙𝐶𝑐[𝑔𝑠ℎ]
[𝑔𝑠ℎ] + 𝑘𝑝𝑟
,  (A-3) 
 Fasted GSH 
[𝑔𝑠ℎ𝑓]: 
𝑑𝑔𝑠ℎ𝑓
𝑑𝑡
= 𝛿𝑘𝑜(𝑔𝑠ℎ0 − [𝑔𝑠ℎ𝑓]) + ζ[NA] −
𝜉𝑘𝑒𝑙𝐶𝑐[𝑔𝑠ℎ𝑓]
[𝑔𝑠ℎ𝑓] + 𝑘𝑝𝑟
,    𝛿 < 1 (A-4) 
ALT and HMGB1, (fed and fasted)  
 𝑟 = [𝑎𝑙𝑡] or 
[ℎ𝑚𝑔𝑏1]: 
𝑑[𝑟]
𝑑𝑡
= 𝑟0𝑘𝑜𝑢𝑡 (
𝑅50
𝑛 + 𝑔𝑠ℎ0
𝑛
𝑅50
𝑛 ) (1 −
𝑔𝑚𝑎𝑥[𝑔𝑠ℎ]
𝑛
𝑅50
𝑛 + [𝑔𝑠ℎ]𝑛
) − 𝑘𝑜𝑢𝑡[𝑟],  (A-5) 
  In the fed case, 𝑔𝑚𝑎𝑥 = 1, in the fasted case, 𝑔𝑚𝑎𝑥 < 1.   
Full K18 (fed and fasted) 
 Full K18 = 
[𝐾18]: 
𝑑[𝐾18]
𝑑𝑡
= 𝑟0
18𝑘𝑜𝑢𝑡
18 + 𝑘𝑚a𝑥𝑘𝑖𝑛
18𝐻(𝑔𝑠ℎ𝜃2 − [𝑔𝑠ℎ]) − 𝑘𝑜𝑢𝑡
18 [𝑘18],  (A-6) 
  In the fed case, 𝑘𝑚𝑎𝑥 = 1, in the fasted case, 𝑘𝑚𝑎𝑥 < 1.     
Fragmented K18 
 𝑑[𝑓𝐾18]
𝑑𝑡
= 𝑟0
𝑓18
𝑘𝑜𝑢𝑡
𝑓18
+ 𝑘𝑖𝑛
𝑓18
(𝐻([𝑔𝑠ℎ] − 𝑔𝑠ℎ𝜃1) − 𝐻([𝑔𝑠ℎ] − g𝑠ℎ𝜃2)) − 𝑘𝑜𝑢𝑡
𝑓18[𝑓𝑘18],   (A-1) 
 𝑑[𝑓𝐾18𝑓]
𝑑𝑡
= 𝑟0
𝑓18
𝑘𝑜𝑢𝑡
𝑓18
+ 𝑘𝑖𝑛
𝑓18
(𝐻([𝑔𝑠ℎ𝑓] − 𝑔𝑠ℎ𝜃1 − 𝜀) − 𝐻([𝑔𝑠ℎ𝑓] − g𝑠ℎ𝜃2)) − 𝑘𝑜𝑢𝑡
𝑓18[𝑓𝑘18f], 
 
(A-2) 
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 Fed fragmented K18 = [𝑓𝐾18], Fasted fragmented K18 = [𝑓𝐾18𝑓], 𝜀 > 0. (A-3) 
NAC 
 𝑑[𝑁𝐴]
𝑑𝑡
=
𝑁𝐷𝑜𝑠𝑒
𝑉𝑁𝐴
+ 𝑘𝑁21[𝑁𝐵] (
𝑉𝑁𝐵
𝑉𝑁𝐴
) + 𝑘𝑁31[𝑁𝐶] (
𝑉𝑁𝐶
𝑉𝑁𝐴
) − (𝑘𝑁12 + 𝑘𝑁13 + 𝑘𝑁𝑒𝑙)[𝑁𝐴],   
(A-10) 
 𝑑[𝑁𝐵]
𝑑𝑡
= 𝑘𝑁12[𝑁𝐴] (
𝑉𝑁𝐴
𝑉𝑁𝐵
) −  𝑘𝑁21[𝑁𝐵], 
(A-11) 
 𝑑[𝑁𝐶]
𝑑𝑡
= 𝑘𝑁13[𝑁𝐴] (
𝑉𝑁𝐴
𝑉𝑁𝐶
) −  𝑘𝑁31[𝑁𝐶], 
(A-12) 
Hepatocyte functionality 
 𝑑𝐻
𝑑𝑡
= 𝑟𝐻 (1 −
𝐻 + 𝑍
𝐻𝑚𝑎𝑥
) − 𝜂[𝑁]𝐻, (A-13) 
 𝑑𝑍
𝑑𝑡
= 𝜂[𝑁]𝐻 − 𝛿𝑧𝑍, 
(A-14) 
Model initial conditions 
Variable Initial condition (fed case) Initial condition (fasted case) 
[𝐶𝑐]  0 𝜇mol/l 0 𝜇mol/l 
[𝐶𝑝]  0 𝜇mol/l 0 𝜇mol/l 
[𝑔𝑠ℎ]  559.47497 𝜇mol/l 374.0909 𝜇mol/l 
[𝑎𝑙𝑡]  0.7626 𝜇mol/l 0.9528 𝜇mol/l 
[ℎ𝑚𝑔𝑏1]  0.0005 𝜇mol/l 0.0007 𝜇mol/l 
[𝑓𝑢𝑙𝑙𝑘18]  0.0088 𝜇mol/l 0.0113 𝜇mol/l 
[𝑓𝑟𝑎𝑔𝑘18]  0.0977 𝜇mol/l 0.1634 𝜇mol/l 
[𝑁𝐴]  0 𝜇mol/l  
[𝑁𝐵]  0 𝜇mol/l  
[𝑁𝐶]  0 𝜇mol/l  
[𝐻]  1  
[𝑍]  0  
Table A1: Initial conditions for each variable within the dynamic APAP systems toxicology pre-
clinical framework. 
